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Clarification and Positioning of Volume 2 of The Thesis 
 
 Volume 2 of this thesis does not form part of the tesis text per se. It is a 
supplementary volume that contains all the addenda to which the thesis text refers. In some 
cases, the addendum is illustrative. However, in other cases, the addendum provides the 
necessary detail that will enable the reader to better understand the statements made in the 
thesis text. Apart from addenda, it also contains a bibliography list. In this list any piece of 
literature is included that was consulted for this thesis research, but to which no reference is 
made in the thesis text in volume 1.  
 Being meant as an assemblage of pieces of supportive information, this volume does 
not contain an introduction, explanations and implications or conclusions. These aspects 
















                      - 2 - 
          
 
IMPROVEMENT OF GLOBAL ACCESS  
TO LIFE-SAVING MEDICINES 
 






submitted for the degree  
of  





School of Management 







                      - 3 - 
          
 
Table of Contents  
              Volume 2 
 
 
            
Declarations         001 
Clarification and Positioning of Volume 2 of The Thesis    002 
Title Page          003 
Table of Contents         004 
List of Abbreviations         005 
List of Addenda          008 
Addenda          011 

































                      - 4 - 
          
List of Abbreviations 
 
AIDS: Acquired immunodeficiency syndrome 
AMC: Advanced market commitment 
AU: Authorities 
AU-FA: Authorities, foreign affairs 
AU-PH: Authorities, public health 
AUTH./POL.: Authorities & Politics 
BM: Bill and Melinda Gates Foundation 
C: Conflict 
CEO: Chief Executive Officer 
DBA: Doctor of Business Administration 
DD: Drug developers 
DD-BIO-gen: Drug developers, biotechnological, generics 
DD-BIO-pat: Drug developers, biotechnological, patent-based 
DD/COMP.: Drug developers and/or companies 
DD-Distr: Drug developers, distributors 
DD-gen: Drug developers, generics 
DD-pat: Drug developers, patent-based 
DD-PHA-gen: Drug developers, pharmaceutical, generics 
DD-PHA-pat: Drug developers, pharmaceutical, patent-based 
DD-Univ: Drug developers, universities 
E: English 
EE.UU: Estados Unidos 
EM7: Seven emerging markets 
F: French 
FDA: Food and Drug Administration 
FHI: Family Health International 
GDP: Gross Domestic Product 
GNP: Gross National Product 
H: High 
HA: Health Authorities 
HDI: Human Development Index 
HIV: Human immunodeficiency virus 
HM: Higher Middle (=upper middle) 
Hof: Hofstede 
I+D: Investigación y desarrollo 
IAS: International Aids Society 
IDH: Indice du développement humain 
IDV: Individualism (index) 




LM: Lower middle 
LT: Long-term  
LTO: Long-term orientation 
M: Medium 
MA: Masculinity 
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MAS: Masculinity (Index) 
MSF: Médecins Sans Frontières 
N: Number of samples 
NC: Non-conflict 
NEG: Negative 
NGO&F: Non-governmental organization and foundation 
NGO/F global: Global non-governmental organization / Foundation 
NGO/F local: Local non-governmental organization / Foundation 
NGO/F regional: Regional non-governmental organization / Foundation 
NGO/F: Non-governmental organization and/or foundation 
NGO: Non-governmental organization 
Non-DD: Non-drug developer 
NR: Number 
No.: Number 
NVIVO8: Software package for text analysis, from QSR 
ODA: Official development assistance 
ODA: Orphan Drug Act 
OECD: Organization for Economic Co-operation and Development 
OMS: Organisation Mondiale de la Santé 
OMS: Organización Mundial de la Salud 
ONG: Organisation non gouvernementale 
ONG: Organización no gubernamental 
P.B.: Postbus 
p: statistical p-value; confidence level 
PD(I): Power distance (index) 
PIB: Producto interno bruto  
PIB: Produit interne brut 
PNB: Produit national brut 
PNB: Producto nacionál bruto 
POS: Positive 
PPP: Public private partnership (also PDP) 
PPR: Países pobres en recursos 
PPR: Pays pauvres en resources 
Q: Question, e.g. Q17: question number 17 
Qt: Quantitative 
R&D: Recherche & développement 
R&D: Research & development 
RAC: Resource-average country 
RLC: Resource-limited country 
RPC: Resource-poor country 
RRC: Resource-rich country 
S: Spanish 
SIDA: Síndrome de inmuno-deficiencia adquirida 
SIDA: Syndrome de l’ImmunoDéficience Acquise 
SPSS: Statistical software package: originally “Statistical Package for the Social Sciences” 
Std. Dev.: Standard deviation 
Std.: Standard 
TB: Tuberculosis 
UA(I): Uncertainty avoidance (index) 
UK: United Kingdom 
                      - 6 - 
          
UN: United Nations 
UNDP: United Nations Human Development Programme 
US or U.S.: United States 
USA: United States of America 
VIH: Virus de la Inmunodeficiencia Humana 
VIH: Virus Immuno-déficitaire Humain 
WB: World Bank 
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Addendum 2-1: The Human Development Report 2007/2008 that was used as the 
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Addendum 2-2: The World Bank list of economies that was used in this thesis to mark 
the income level of the countries. 
p.1/6: sheet 1 
 
 
World Bank list of economies (July 2009)
Economy Income group
1 Afghanistan Low income
2 Albania Lower middle income
3 Algeria Upper middle income
4 American Samoa Upper middle income
5 Andorra High income: nonOECD
6 Angola Lower middle income
7 Antigua and Barbuda High income: nonOECD
8 Argentina Upper middle income
9 Armenia Lower middle income
10 Aruba High income: nonOECD
11 Australia High income: OECD
12 Austria High income: OECD
13 Azerbaijan Lower middle income
14 Bahamas, The High income: nonOECD
15 Bahrain High income: nonOECD
16 Bangladesh Low income
17 Barbados High income: nonOECD
18 Belarus Upper middle income
19 Belgium High income: OECD
20 Belize Lower middle income
21 Benin Low income
22 Bermuda High income: nonOECD
23 Bhutan Lower middle income
24 Bolivia Lower middle income
25 Bosnia and Herzegovina Upper middle income
26 Botswana Upper middle income
27 Brazil Upper middle income
28 Brunei Darussalam High income: nonOECD
29 Bulgaria Upper middle income
30 Burkina Faso Low income
31 Burundi Low income
32 Cambodia Low income
33 Cameroon Lower middle income
34 Canada High income: OECD
35 Cape Verde Lower middle income
36 Cayman Islands High income: nonOECD
37 Central African Republic Low income
38 Chad Low income
39 Channel Islands High income: nonOECD
40 Chile Upper middle income
41 China Lower middle income
42 Colombia Upper middle income
43 Comoros Low income
44 Congo, Dem. Rep. Low income
45 Congo, Rep. Lower middle income
46 Costa Rica Upper middle income
47 Côte d'Ivoire Lower middle income
48 Croatia High income: nonOECD
49 Cuba Upper middle income
50 Cyprus High income: nonOECD  
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Addendum 2-2: The World Bank list of economies that was used in this thesis to mark 
the income level of the countries. 
p.2/6: sheet 2 
 
 
World Bank list of economies (July 2009)
Economy Income group
51 Czech Republic High income: OECD
52 Denmark High income: OECD
53 Djibouti Lower middle income
54 Dominica Upper middle income
55 Dominican Republic Upper middle income
56 Ecuador Lower middle income
57 Egypt, Arab Rep. Lower middle income
58 El Salvador Lower middle income
59 Equatorial Guinea High income: nonOECD
60 Eritrea Low income
61 Estonia High income: nonOECD
62 Ethiopia Low income
63 Faeroe Islands High income: nonOECD
64 Fiji Upper middle income
65 Finland High income: OECD
66 France High income: OECD
67 French Polynesia High income: nonOECD
68 Gabon Upper middle income
69 Gambia, The Low income
70 Georgia Lower middle income
71 Germany High income: OECD
72 Ghana Low income
73 Greece High income: OECD
74 Greenland High income: nonOECD
75 Grenada Upper middle income
76 Guam High income: nonOECD
77 Guatemala Lower middle income
78 Guinea Low income
79 Guinea-Bissau Low income
80 Guyana Lower middle income
81 Haiti Low income
82 Honduras Lower middle income
83 Hong Kong, China High income: nonOECD
84 Hungary High income: OECD
85 Iceland High income: OECD
86 India Lower middle income
87 Indonesia Lower middle income
88 Iran, Islamic Rep. Lower middle income
89 Iraq Lower middle income
90 Ireland High income: OECD
91 Isle of Man High income: nonOECD
92 Israel High income: nonOECD
93 Italy High income: OECD
94 Jamaica Upper middle income
95 Japan High income: OECD
96 Jordan Lower middle income
97 Kazakhstan Upper middle income
98 Kenya Low income
99 Kiribati Lower middle income
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Addendum 2-2: The World Bank list of economies that was used in this thesis to mark 
the income level of the countries. 
p.3/6: sheet 3 
 
 
World Bank list of economies (July 2009)
Economy Income group
101 Korea, Rep. High income: OECD
102 Kosovo Lower middle income
103 Kuwait High income: nonOECD
104 Kyrgyz Republic Low income
105 Lao PDR Low income
106 Latvia Upper middle income
107 Lebanon Upper middle income
108 Lesotho Lower middle income
109 Liberia Low income
110 Libya Upper middle income
111 Liechtenstein High income: nonOECD
112 Lithuania Upper middle income
113 Luxembourg High income: OECD
114 Macao, China High income: nonOECD
115 Macedonia, FYR Upper middle income
116 Madagascar Low income
117 Malawi Low income
118 Malaysia Upper middle income
119 Maldives Lower middle income
120 Mali Low income
121 Malta High income: nonOECD
122 Marshall Islands Lower middle income
123 Mauritania Low income
124 Mauritius Upper middle income
125 Mayotte Upper middle income
126 Mexico Upper middle income
127 Micronesia, Fed. Sts. Lower middle income
128 Moldova Lower middle income
129 Monaco High income: nonOECD
130 Mongolia Lower middle income
131 Montenegro Upper middle income
132 Morocco Lower middle income
133 Mozambique Low income
134 Myanmar Low income
135 Namibia Upper middle income
136 Nepal Low income
137 Netherlands High income: OECD
138 Netherlands Antilles High income: nonOECD
139 New Caledonia High income: nonOECD
140 New Zealand High income: OECD
141 Nicaragua Lower middle income
142 Niger Low income
143 Nigeria Lower middle income
144 Northern Mariana Islands High income: nonOECD
145 Norway High income: OECD
146 Oman High income: nonOECD
147 Pakistan Lower middle income
148 Palau Upper middle income
149 Panama Upper middle income
150 Papua New Guinea Lower middle income  
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Addendum 2-2: The World Bank list of economies that was used in this thesis to mark 
the income level of the countries. 
p.4/6: sheet 4 
 
 
World Bank list of economies (July 2009)
Economy Income group
151 Paraguay Lower middle income
152 Peru Upper middle income
153 Philippines Lower middle income
154 Poland Upper middle income
155 Portugal High income: OECD
156 Puerto Rico High income: nonOECD
157 Qatar High income: nonOECD
158 Romania Upper middle income
159 Russian Federation Upper middle income
160 Rwanda Low income
161 Samoa Lower middle income
162 San Marino High income: nonOECD
163 São Tomé and Principe Lower middle income
164 Saudi Arabia High income: nonOECD
165 Senegal Low income
166 Serbia Upper middle income
167 Seychelles Upper middle income
168 Sierra Leone Low income
169 Singapore High income: nonOECD
170 Slovak Republic High income: OECD
171 Slovenia High income: nonOECD
172 Solomon Islands Lower middle income
173 Somalia Low income
174 South Africa Upper middle income
175 Spain High income: OECD
176 Sri Lanka Lower middle income
177 St. Kitts and Nevis Upper middle income
178 St. Lucia Upper middle income
179 St. Vincent and the Grenadines Upper middle income
180 Sudan Lower middle income
181 Suriname Upper middle income
182 Swaziland Lower middle income
183 Sweden High income: OECD
184 Switzerland High income: OECD
185 Syrian Arab Republic Lower middle income
186 Tajikistan Low income
187 Tanzania Low income
188 Thailand Lower middle income
189 Timor-Leste Lower middle income
190 Togo Low income
191 Tonga Lower middle income
192 Trinidad and Tobago High income: nonOECD
193 Tunisia Lower middle income
194 Turkey Upper middle income
195 Turkmenistan Lower middle income
196 Uganda Low income
197 Ukraine Lower middle income
198 United Arab Emirates High income: nonOECD
199 United Kingdom High income: OECD
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Addendum 2-2: The World Bank list of economies that was used in this thesis to mark 
the income level of the countries. 
p.5/6: sheet 5 
 
 
World Bank list of economies (July 2009)
Economy Income group
151 Paraguay Lower middle income
152 Peru Upper middle income
153 Philippines Lower middle income
154 Poland Upper middle income
155 Portugal High income: OECD
156 Puerto Rico High income: nonOECD
157 Qatar High income: nonOECD
158 Romania Upper middle income
159 Russian Federation Upper middle income
160 Rwanda Low income
161 Samoa Lower middle income
162 San Marino High income: nonOECD
163 São Tomé and Principe Lower middle income
164 Saudi Arabia High income: nonOECD
165 Senegal Low income
166 Serbia Upper middle income
167 Seychelles Upper middle income
168 Sierra Leone Low income
169 Singapore High income: nonOECD
170 Slovak Republic High income: OECD
171 Slovenia High income: nonOECD
172 Solomon Islands Lower middle income
173 Somalia Low income
174 South Africa Upper middle income
175 Spain High income: OECD
176 Sri Lanka Lower middle income
177 St. Kitts and Nevis Upper middle income
178 St. Lucia Upper middle income
179 St. Vincent and the Grenadines Upper middle income
180 Sudan Lower middle income
181 Suriname Upper middle income
182 Swaziland Lower middle income
183 Sweden High income: OECD
184 Switzerland High income: OECD
185 Syrian Arab Republic Lower middle income
186 Tajikistan Low income
187 Tanzania Low income
188 Thailand Lower middle income
189 Timor-Leste Lower middle income
190 Togo Low income
191 Tonga Lower middle income
192 Trinidad and Tobago High income: nonOECD
193 Tunisia Lower middle income
194 Turkey Upper middle income
195 Turkmenistan Lower middle income
196 Uganda Low income
197 Ukraine Lower middle income
198 United Arab Emirates High income: nonOECD
199 United Kingdom High income: OECD
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Addendum 2-2: The World Bank list of economies that was used in this thesis to mark 
the income level of the countries. 
p.6/6: sheet 6 
 
 
World Bank list of economies (July 2009)
Economy Income group
201 Uruguay Upper middle income
202 Uzbekistan Low income
203 Vanuatu Lower middle income
204 Venezuela, RB Upper middle income
205 Vietnam Low income
206 Virgin Islands (U.S.) High income: nonOECD
207 West Bank and Gaza Lower middle income
208 Yemen, Rep. Low income
209 Zambia Low income
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Addendum 2-3: The system of hybrid classes of resource levels that was developed 
particularly for this research programme. 
p.1/3: sheet 1 
 
No. Country UNDP WB WB income EM7 Own classification
1 Iceland H H RRC
2 Norway H H RRC
3 Australia H H RRC
4 Canada H H
5 Ire
RRC
land H H RRC
6 Sweden H H RRC
7 Switzerland H H RRC
8 Japan H H RRC
9 Netherlands H H RRC
10 France H H RRC
11 Finland H H RRC
12 United States H H RRC
13 Spain H H RRC
14 Denmark H H RRC
15 Austria H H RRC
16 United Kingdom H H RRC
17 Belgium H H RRC
18 Luxembourg H H RRC
19 New Zealand H H RRC
20 Italy H H RRC
21 Hong Kong, China (SAR) H H RRC
22 Germany H H RRC
23 Israel H H RRC
24 Greece H H RRC
25 Singapore H H RRC
26 Korea (Republic of) H H X RRC
27 Slovenia H H RRC
28 Cyprus H H RRC
29 Portugal H H RRC
30 Brunei Darussalam H H RRC
31 Barbados H H RRC
32 Czech Republic H H RRC
33 Kuwait H H RRC
34 Malta H H RRC
35 Qatar H H RRC
36 Hungary H H RRC
37 Poland H HM RRC
38 Argentina H HM RRC
39 United Arab Emirates H H RRC
40 Chile H HM RRC
41 Bahrain H H RRC
42 Slovakia H H RRC
43 Lithuania H HM RRC
44 Estonia H H RRC
45 Latvia H HM RRC
46 Uruguay H HM RRC
47 Croatia H H RRC
48 Costa Rica H HM RRC
49 Bahamas H H RRC
50 Seychelles H HM RRC
51 Cuba H HM
52 Mexico H HM X RAC
53 Bu
RAC
lgaria H HM RAC
54 Saint Kitts and Nevis H HM RAC
55 Tonga H LM RAC
56 Libyan Arab Jamahiriya H HM RAC
57 Antigue and Barbuda H H RAC
58 Oman H H RAC
59 Trinidad and Tobago H H RAC
60 Romania H HM RAC
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Addendum 2-3: The system of hybrid classes of resource levels that was developed 
particularly for this research programme. 
p.2/3: sheet 2 
 
No. Country UNDP WB WB income EM7 Own classification
62 Panama H HM RAC
63 Malaysia H HM RAC
64 Belarus H HM RAC
65 Mauritius H HM RAC
66 Bosnia and Herzegovina H HM RAC
67 Russian Federation H HM X RAC
68 Albania H LM RAC
69 Macedonia (TFYR) H HM RAC
70 Brazil H HM X RAC
71 Dominica M HM RAC
72 Saint Lucia M HM RAC
73 Kazakhstan M HM RAC
74 Venezuela (Bolivarian Republic of) M HM RAC
75 Colombia M HM RAC
76 Ukraine M LM RAC
77 Samoa M LM RAC
78 Thailand M LM RAC
79 Dominican Republic M HM RAC
80 Belize M LM RAC
81 China M LM X RAC
82 Grenada M HM
83 Armenia M LM RAC
84 Tur
RAC
key M HM X RAC
85 Suriname M HM RAC
86 Jordan M LM RAC
87 Peru M HM RAC
88 Lebanon M HM RAC
89 Ecuador M LM RAC
90 Philippines M LM RAC
91 Tunisia M LM RAC
92 Fiji M HM RAC
93 Saint Vincent and the Grenadines M HM RAC
94 Iran (Islamic Republic of) M LM RAC
95 Paraguay M LM RAC
96 Georgia M LM RAC
97 Guyana M LM RAC
98 Azerbaijan M LM RAC
99 Sri Lanka M LM
100 Ma
RAC
ldives M LM RAC
101 Jamaica M HM RAC
102 Cape Verde M LW
103 E
RAC
l Salvador M LM RAC
104 Algeria M HM RAC
105 Vietnam M L RAC
106 Occupied Palestinian Territories M RAC
107 Indonesia M LM RAC
108 Syrian Arab Republic M LM RAC
109 Turkmenistan M LM RAC
110 Nicaragua M LM RAC
111 Moldova M LM RAC
112 Egypt M LM RAC
113 Uzbekistan M L RAC
114 Mongolia M LM RAC
115 Honduras M LM RAC
116 Kyrgyzstan M L RAC
117 Bolivia M LM RAC
118 Guatemala M LM
119 Ga
RAC
bon M HM RAC
120 Vanuatu M LM RAC
121 South Africa M HM RAC
122 Tajikistan M L RAC  
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Addendum 2-3: The system of hybrid classes of resource levels that was developed 
particularly for this research programme. 
p.3/3: sheet 3 
 
No. Country UNDP WB WB income EM7 Own classification
123 Sao Tome and Principe M LM RAC
124 Botswana M HM RAC
125 Namibia M HM RAC
126 Morocco M LM RAC
127 Equatorial Guinea M H RAC
128 India M LM X RAC
129 Solomon Islands M LM R
130 Lao Peop
AC
le's Democratic Republic M L RAC
131 Cambodia M L RAC
132 Myanmar M L RAC
133 Bhutan M LM RAC
134 Comoros M L RAC
135 Ghana M L RAC
136 Pakistan M LM RAC
137 Mauritania M L RAC
138 Lesotho M LM
139 Congo M LM RPC
140 Bang
RPC
ladesh M L RPC
141 Swaziland M LM RPC
142 Nepal M L RPC
143 Madagascar M L RPC
144 Cameroon M LM RPC
145 Papua New Guinea M LM RPC
146 Haïti M L RPC
147 Sudan M LM RPC
148 Kenya M L RPC
149 Djibouti M LM RPC
150 Timor‐Leste M LM RPC
151 Zimbabwe M L RPC
152 Togo M L RPC
153 Yemen M L RPC
154 Uganda M L
155 Gam
RPC
bia M L RPC
156 Senegal L L RPC
157 Eritrea L L RPC
158 Nigeria L LM RPC
159 Tanzania (United Republic of) L L RPC
160 Guinea L L RPC




163 Benin L L RPC
164 Ma
RPC
lawi L L RPC
165 Zambia L L RPC
166 Côte d'Ivoire L LM RPC
167 Burundi L L RPC
168 Congo (Democratic Republic of the) L L RPC
169 Ethiopia L L RPC
170 Chad L L RPC
171 Central African Republic L L RPC
172 Mozambique L L RPC
173 Mali L L
174 Niger L LM RPC
175 Guinea‐Bissau L L RPC
176 Bur
RPC
kina Faso L L RPC
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Addendum 2-4: The types of organizations and corresponding coordination mechanisms 





Professional Bureaucracy : 
Standardization of Skills  




























Adhocracy : Mutual Adjustment 
(Applied to 1 on 1 working relationships or 
small sub-sets of simple or complex 
organizations) 
 
Machine Bureaucracy : Standardization of 
Work (Large organization) 
 
Divisional Structure : Standardization of 
Outputs (Very large organization) 
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Addendum 2-5: The overview of scores for cultural components in different countries, 
that were obtained by Hofstede.  
 
Country PDI UAI IDV MAS
Argentina 49 96 46 56
Australia 36 51 90 61
Austria 11 70 55 79
Belgium 65 94 75 54
Brazil 69 76 38 49
Canada 39 48 80 52
Chile 63 86 23 28
Colombia 67 80 13 64
Denmark 18 23 74 16
Finland 33 59 63 26
France 68 86 71 43
Great Britain 35 35 89 66
Germany (F.R.) 35 65 67 66
Greece 60 112 35 57
Hong Kong 68 29 25 57
India 77 40 48 56
Iran 58 59 41 43
Ireland 28 35 70 68
Israel 13 81 54 47
Italy 50 75 76 70
Japan 54 92 46 95
Mexico 81 82 30 69
Netherlands 38 53 80 14
Norway 31 50 69 8
New Zealand 22 49 79 58
Pakistan 55 70 14 50
Peru 64 87 16 42
Philippines 94 44 32 64
Portugal 63 104 27 31
South Africa 49 49 65 63
Singapore 74 8 20 48
Spain 57 86 51 42
Sweden 31 29 71 5
Switzerland 34 58 68 70
Taiwan 58 69 17 45
Thailand 64 64 20 34
Turkey 66 85 37 45
USA 40 46 91 62
Venezuela 81 76 12 73
Yugoslavia 76 88 27 21
Mean 52 64 50 50
Standard Deviation 20 24 25 20
Legend:
PDI: Power Distance Index
UAI: Uncertainty Avoidance Index
IDV: Individualism
MAS: Masculinity
USA: United States of America  
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Addendum 3-1-A: The introduction letter to the pilot-run questionnaire that was used for 




To : ……………………. 
…………………………. 
………………………….          
         
       Leo Versteynen 
 
        P.B. 35 
        2340 Beerse 
        Belgium 
 
 
        Beerse, August 18, 2008 
          
 
Dear Sir/Madam,     
 
The World’s Health inequity, especially for infectious diseases (mainly HIV/AIDS, 
tuberculosis and malaria), is gaining importance on the agenda of international assemblies 
of authorities, non-governmental organisations and drug-developers. Will the World be 
able to cope with the issue of the limited access to medicines in resource-poor countries 
(RPCs)? 
 
My name is Leo Versteynen. I am a student on the DBA programme (Doctor of Business 
Administration) at Bradford University, United Kingdom (Student no. 06023738), via 
TiasNimbas, a Business School located in The Netherlands. I am asking for your help for a 
doctoral research programme. 
 
The purpose of my research project is to find out which measures to increase 
access to life-saving drugs are most preferred by Health Authorities, Foundations & 
Non-Governmental Organisations (NGOs) and Drug Developers, Manufacturers or 
Distributors.  
 
A final questionnaire will be sent to 34 Health Authorities of countries with different 
rankings in the WHO Human Development Index (HDI). In these countries (countries that 
score “low” and “medium” but also countries that score “high” in the WHO-HDI), a number 
of Aid Foundations/Non-Governmental Organisations and Drug-Developers, 
Manufacturers or Distributors will also receive the questionnaire. 
 
This first initiative is a pilot run to validate the questionnaire and the process. The pilot 
study will run in countries, randomly selected and at one randomly chosen Global Aid 
Foundation. Based on the feedback, the questionnaire will be finalized and used for the 
full-blown survey. Therefore, I would appreciate to receive your marks for sections 1 to 8 
and  your comments on the content (under section 9a) and on the lay-out, the user-
friendliness and linguistic aspects (under section 9b) of the questionnaire. 
 
Although a lot of measures to increase access to life-saving medicines in resource-poor 
countries are described in the literature, so far there has been no attempt to find out which 
of the approaches are most preferred by the key stakeholders. The aim of my  
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research is to identify these most commonly preferred measures, assuming they will have 
the highest probability of success in the future.  
In this way, I hope to contribute to theoretical knowledge and actual management practice 
in the field of improvement of access to life-saving drugs in RPCs. 
 
Although my employer, Tibotec-Virco BVBA, located in Mechelen, Belgium, has paid part 
of the general subscription and tuition fees for my DBA programme at the University of 
Bradford, I am operating totally independent from my employer in setting up this survey, 
safeguarding and analysing the data and drawing conclusions.  
 
The ultimate outcomes of my research programme will be a doctoral thesis and a 
publication in a renowned journal. I guarantee that names of responding parties and 
organizations will remain anonymous in any written reports from my study and that your 
responses will be handled with the strictest confidentiality. 
  
I hereby assume that I can use your inputs for these reports under the above-described 
conditions of anonymity and confidentiality : no raw data will be published, only the 
analyses and conclusions. My employer will only have access to the two above-mentioned 
documents, just like anyone else, after they are finalized or published. 
 
Therefore, I sincerely invite you or one of your collaborators to complete this questionnaire 
and to return it to me by means of the “pre-addressed postage pre-paid” envelope. 
Completing the questionnaire, based on the guidance provided, should not take you longer 
than 30 minutes. I would be very grateful if you could put the filled out questionnaire in the 
ordinary post, within two weeks after receipt.  
 
To guide you in completing the questionnaire, I have enclosed a supportive document 
named “Guidance & Narrative”. It contains some instructions to complete the 
questionnaire, as well as descriptions of the surveyed measures by several renowned 
authors. 
 
After finalization of my research project, all returned completed questionnaires will be 
destroyed. 
 






Leo Versteynen   
 
P.B. 35  
2340 Beerse 
Belgium 
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Addendum 3-1-B: The pilot-run questionnaire that was used for this thesis. (English) 
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Addendum 3-1-B: The pilot-run questionnaire that was used for this thesis. (English) 
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Addendum 3-1-B: The pilot-run questionnaire that was used for this thesis. (English) 
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GUIDANCE AND NARRATIVE 
 
1. INSTRUCTIONS 
1.1 Please fill out the yellow sections 1 and (if applicable) 2, related to the type and size of your 
organization. 
 
1.2 Please mark for each statement the one response option that most appropriately corresponds 
with the extent of your agreement or disagreement with each statement. Your rating should reflect 
the opinion of your organization.  
 
Example : 
      
Fully Mainly Slightly Neither Agree Slightly Mainly Fully
Disagree Disagree Disagree Nor Disagree Agree Agree Agree
 
1.3 Please put the completed questionnaire in the regular mail by means of the enclosed “pre-
addressed & pre-paid” envelope, within two weeks of  receipt of the questionnaire. Thank you. 
 
1. BASIC DEFINITIONS 
 
-Access to medicines : availability of affordable medicines 
 
-Availability of medicines : in the scope of this research project, this term is restricted to the output 
side of the drug-development process and to the extent that facilities can provide the drugs that are 
prescribed. It does not relate to infrastructure of the local health care, the organization of public 
transportation to medical centres and the like. 
 
-Affordability of medicines : expressed as the number of days’ salary of the lowest-paid 
government worker to pay for a one month treatment with a particular medicine. 
 
2.  DESCRIPTIONS FOR APPROACHES MENTIONED IN THE 
QUESTIONNARIE 
 
(1) : Advanced market commitments (AMCs) (Derived from : Hollis, 2007:80) 
An advanced market commitment, proposed by Kremer and Glennerster and the Center for Global 
Development in 2004 and 2005, could be useful for certain types of pharmaceutical products, principally 
vaccines, to stimulate research by promising a subsidy of a fixed value per unit for a given number of 
units. 
 
(2) : Optional rewards based on therapeutic effect  (Derived from : Hollis, 2007:82-83) 
An optional reward system was proposed in 2005 by Hollis and Pogge, in which a sponsoring agency 
would pay rewards annually based on the therapeutic effectiveness of drugs for neglected diseases.  
 
(3) : Priority review voucher systems (Derived from : Ridley et al, 2006:313) 
This mechanism provides developers of treatments for neglected diseases with a priority review 
voucher. The voucher could save an average of one year of U.S. Food and Drug Administration (FDA) 
review time and be sold by the developer to the manufacturer of a blockbuster drug.  
 
(4) : Transferable intellectual property rights (prolonging exclusivity) (Derived from : Barton 
and Emanuel, 2007:2080) 
Prolonging exclusivity is granting firms longer periods of exclusivity on a blockbuster drug in return for 
developing new products of substantial developing-nation value. 
 
                      - 29 - 
          
(5) : Tax reliefs (Derived from : Gerhardsen, 2006:348) 
For example, the United Kingdom offers enhanced tax relief for R&D into vaccines or medicines for 
diseases that mainly affect developing countries, such as malaria, tuberculosis and HIV/AIDS. 
 
(6) : Re-location of R&D to low-cost countries (Derived from : Reddy and Sigurdson, 1997:344) 
Performing (some of) the strategic R&D in developing and East European countries in an effort to gain 
access to scientific personnel as well as to reduce R&D costs. 
 
(7) : Medical innovation prizes (Derived from : Gerhardsen, 2006:348) 
An alternative to the patent system and to raise R&D funding is the Medical Innovation Prize which has 
been put forward in a bill in the US Congress. Under the proposed legislation, new drugs would be 
treated as generics as soon as they receive regulatory approval and patent holders would be rewarded 
from a US$ 60-billion award fund for coming up with innovations for better health. The fund would 
receive 0.5% of US GDP every year. 
 
(8) : Breakthrough innovation to create a low-cost, high-quality business model (Derived from 
: Prahalad, 2006a:3; Prahalad, 2006b) 
Innovations that result in a product or service of world-class quality, achieving at least 90 percent cost 
reduction of a comparable product or service in the West, and which are scalable and affordable by the 
bottom of the economic pyramid, reaching people with the lowest levels of income in any given society. 
 
(9) : Public sector funding of Research and Development of medicines (Derived from : Kim, 
2007:7) 
An obvious method for improving access to patented drugs is to finance public pharmaceutical research. 
In this way, patented drugs can directly enter the public domain. The notion is that as more patented 
drugs are directly placed in the public domain, pharmaceutical companies would be forced to compete 
with similar drugs that are already being sold in the market as generics, thereby driving down prices. 
 
(10) : Disease burden incentive systems (Derived from : Ridley et al, 2006:317) 
As an example, the US Orphan Drug Act (ODA) of 1983 provides seven years of marketing exclusivity 
upon FDA approval. Second, drug makers can qualify for tax credits for up to half of their clinical 
testing expenses. Third, developers can receive modest FDA grant support to investigate treatments for 
rare diseases. Fourth, the FDA provides counselling regarding conditions for approval.  
 
(11) : Addressing the regulatory excess (Derived from : Farrugia, 2004:83) 
Systems of official regulation mandating standards and other measures are now coupled with voluntary 
standards adopted by industry bodies as additional features of a comprehensive nexus of arrangements 
contributing to product quality and risk minimization. “Addressing” means in this context simplification. 
 
(12) : Public-private partnerships (PPP) (Derived from : Hale et al, 2005:1058) 
Partnerships among global health organizations, pharmaceutical manufacturers, biotech firms, academia, 
and developing-world governments focusing on completing the development and distribution of drugs. 
 
(13) : Non-profit drug companies/non-profit medicine organization (Derived from : Hale et al, 
2005:1059) 
Operationally, a non-profit pharmaceutical company shares the core characteristics of classic public-
private partnerships (PPP) but differs from them in several ways. Its in-house R&D team is larger than 
that of a classic PPP, it tackles a wide variety of neglected diseases and can select the best development 
opportunities available in each, and it is not limited in the modality of treatment: drugs, vaccines, and 
diagnostics could be developed as needed. 
 
(14) : Global “Marshall plan” (Derived from : Yunker, 2004:1109) 
A very-large scale foreign development assistance program on the future development of the world 
economy with the potential to bring a dramatic reduction in world economic inequality, at the cost of 
only a very minor retardation in the economic growth of the rich countries. 
 
(15) : 0.5% of GNP by rich countries, to combat poverty in the resource-poor countries 
(Derived from : Sachs, 2005:299-301) 
Jeffrey Sachs has calculated that some $135 to $195 billion per year for the period 2005-2015 which is 
about 0.44 to 0.54 percent of the rich-world GNP each year during the forthcoming decade is needed, to 
eradicate extreme poverty in the world. The point is to bring the current average 0.25 percent of donor 
GNP to around 0.5% of donor GNP. 
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(16) : 0.1% of GNP dedicated to development of drugs for neglected diseases (Derived from : 
Gerhardsen, 2006:348)  
A WHO resolution (EB117 R13) sponsored by Brazil and Kenya, called for additional R&D funding for 
new vaccines and medicines for diseases that mainly affect developing countries as part of a new global 
framework on essential health research and development. It draws on a 2002 proposal for a Medical 
Research and Development Treaty by the non-governmental organization CPTech, which campaigns to 
improve access to medicines. The idea is that governments of rich countries raise funds for R&D on 
neglected diseases by allocating a portion of GNP (e.g. 0.1%). 
 
(17) : Infection prevention (including preventive medication) (Derived from : Mascarenhas et 
al, 2005:409) 
The drug companies, who grant voluntary licenses and accelerate generic production, exert pressure on 
local governments and on affected people and their families to do their part in preventing the disease by 
appropriate behaviour modifications. 
 
(18) : Subsidisation/reimbursement of drugs (Derived from : Henry and Lexchin, 2002:1591) 
Because of market forces, government subsidisation of the use of drugs in their communities is 
widespread. 
 
(19) : Price controls/reference pricing (Derived from : Henry and Lexchin, 2002:1591) 
-Price controls : governments generally want prices at levels that will not exceed their drug budget, but 
recognise that if they demand too low a price, companies might decide not to market a product, and 
could reduce local investment. 
-Reference pricing : assigns a drug to a group of products, which receive the same level of 
reimbursement. Drugs can be referenced on the basis of clinical performance, sometimes to the cheapest 
generic product. In such systems, innovative products can be priced somewhat closer to the average of 
the price in comparison countries, suggesting that this approach to pricing can reward advances in 
treatment. 
 
(20) : Compulsory licensing (Derived from : Wise, 2006:344) 
Compulsory licenses allow third parties to use an invention without the patent holder’s consent. For 
example, local pharmaceutical companies may obtain compulsory licenses to produce generic  
versions of patented medicines or to import generic versions of medicines from foreign manufacturers. 
 
(21) : Parallel importation / parallel trade (Derived from : Wise, 2006:343) 
Parallel import is the import and resale in a country, without the consent of the patent holder, of a 
patented product that has been legitimately put on the market of the exporting country. This means that 
drugs sold at a lower price in one country can be imported into another country where the same drug is 
sold at a higher price. 
 
(22) : Drug donation (Derived from : Henry and Lexchin, 2002:1590) 
Some companies have maintained excellent programmes of drug donation, e.g. some have given away 
well over 100 million treatments or have offered to supply a particular product free in particular 
countries. 
 
(23) : Patent donation (free licenses) (Derived from : Gerhardsen, 2006:348) 
Donation of patents to parties in resource-poor settings.  
 
(24) : Enterprise-level initiatives (Derived from : Katrak, 2004:316) 
This concept proposes enterprise-level measures (not only pharmaceutical enterprises, but companies of 
any kind) that could make medicines more affordable for their infected employees. One measure would 
be to provide free, or subsidised, medicines to the employees. Another measure would be to help 
infected employees by allowing them to continue to work, to avoid reduced income. 
 
(25) : Differential pricing/tiered pricing/discriminatory pricing (Derived from : Scherer and 
Watal, 2002:913-928) 
Differential pricing, tiered pricing, equity pricing or discriminatory pricing (e.g. Ramsey-Baumol-
Bradford pricing or simply Ramsey pricing) is a mechanism used by multinational pharmaceutical 
companies, under which prices are much lower in nations with low ability to pay and/or high price 
elasticities of demand than in wealthy nations. 
 
(26) : Voluntary discount pricing, beyond differential pricing (Derived from : Mascarenhas et 
al, 2005:407) 
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Price discounts offered by manufacturers, (often after intense and increasing pressure from protestors, 
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Addendum 3-2-A: The introduction letter of the full-run questionnaire that was used for 
this thesis. (English) 
 
To :             
  
       Leo Versteynen 
        P.B. 35 
        2340 Beerse 
        Belgium 
 
        Beerse, November 15, 2008. 
          
Dear Sir/Madam,     
 
The World’s Health inequity, especially for infectious diseases, is gaining importance on the agenda 
of international assemblies of authorities, non-governmental organisations and drug-developers. 
Will the World be able to cope with the issue of the limited access to medicines in resource-poor 
countries (RPCs)? 
 
My name is Leo Versteynen. I am a student on the DBA programme (Doctor of Business 
Administration) at Bradford University, United Kingdom (Student no. 06023738). I am requesting 
your help for a doctoral research programme. 
 
The purpose of my research project is to find out which measures to increase access to life-
saving drugs are preferred by Health Authorities, Foundations & Non-Governmental 
Organisations (NGOs) and Drug Developers (including medical branches of universities), 
Manufacturers or Distributors.  
Therefore, I am sending out this questionnaire to key stakeholders in approx. 50 countries with 
“High”, “Medium” or “Low” rankings in the WHO Human Development Index (HDI).  
 
I am running this particular questionnaire survey totally independently : I have complete freedom 
in setting up the survey, safeguarding and analysing the data and drawing conclusions. I guarantee 
that names of responding parties and organizations will remain anonymous in all written reports 
from my study and that your responses will be handled with the strictest confidentiality. The 
ultimate outcomes of my research programme will be included in my doctoral thesis and a 
publication in a renowned journal. Each organization that completes and returns the questionnaire 
will receive a free copy of my doctoral thesis script at the end of my study (2010). 
  
Therefore, I sincerely invite you or one of your associates to complete this questionnaire and to 
return it to me via the “pre-addressed postage pre-paid” envelope. Completing the questionnaire, 
based on the guidance document provided, should take less than 30 minutes. I would be very 
grateful if you would be so kind to mail the completed questionnaire in the ordinary post, within two 
weeks after receipt.  
 
In case you could advise me on other organizations in your country that would be interested and 
willing to complete this questionnaire, please let me know, so I can send them a copy. 
 





Leo Versteynen   
 
P.B. 35, 2340 Beerse, Belgium 
E-mail address : leopold.versteynen@pandora.be 
 
                      - 33 - 
          
Addendum 3-2-B: The full-run questionnaire that was used for this thesis. (English)  
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Addendum 3-2-B: The full-run questionnaire that was used for this thesis. (English)  
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Addendum 3-2-B: The full-run questionnaire that was used for this thesis. (English)  
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Addendum 3-2-C: The narrative of the full-run questionnaire that was used for this 
thesis. (English)  
 
    GUIDANCE AND NARRATIVE 
 
1.  INSTRUCTIONS 
1.1 Please fill out the yellow sections 1 and (if applicable) 2, related to the type and size of your organization. 
1.2 Please mark for each statement the one response option that most appropriately corresponds with the 
extent of your agreement or disagreement with each statement.   
Example : 
      
 
1.3 Please put the completed questionnaire in the regular mail by means of the enclosed “pre-addressed & 
pre-paid” envelope, within two weeks of  receipt of the questionnaire. Thank you. 
 
Fully Mainly Slightly Neither Agree Slightly Mainly Fully
Disagree Disagree Disagree Nor Disagree Agree Agree Agree
  2.  BASIC DEFINITIONS 
 
-Access to medicines : availability of affordable medicines 
-Availability of medicines : in the scope of this research project, this term is focussed on innovations in the 
drug-development process and to the extent that facilities can provide the drugs that are prescribed. It does 
not relate to infrastructure of the local health care, the organization of public transportation to medical centres 
and the like. 
-Affordability of medicines : expressed as the number of days’ salary of the lowest-paid government worker 
to pay for a one month treatment with a particular medicine. 
 
3.  DESCRIPTIONS FOR APPROACHES MENTIONED IN THE QUESTIONNARIE 
(1) : Advanced market commitments (AMCs) (Derived from : Hollis, 2007:80) 
An advanced market commitment, proposed by Kremer and Glennerster and the Center for Global 
Development in 2004 and 2005, could be useful for certain types of pharmaceutical products, principally 
vaccines, to stimulate research by promising a subsidy of a fixed value per unit for a given number of units. 
(2) : Optional rewards based on therapeutic effect  (Derived from : Hollis, 2007:82-83) 
An optional reward system was proposed in 2005 by Hollis and Pogge, in which a sponsoring agency would 
pay rewards annually based on the therapeutic effectiveness of drugs for neglected diseases.  
(3) : Priority review voucher systems (Derived from : Ridley et al, 2006:313) 
This mechanism provides developers of treatments for neglected diseases with a priority review voucher. The 
voucher could save an average of one year of U.S. Food and Drug Administration (FDA) review time and be 
sold by the developer to the manufacturer of a blockbuster drug.  
(4) : Transferable intellectual property rights (prolonging exclusivity) (Derived from : Barton and 
Emanuel, 2007:2080) 
Prolonging exclusivity is granting firms longer periods of exclusivity on a blockbuster drug in return for 
developing new products of substantial developing-nation value. 
(5) : Tax reliefs (Derived from : Gerhardsen, 2006:348) 
For example, the United Kingdom offers enhanced tax relief for R&D into vaccines or medicines for diseases 
that mainly affect developing countries, such as malaria, tuberculosis and HIV/AIDS. 
(6) : Re-location of R&D to low-cost countries (Derived from : Reddy and Sigurdson, 1997:344) 
Performing (some of) the strategic R&D in developing and East European countries in an effort to gain access 
to scientific personnel as well as to reduce R&D costs. 
(7) : Medical innovation prizes (Derived from : Gerhardsen, 2006:348) 
An alternative to the patent system and to raise R&D funding is the Medical Innovation Prize which has been 
put forward in a bill in the US Congress. Under the proposed legislation, new drugs would be treated as 
generics as soon as they receive regulatory approval and patent holders would be rewarded from a US$ 60-
billion award fund for coming up with innovations for better health. The fund would receive 0.5% of US 
GDP every year. 
(8) : Breakthrough innovation to create a low-cost, high-quality business model (Derived from : Prahalad, 
2006a:3; Prahalad, 2006b) 
Innovations that result in a product or service of world-class quality, achieving at least 90 percent cost 
reduction of a comparable product or service in the West, and which are scalable and affordable by the 
bottom of the economic pyramid, reaching people with the lowest levels of income in any given society. 
(9) : Public sector funding of Research and Development of medicines (Derived from : Kim, 2007:7) 
An obvious method for improving access to patented drugs is to finance public pharmaceutical research. In 
this way, patented drugs can directly enter the public domain. The notion is that as more patented drugs are 
directly placed in the public domain, pharmaceutical companies would be forced to compete with similar 
drugs that are already being sold in the market as generics, thereby driving down prices. 
(10) : Disease burden incentive systems (Derived from : Ridley et al, 2006:317) 
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As an example, the US Orphan Drug Act (ODA) of 1983 provides seven years of marketing exclusivity upon 
FDA approval. Second, drug makers can qualify for tax credits for up to half of their clinical testing expenses. 
Third, developers can receive modest FDA grant support to investigate treatments for rare diseases. Fourth, 
the FDA provides counselling regarding conditions for approval.  
(11) : Addressing the regulatory excess (Derived from : Farrugia, 2004:83) 
Systems of official regulation mandating standards and other measures are now coupled with voluntary 
standards adopted by industry bodies as additional features of a comprehensive nexus of arrangements 
contributing to product quality and risk minimization. “Addressing” means in this context simplification. 
(12) : Public-private partnerships (PPP) (Derived from : Hale et al, 2005:1058) 
Partnerships among global health organizations, pharmaceutical manufacturers, biotech firms, academia, and 
developing-world governments focusing on completing the development and distribution of drugs. 
(13) : Non-profit drug companies/non-profit medicine organization (Derived from : Hale et al, 
2005:1059) 
Operationally, a non-profit pharmaceutical company shares the core characteristics of classic public-private 
partnerships (PPP) but differs from them in several ways. Its in-house R&D team is larger than that of a 
classic PPP, it tackles a wide variety of neglected diseases and can select the best development opportunities 
available in each, and it is not limited in the modality of treatment: drugs, vaccines, and diagnostics could be 
developed as needed. 
(14) : Global “Marshall plan” (Derived from : Yunker, 2004:1109) 
A very-large scale foreign development assistance program on the future development of the world economy 
with the potential to bring a dramatic reduction in world economic inequality, at the cost of only a very minor 
retardation in the economic growth of the rich countries. 
(15) : 0.5% of GNP by rich countries, to combat poverty in the resource-poor countries (Derived from : 
Sachs, 2005:299-301) 
Jeffrey Sachs has calculated that some $135 to $195 billion per year for the period 2005-2015 which is about 
0.44 to 0.54 percent of the rich-world GNP each year during the forthcoming decade is needed, to eradicate 
extreme poverty in the world. The point is to bring the current average 0.25 percent of donor GNP to around 
0.5% of donor GNP. 
(16) : 0.1% of GNP dedicated to development of drugs for neglected diseases (Derived from : 
Gerhardsen, 2006:348)  
A WHO resolution (EB117 R13) sponsored by Brazil and Kenya, called for additional R&D funding for new 
vaccines and medicines for diseases that mainly affect developing countries as part of a new global 
framework on essential health research and development. It draws on a 2002 proposal for a Medical Research 
and Development Treaty by the non-governmental organization CPTech, which campaigns to improve access 
to medicines. The idea is that governments of rich countries raise funds for R&D on neglected diseases by 
allocating a portion of GNP (e.g. 0.1%). 
(17) : Infection prevention (including preventive medication) (Derived from : Mascarenhas et al, 
2005:409) 
The drug companies, who grant voluntary licenses and accelerate generic production, exert pressure on local 
governments and on affected people and their families to do their part in preventing the disease by 
appropriate behaviour modifications. 
(18) : Subsidisation/reimbursement of drugs (Derived from : Henry and Lexchin, 2002:1591) 
Because of market forces, government subsidisation of the use of drugs in their communities is widespread. 
(19) : Price controls/reference pricing (Derived from : Henry and Lexchin, 2002:1591) 
-Price controls : governments generally want prices at levels that will not exceed their drug budget, but 
recognise that if they demand too low a price, companies might decide not to market a product, and could 
reduce local investment. 
-Reference pricing : assigns a drug to a group of products, which receive the same level of reimbursement. 
Drugs can be referenced on the basis of clinical performance, sometimes to the cheapest generic product. In 
such systems, innovative products can be priced somewhat closer to the average of the price in comparison 
countries, suggesting that this approach can reward advances in treatment. 
(20) : Compulsory licensing (Derived from : Wise, 2006:344) 
Compulsory licenses allow third parties to use an invention without the patent holder’s consent. For example, 
local pharmaceutical companies may obtain compulsory licenses to produce generic  
versions of patented medicines or to import generic versions of medicines from foreign manufacturers. 
(21) : Parallel importation / parallel trade (Derived from : Wise, 2006:343) 
Parallel import is the import and resale in a country, without the consent of the patent holder, of a patented 
product that has been legitimately put on the market of the exporting country. This means that drugs sold at a 
lower price in one country can be imported into another country where the same drug is sold (=availability), 
but at a higher price. 
(22) : Drug donation (Derived from : Henry and Lexchin, 2002:1590) 
Some companies have maintained excellent programmes of drug donation, e.g. some have given away well 
over 100 million treatments or have offered to supply a particular product free in particular countries. 
(23) : Patent donation (free licenses) (Derived from : Gerhardsen, 2006:348) 
Donation of patents to parties in resource-poor settings.  
(24) : Enterprise-level initiatives (Derived from : Katrak, 2004:316) 
This concept proposes enterprise-level measures (not only pharmaceutical enterprises, but companies of any 
kind) that could make medicines more affordable for their infected employees. One measure would be to 
provide free, or subsidised, medicines to the employees. Another measure would be to help infected 
employees by allowing them to continue to work, to avoid reduced income. 
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(25) : Differential pricing/tiered pricing/discriminatory pricing (Derived from : Scherer and Watal, 
2002:913-928) 
Differential pricing, tiered pricing, equity pricing or discriminatory pricing (e.g. Ramsey-Baumol-Bradford 
pricing or simply Ramsey pricing) is a mechanism used by multinational pharmaceutical companies, under 
which prices are much lower in nations with low ability to pay and/or high price elasticities of demand than in 
wealthy nations. 
(26) : Voluntary discount pricing, beyond differential pricing (Derived from : Mascarenhas et al, 
2005:407) 
Price discounts offered by manufacturers, (often after intense and increasing pressure from protestors, 
including policy makers), to provide a common solution in distributing life-saving drugs to developing 
countries. 
 
4.  BIBLIOGRAPHY 
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Addendum 3-3-A: The introduction letter of the pilot-run questionnaire that was used for 
this thesis. (French) 
 
 
A : ……………………. 
…………………………. 
…………………………. 
          
         Leo Versteynen 
 
         B.P. 35 
         2340 Beerse 
         Belgique 
 
 
         Beerse, le 18 août 2008. 
 
           
Madame, Monsieur,     
 
Les injustices mondiales en matière de santé, en particulier dans le domaine des maladies 
infectieuses (principalement le VIH/SIDA, la tuberculose et la malaria), occupent une place 
de plus en plus importante à l'ordre de jour des assemblées internationales d'autorités, 
d'organisations non gouvernementales et de sociétés pharmaceutiques. Le monde pourra-
t-il faire face au problème de l'accès limité aux médicaments dans les pays pauvres en 
ressources (PPR) ? 
 
Je m'appelle Leo Versteynen. Je suis un étudiant inscrit au programme DBA (Doctor of 
Business Administration) de l'Université de Bradford, au Royaume-Uni (Numéro d’étudiant 
06023738), dont je suis les cours à la TiasNimbas, une école de commerce des Pays-Bas. 
Je sollicite votre aide dans le cadre de ma thèse de doctorat. 
 
Mon projet de recherche a pour objectif d'identifier les mesures d'amélioration de 
l'accès aux médicaments d'importance vitale privilégiées par les autorités 
sanitaires, les fondations et organisations non gouvernementales (ONG), ainsi que 
par les développeurs, fabricants et distributeurs de produits pharmaceutiques.  
 
Un questionnaire final sera transmis à 34 autorités sanitaires de pays présentant un 
classement différent à l'indice du développement humain (IDH) de l'OMS. Dans ces pays 
(dont le classement peut être bas, moyen ou élevé dans l'IDH), plusieurs fondations 
d'aide/organisations non gouvernementales et développeurs, fabricants ou distributeurs 
de produits pharmaceutiques recevront également ce questionnaire. 
 
Cette première initiative constitue une phase pilote visant à valider le questionnaire et le 
processus. L'étude pilote portera sur des pays et une fondation d'aide mondiale, tous 
choisis de manière aléatoire. Le questionnaire sera ensuite finalisé sur la base des 
commentaires reçus et utilisé pour l'étude proprement dite. Je vous invite donc à me faire 
part de vos marques sur les sections 1 à 8 et vos réactions concernant son contenu (à la 
section 9a), ainsi que sur sa mise en page, sa convivialité et son aspect linguistique (à la 
section 9b). 
 
Bien qu'une grande partie des mesures d'amélioration de l'accès aux médicaments 
d'importance vitale dans les pays pauvres en ressources soit décrite dans la littérature, les 
acteurs clés n'ont encore jamais été interrogés sur leurs préférences en la matière. Mes 
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recherches ont pour objectif d'identifier les mesures privilégiées, en supposant qu'elles 
présentent le potentiel de réussite le plus élevé pour l'avenir.  
J'espère pouvoir ainsi contribuer aux connaissances théoriques et aux méthodes de 
gestion pratiques en vue d'améliorer l'accès aux médicaments d'importance vitale dans 
les PPR. 
 
Bien que mon employeur, Tibotec-Virco BVBA, établi à Malines, en Belgique, ait payé une 
partie des frais d'inscription et de scolarité relatifs à ma participation au programme DBA 
de l'Université de Bradford, je travaille en toute indépendance en ce qui concerne la mise 
en place de cette étude, la préservation et l'analyse des données, ainsi que la rédaction 
des conclusions.  
 
Mon programme de recherche aura pour finalité une thèse de doctorat et une publication 
dans une revue réputée. Je garantis que les organisations et parties interrogées resteront 
anonymes dans tous les rapports écrits reposant sur mon étude et que vos réponses 
seront traitées dans le respect le plus strict des règles de confidentialité. 
  
J'espère ainsi pouvoir utiliser vos contributions pour ces rapports dans les conditions 
d'anonymat et de confidentialité susmentionnées : aucune donnée brute ne sera publiée, 
seules les analyses et conclusions seront rendues publiques. Mon employeur n'aura ainsi 
accès qu'aux deux documents susmentionnés, comme tout autre tiers, après leur 
finalisation ou leur publication. 
 
Je vous invite donc, ou l'un de vos collaborateurs, à ce compléter ce questionnaire et à 
me le renvoyer à l'aide de l'enveloppe "préaffranchie" jointe. Répondre à ce questionnaire, 
sur la base des indications fournies, ne doit pas prendre plus de 30 minutes. Je vous 
serais très reconnaissant de bien vouloir poster le questionnaire complété par courrier 
ordinaire dans les deux semaines suivant sa réception.  
 
Pour vous aider à remplir le questionnaire, j'ai joint un document d'accompagnement 
intitulé "Indications et Explications". Il contient quelques instructions permettant de 
compléter le questionnaire, ainsi que des descriptions des mesures étudiées, émanant de 
plusieurs auteurs réputés. 
 
Après finalisation de mon projet de recherche, tous les questionnaires complétés seront 
détruits. 
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Addendum 3-3-B:The pilot-run questionnaire that was used for this thesis. (French)  
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Addendum 3-3-B: The pilot-run questionnaire that was used for this thesis. (French)  
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Addendum 3-3-B:The pilot-run questionnaire that was used this thesis. (French)  
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Addendum 3-3-C: The na at was used for this rrative of the pilot-run questionnaire th
thesis. (French) 
 
INDICATIONS ET EXPLICATIONS 
1.  INSTRUCTIONS 
 
1.1 Complétez les sections jaunes 1 et (le cas échéant) 2 concernant le type et la taille de votre 
1.2 Pour chaque énoncé, cochez la réponse unique
organisation. 
 
 qui correspond le mieux à votre opinion. Votre note 
doit refléter la position de votre organisation.  
 
Exemple :      
Pas du tout Plutôt en Légèrement Sans Assez Plutôt Totalement
d'accord désaccord en désaccord opinion d'accord d'accord d'accord
 
1.3 Postez le questionnaire complété par courrier ordinaire à l'aide de l'env
fournie dans les deux semaines suivant sa réception. Merci. 
eloppe "préaffranchie" 
 
2. DEFINITIONS DE BASE 
 
-Accès aux médicaments : disponibilité des médicaments à prix abordable 
 
-Disponibilité des médicaments : dans le cadre de ce projet de recherche, ce terme est limité à 
aux, l'organisation des transports publics vers les centres médicaux, etc. 
loyé 
l'aspect "résultats" du processus de développement de médicaments et à la mesure dans laquelle les 
centres peuvent fournir les médicaments prescrits. Il ne concerne pas l'infrastructure des soins de 
santé loc
 
- Abordabilité des médicaments : exprimée en nombre de jours de salaires de l'emp
gouvernemental le moins payé nécessaires pour payer un mois de traitement avec un médicament 
donné. 
 
3.  DESCRIPTIONS DES APPROCHES MENTIONNEES DANS LE QUESTIONNARIE 
 
(1) : Engagements avancés du marché (Advanced market commitments - AMC) (d'après Hollis, 
2007:80) 
n engagement avancé du marché, U proposé par Kremer et Glennerster et le Center for Global 
utiques, en 
ives en fonction de l'effet thérapeutique
Development en 2004 et 2005, pourrait être utile pour certains types de produits pharmace
particulier les vaccins, afin de stimuler la recherche en promettant une subvention d'une valeur fixe par 
unité pour un nombre donné d'unités. 
 
2) : Primes facultat(  (d'après Hollis, 2007:82-83) 
quel un organisme Un système de primes facultatives a été proposé en 2005 par Hollis et Pogge, selon le
promoteur verserait des primes annuelles basées sur l'efficacité thérapeutique de médicaments pour des 
maladies négligées.  
 
(3) : Systèmes de bons pour traitement prioritaire (d'après Ridley et al, 2006:313) 
stème fournit un bon pour traiteCe sy ment prioritaire aux développeurs de traitements pour des maladies 
dministration (FDA) et pourrait ensuite être vendu par le développeur au 
négligées, qui permettrait de réduire d'un an en moyenne le délai nécessaire à l'examen du médicament 
par la Food and Drug A
fabricant d'un médicament vedette.  
 
(4) : Droits de propriété intellectuelle transférables (prolongation de l'exclusivité) (d'après Barton 
 Emanuel, 2007:2080) et
La prolongation de l'exclusivité consiste à accorder aux entreprises une période d'exclusivité plus longue 
sur un médicament vedette en échange du développement de nouveaux produits présentant un grand 
intérêt pour les pays en développement. 
 
(5) : Allègement fiscal (d'après Gerhardsen, 2006:348) 
nts pour les maladies affectant principalement les pays en développement, telles que la 
malaria, la tuberculose et le VIH/SIDA. 
Par exemple, le Royaume-Uni offre un allègement fiscal accru pour la R&D concernant les vaccins ou 
les traiteme
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(6) : Délocalisation de la R&D dans des pays à faibles prix de revient (d'après Reddy et Sigurdson, 
1997:344) 
L'exécution de (certaines des) tâches de R&D stratégiques dans des pays en développement et en Europe 
de l'Est vise à accéder au personnel scientifique et à réduire les coûts de R&D. 
 
(7) : Prix d'innovation médicale (d'après Gerhardsen, 2006:348) 
Alternative au système de brevet, visant à accroître le financement de la R&D, le Prix d'innovation 
médicale a fait l'objet d'un projet de loi présenté au Congrès américain. Dans le cadre de la proposition 
de législation, de nouveaux médicaments seraient considérés comme génériques dès leur homologation 
et les détenteurs de brevet recevraient une somme de 60 milliards de dollars pour la découverte d'une 
innovation dans les soins de santé. Le fonds se verrait attribuer chaque année 0,5 % du PIB des Etats-
Unis. 
 
(8) : Innovation permettant la création d'un modèle commercial à faible coût et qualité élevée 
(d'après Prahalad, 2006a:3; Prahalad, 2006b) 
Innovations permettant de proposer un produit ou service de qualité mondiale tout en assurant une 
réduction d'au moins 90 % des coûts par rapport à un produit ou service comparable en Occident et en 
ersonnes les plus démunies de toute société. 
étant modulables et abordables pour les populations situées en bas de la pyramide économique, afin de 
rester accessibles aux p
 
(9) : Financement par le secteur public de la recherche et du développement de médicaments 
(d'après Kim, 2007:7) 
Le financement public de la recherche pharmaceutique constitue une méthode évidente pour améliorer 
l'accès aux médicaments brevetés, qui peuvent ainsi entrer directement dans le domaine public. A 
mesure qu'un nombre croissant de médicaments brevetés sont directement placés dans le domaine 
ec des public, les entreprises pharmaceutiques seraient ainsi contraintes d'entrer en concurrence av
produits similaires déjà commercialisés comme génériques, ce qui tirerait les prix vers le bas. 
 
(10) : Systèmes d'incitation basés sur la charge de morbidité (d'après Ridley et al, 2006:317) 
Par exemple, la loi américaine de 1983 sur les médicaments orphelins (Orphan Drug Act - ODA) assure 
sept ans d'exclusivité commerciale à compter de l'approbation par la FDA. Ensuite, les fabricants de 
médicaments peuvent bénéficier d'un dégrèvement fiscal à hauteur de la moitié de leurs frais d'essais 
cliniques. Alors, les développeurs peuvent recevoir une modeste subvention d'aide de la FDA afin de 
in, la FDA fournit des mener des recherches concernant des traitements pour des maladies rares. Enf
conseils concernant les conditions d'approbation.  
 
(11) : L’adaptation de l'excès de réglementation (d'après Farrugia, 2004:83) 
Les systèmes de réglementation officiels exigeant des normes et d'autres mesures sont désormais 
associés aux normes volontairement adoptées par les entités industrielles dans le cadre d'un réseau 
ion des risques. « Adaptation » complet d'accords contribuant à la qualité des produits et à la minimisat
dans ce contexte signifie la simplification. 
 
(12) : Partenariats public-privé (PPP) (d'après Hale et al, 2005:1058) 
Partenariats entre des organisations mondiales de la santé, des fabricants de produits pharmaceutiques, 
omotion du développement et de la distribution de médicaments. 
des sociétés de biotechnologie, le monde universitaire et des gouvernements de pays en développement 
axés sur la pr
 
(13) : Organisations médicales/sociétés pharmaceutiques à but non lucratif (d'après Hale et al, 
2005:1059) 
D'un point de vue opérationnel, une société pharmaceutique à but non lucratif possède les 
caractéristiques de base d'un partenariat public-privé (PPP) classique, bien qu'elle présente plusieurs 
particularités. Son équipe de R&D interne est en effet plus grande que celle d'un PPP classique, elle se 
acre à une grande variété de maladies négligées et peut choisir les meilleures oppocons rtunités de 
tion des modalités de traitement : des développement disponibles dans chaque domaine, sans limita
médicaments, vaccins et outils de diagnostic peuvent ainsi être développés selon les besoins. 
 
(14) : "Plan Marshall" mondial (d'après Yunker, 2004:1109) 
Programme d'assistance au développement étranger à très grande échelle pour le développement futur de 
ce économique des pays riches. 
l'économie mondiale, susceptible d'entraîner une réduction considérable des injustices économiques 
mondiales, au prix d'un retard très mineur de la croissan
 
(15) : Attribution de 0,5 % du PNB des pays riches à la lutte contre la pauvreté dans les pays 
pauvres en ressources (d'après Sachs, 2005:299-301) 
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Jeffrey Sachs a calculé qu'environ 135 à 195 milliards de dollars seraient nécessaires chaque année entre 
2005 et 2015 (soit environ 0,44 à 0,54 % du PIB annuel des pays riches pendant la décennie à venir) 
pour éradiquer la pauvreté extrême dans le monde. L'objectif est de faire passer le pourcentage de PNB 
contribué de 0,25 à 0,5 %. 
 
(16) : Attribution de 0,1 % du PNB au développement de médicaments pour les maladies négligées 
(d'après Gerhardsen, 2006:348)  
Une résolution de l'OMS (EB117 R13) parrainée par le Brésil et le Kenya réclamait un financement 
accru de la R&D concernant les nouveaux vaccins et les traitements pour des maladies affectant 
principalement les pays en développement dans le cadre d'un nouveau contexte mondial sur la recherche 
et le développement essentiels en matière de santé. Elle repose sur une proposition de Traité relatif à la 
recherche et au développement dans le domaine médical, émise en 2002 par l'organisation non 
gouvernementale CPTech, qui lutte pour améliorer l'accès aux médicaments. Selon cette proposition, les 
gouvernements des pays riches rassembleraient des fonds pour la R&D sur les maladies négligées en y 
attribuant un pourcentage de leur PNB (p. ex. 0,1 %). 
 
(17) : Prévention de l'infection (notamment par des traitements prophylactiques) (d'après 
Mascarenhas et al, 2005:409) 
Les sociétés pharmaceutiques, qui octroient des licences volontaires et accélèrent la production de 
médicaments génériques, exercent une pression sur les gouvernements locaux, ainsi que sur les 
nt 
nt de médicaments
personnes touchées et leur famille, afin de les engager à participer à l'effort de prévention en modifia
leur comportement. 
 
(18) : Subventionnement/rembourseme  (d'après Henry et Lexchin, 2002:1591) 
médicaments En raison des forces du marché, le subventionnement gouvernemental de l'utilisation de 
dans la communauté locale est répandu. 
 
(19) : Réglementation des prix/prix de référence (d'après Henry et Lexchin, 2002:1591) 
-Réglementation des prix : les gouvernements souhaitent généralement que les prix restent à un niveau 
compatible avec leur budget pharmaceutique, tout en sachant que s'ils exigent un prix trop bas, les 
sociétés pourraient renoncer à commercialiser un produit et réduire les investissements locaux. 
-Prix de référence : classe le médicament dans un groupe de produits, auquel est attribué le même niveau 
de remboursement. La référence des médicaments peut dépendre de leurs performances cliniques ou 
parfois de leur comparaison avec le produit générique le moins cher. Dans ces systèmes, le prix de 
e des prix dans les pays de comparaison, ce qui produits novateurs peut être plus proche de la moyenn
indique que cette approche tarifaire pourrait récompenser les innovations thérapeutiques. 
 
(20) : Licences obligatoires (d'après Wise, 2006:344) 
Les licences obligatoires permettent à des tiers d'utiliser une invention sans l'autorisation du détenteur du 
brevet. Par exemple, les entreprises pharmaceutiques locales peuvent obtenir des licences obligatoires 
ur l'importation de versions pour la production de versions génériques de médicaments brevetés ou po
génériques des médicaments de sociétés étrangères. 
 
(21) : Importation/commerce parallèle (d'après Wise, 2006:343) 
L'importation parallèle désigne l'importation et la revente dans un pays, sans l'autorisation du détenteur 
du brevet, d'un produit breveté qui a été légitimement commercialisé dans le pays d'exportation. En 
ays peuvent être importés dans un d'autres termes, des médicaments vendus à moindre prix dans un p
autre pays, où ils seront vendus à un prix supérieur. 
 
(22) : Don de médicaments (d'après Henry et Lexchin, 2002:1590) 
Certaines sociétés organisent d'excellents programmes de dons de médicaments, p. ex. certaines ont fait 
'un certain traitement dans don de plus de 100 millions de traitements ou offert la fourniture gratuite d
certains pays. 
 
(23) : Don de brevets (licences gratuites) (d'après Gerhardsen, 2006:348) 
Dons de brevets à des parties actives dans des pays pauvres en ressources.  
 
(24) : Initiatives de niveau d'entreprise (d'après Katrak, 2004:316) 
Ce concept propose des mesures à l'échelle de l'entreprise (de sociétés de toutes sortes, pas seulement de 
firmes pharmaceutiques) qui permettent de rendre les médicaments plus accessibles pour leurs employés 
atteints. Un exemple de mesure pourrait être la fourniture de médicaments gratuits ou subventionnés aux 
 
employés. Un autre exemple pourrait constituer à aider les employés atteints en leur permettant de 
continuer à travailler, afin d'éviter une baisse des revenus. 
                      - 47 - 
          
(25) : Prix différentiels/graduation des prix/prix de faveur (d'après Scherer et Watal, 2002:913-928) 
Le mécanisme de prix différentiels, de graduation des prix, de prix équitables ou de prix de faveur (p. 
ex. discrimination à la Ramsey-Baumol-Bradford ou tout simplement prix de Ramsey), utilisé par les 
entreprises pharmaceutiques multinationales, applique, dans les pays dont la capacité de paiement est 
limitée et/ou présentant une grande élasticité de la demande par rapport au prix, des prix nettement 
inférieurs à ceux des pays riches. 
 
(26) : Remise de prix volontaire, au-delà des prix différentiels (d'après Mascarenhas et al, 2005:407) 
Remises de prix offertes par les fabricants, souvent après une pression intense et croissante émanant de 
contestataires, notamment des décideurs, afin de proposer une solution commune pour la distribution de 
édicaments d'importance vitale dans les pays en développement. m
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Addendum 3-4-A: The introduction letter of the full-run questionnaire that was used for 
this thesis. (French)  
 
A :      
        Leo Versteynen 
        B.P. 35 
        2340 Beerse 
        Belgique 
 
        Beerse, le 15 novembre 2008. 
 
           
Madame, Monsieur,     
 
Les injustices mondiales en matière de santé, en particulier dans le domaine des maladies 
infectieuses, occupent une place de plus en plus importante à l'ordre de jour des assemblées 
internationales d'autorités, d'organisations non gouvernementales et de sociétés pharmaceutiques. 
Le monde pourra-t-il faire face au problème de l'accès limité aux médicaments dans les pays 
pauvres en ressources (PPR) ? 
 
Je m'appelle Leo Versteynen. Je suis un étudiant inscrit au programme DBA (Doctor of Business 
Administration) de l'Université de Bradford, au Royaume-Uni (Numéro d’étudiant 06023738). Je 
sollicite votre aide dans le cadre de ma thèse de doctorat. 
 
Mon projet de recherche a pour objectif d'identifier les mesures d'amélioration de l'accès 
aux médicaments d'importance vitale privilégiées par les autorités sanitaires, les fondations 
et organisations non gouvernementales (ONG), ainsi que par les développeurs (inclus les 
facultés universitaires de médecine), fabricants et distributeurs de produits pharmaceutiques.  
Pour ça, je suis en train de transmettre ce questionnaire à ces parties dans env. 50 pays avec 
classement « élevé », « moyen » ou « bas » à l’indice du développement humain (IDH) de l’OMS.  
 
Avec ce questionnaire particulier, je travaille en toute indépendance : j’ai toute liberté en ce qui 
concerne la mise en place de cette étude, la préservation et l'analyse des données, ainsi que la 
rédaction des conclusions. Je garantis que les organisations et parties interrogées resteront 
anonymes dans tous les rapports écrits reposant sur mon étude et que vos réponses seront 
traitées dans le respect le plus strict des règles de confidentialité. 
 
Les conclusions finales de mon programme de recherche seront inclus dans une thèse de doctorat 
et une publication dans une revue réputée. Chaque organisation qui complète et renvoie ce 
questionnaire recevra une copie gratuite du texte de ma thèse de doctorat à la fin de ma 
étude (2010). 
  
Je vous invite donc, ou l'un de vos collaborateurs, à ce compléter ce questionnaire et à me le 
renvoyer à l'aide de l'enveloppe "préaffranchie" jointe. Répondre à ce questionnaire, sur la base 
des indications fournies, prend moins de 30 minutes. Je vous serais très reconnaissant de bien 
vouloir poster le questionnaire complété par courrier ordinaire dans les deux semaines suivant sa 
réception.  
 
Si vous pourriez me conseiller sur d'autres organisations dans votre pays qui seraient intéressées 
et bienveillantes remplir ce questionnaire, faites-le moi savoir, ainsi je peut leur envoyer une copie. 
 






B.P. 35, 2340 Beerse, Belgique 
Adresse e-mail : leopold.versteynen@pandora.be 
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Addendum 3-4-B: The full-run questionnaire that was used for this thesis. (French)  
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Addendum 3-4-B: The full-run questionnaire that was used for this thesis. (French)  
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Addendum 3-4-B: The full-run questionnaire that was used for this thesis. (French)  
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Addendum 3-4-C: The narrative of the full-run questionnaire that was used for this 
thesis. (French)  
 
    INDICATIONS ET EXPLICATIONS 
 
1.  INSTRUCTIONS 
1.1 Complétez les sections jaunes 1 et (le cas échéant) 2 concernant le type et la taille de votre organisation. 
1.2 Pour chaque énoncé, cochez la réponse unique qui correspond le mieux à votre opinion.  
 
Exemple : 
      
Pas du tout Plutôt en Légèrement Sans Assez Plutôt Totalement
d'accord désaccord en désaccord opinion d'accord d'accord d'accord
 
1.3 Postez le questionnaire complété par courrier ordinaire à l'aide de l'enveloppe "préaffranchie" fournie 
dans les deux semaines suivant sa réception. Merci. 
 
    2.  DEFINITIONS DE BASE 
-Accès aux médicaments : disponibilité des médicaments à prix abordable  
-Disponibilité des médicaments : dans le cadre de ce projet de recherche, ce terme est dirigé sur les 
innovations du processus de développement de médicaments et à la mesure dans laquelle les centres peuvent 
fournir les médicaments prescrits. Il ne concerne pas l'infrastructure des soins de santé locaux, l'organisation 
des transports publics vers les centres médicaux, etc. 
-Abordabilité des médicaments : exprimée en nombre de jours de salaires de l'employé gouvernemental le 
moins payé nécessaires pour payer un mois de traitement avec un médicament donné. 
 
3.  DESCRIPTIONS DES APPROCHES MENTIONNEES DANS LE QUESTIONNARIE 
(1) : Engagements avancés du marché (Advanced market commitments - AMC) (d'après Hollis, 
2007:80) 
Un engagement avancé du marché, proposé par Kremer et Glennerster et le Center for Global Development 
en 2004 et 2005, pourrait être utile pour certains types de produits pharmaceutiques, en particulier les vaccins, 
afin de stimuler la recherche en promettant une subvention d'une valeur fixe par unité pour un nombre donné 
d'unités. 
(2) : Primes facultatives en fonction de l'effet thérapeutique (d'après Hollis, 2007:82-83) 
Un système de primes facultatives a été proposé en 2005 par Hollis et Pogge, selon lequel un organisme 
promoteur verserait des primes annuelles basées sur l'efficacité thérapeutique de médicaments pour des 
maladies négligées.  
(3) : Systèmes de bons pour traitement prioritaire (d'après Ridley et al, 2006:313) 
Ce système fournit un bon pour traitement prioritaire aux développeurs de traitements pour des maladies 
négligées, qui permettrait de réduire d'un an en moyenne le délai nécessaire à l'examen du médicament par la 
Food and Drug Administration (FDA) et pourrait ensuite être vendu par le développeur au fabricant d'un 
médicament vedette.  
(4) : Droits de propriété intellectuelle transférables (prolongation de l'exclusivité) (d'après Barton et 
Emanuel, 2007:2080) 
La prolongation de l'exclusivité consiste à accorder aux entreprises une période d'exclusivité plus longue sur 
un médicament vedette en échange du développement de nouveaux produits présentant un grand intérêt pour 
les pays en développement. 
(5) : Allègement fiscal (d'après Gerhardsen, 2006:348) 
Par exemple, le Royaume-Uni offre un allègement fiscal accru pour la R&D concernant les vaccins ou les 
traitements pour les maladies affectant principalement les pays en développement, telles que la malaria, la 
tuberculose et le VIH/SIDA. 
(6) : Délocalisation de la R&D dans des pays à faibles prix de revient (d'après Reddy et Sigurdson, 
1997:344) 
L'exécution de (certaines des) tâches de R&D stratégiques dans des pays en développement et en Europe de 
l'Est vise à accéder au personnel scientifique et à réduire les coûts de R&D. 
(7) : Prix d'innovation médicale (d'après Gerhardsen, 2006:348) 
Alternative au système de brevet, visant à accroître le financement de la R&D, le Prix d'innovation médicale a 
fait l'objet d'un projet de loi présenté au Congrès américain. Dans le cadre de la proposition de législation, de 
nouveaux médicaments seraient considérés comme génériques dès leur homologation et les détenteurs de 
brevet recevraient une somme de 60 milliards de dollars pour la découverte d'une innovation dans les soins de 
santé. Le fonds se verrait attribuer chaque année 0,5 % du PIB des Etats-Unis. 
(8) : Innovation permettant la création d'un modèle commercial à faible coût et qualité élevée (d'après 
Prahalad, 2006) 
Innovations permettant de proposer un produit ou service de qualité mondiale tout en assurant une réduction 
d'au moins 90 % des coûts par rapport à un produit ou service comparable en Occident et en étant modulables 
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et abordables pour les populations situées en bas de la pyramide économique, afin de rester accessibles aux 
personnes les plus démunies de toute société. 
(9) : Financement par le secteur public de la recherche et du développement de médicaments (d'après 
Kim, 2007:7) 
Le financement public de la recherche pharmaceutique constitue une méthode évidente pour améliorer l'accès 
aux médicaments brevetés, qui peuvent ainsi entrer directement dans le domaine public. A mesure qu'un 
nombre croissant de médicaments brevetés sont directement placés dans le domaine public, les entreprises 
pharmaceutiques seraient ainsi contraintes d'entrer en concurrence avec des produits similaires déjà 
commercialisés comme génériques, ce qui tirerait les prix vers le bas. 
(10) : Systèmes d'incitation basés sur la charge de morbidité (d'après Ridley et al, 2006:317) 
Par exemple, la loi américaine de 1983 sur les médicaments orphelins (Orphan Drug Act - ODA) assure sept 
ans d'exclusivité commerciale à compter de l'approbation par la FDA. Ensuite, les fabricants de médicaments 
peuvent bénéficier d'un dégrèvement fiscal à hauteur de la moitié de leurs frais d'essais cliniques. Alors, les 
développeurs peuvent recevoir une modeste subvention d'aide de la FDA afin de mener des recherches 
concernant des traitements pour des maladies rares. Enfin, la FDA fournit des conseils concernant les 
conditions d'approbation.  
(11) : L’adaptation de l'excès de réglementation (d'après Farrugia, 2004:83) 
Les systèmes de réglementation officiels exigeant des normes et d'autres mesures sont désormais associés aux 
normes volontairement adoptées par les entités industrielles dans le cadre d'un réseau complet d'accords 
contribuant à la qualité des produits et à la minimisation des risques. « Adaptation » dans ce contexte signifie 
la simplification. 
(12) : Partenariats public-privé (PPP) (d'après Hale et al, 2005:1058) 
Partenariats entre des organisations mondiales de la santé, des fabricants de produits pharmaceutiques, des 
sociétés de biotechnologie, le monde universitaire et des gouvernements de pays en développement axés sur 
la promotion du développement de médicaments. 
(13) : Organisations médicales/sociétés pharmaceutiques à but non lucratif (d'après Hale et al, 
2005:1059) 
D'un point de vue opérationnel, une société pharmaceutique à but non lucratif possède les caractéristiques de 
base d'un partenariat public-privé (PPP) classique, bien qu'elle présente plusieurs particularités. Son équipe de 
R&D interne est en effet plus grande que celle d'un PPP classique, elle se consacre à une grande variété de 
maladies négligées et peut choisir les meilleures opportunités de développement disponibles dans chaque 
domaine, sans limitation des modalités de traitement : des médicaments, vaccins et outils de diagnostic 
peuvent ainsi être développés selon les besoins. 
(14) : "Plan Marshall" mondial (d'après Yunker, 2004:1109) 
Programme de développement étranger à très grande échelle pour le développement futur de l'économie 
mondiale, susceptible d'entraîner une réduction considérable des injustices économiques, au prix d'un retard très 
mineur de la croissance économique des pays riches. 
(15) : Attribution de 0,5 % du PNB des pays riches à la lutte contre la pauvreté dans les pays pauvres en 
ressources (d'après Sachs, 2005:299-301) 
Jeffrey Sachs a calculé qu'environ 135 à 195 milliards de dollars seraient nécessaires chaque année entre 2005 
et 2015 (soit environ 0,44 à 0,54 % du PIB annuel des pays riches pendant la décennie à venir) pour éradiquer 
la pauvreté extrême dans le monde. L'objectif est de faire passer le pourcentage de PNB contribué de 0,25 à 
0,5 %. 
(16) : Attribution de 0,1 % du PNB au développement de médicaments pour les maladies négligées (d'après 
Gerhardsen, 2006:348)  
Une résolution de l'OMS (EB117 R13) parrainée par le Brésil et le Kenya réclamait un financement accru de 
la R&D concernant les nouveaux vaccins et les traitements pour des maladies affectant principalement les 
pays en développement dans le cadre d'un nouveau contexte mondial sur la recherche et le développement 
essentiels en matière de santé. Elle repose sur une proposition de Traité relatif à la recherche et au 
développement dans le domaine médical, émise en 2002 par l'organisation non gouvernementale CPTech, qui 
lutte pour améliorer l'accès aux médicaments. Selon cette proposition, les gouvernements des pays riches 
rassembleraient des fonds pour la R&D sur les maladies négligées en y attribuant un pourcentage de leur PNB 
(p. ex. 0,1 %). 
(17) : Prévention de l'infection (notamment par des traitements prophylactiques) (d'après Mascarenhas 
et al, 2005:409) 
Les sociétés pharmaceutiques, qui octroient des licences volontaires et accélèrent la production de 
médicaments génériques, exercent une pression sur les gouvernements locaux, ainsi que sur les personnes 
touchées et leur famille, afin de les engager à participer à l'effort de prévention en modifiant leur 
comportement. 
(18) : Subventionnement/remboursement de médicaments (d'après Henry et Lexchin, 2002:1591) 
En raison des forces du marché, le subventionnement gouvernemental de l'utilisation de médicaments dans la 
communauté locale est répandu. 
(19) : Réglementation des prix/prix de référence (d'après Henry et Lexchin, 2002:1591) 
-Réglementation des prix : les gouvernements souhaitent généralement que les prix restent à un niveau 
compatible avec leur budget pharmaceutique, tout en sachant que s'ils exigent un prix trop bas, les sociétés 
pourraient renoncer à commercialiser un produit et réduire les investissements locaux. 
-Prix de référence : classe le médicament dans un groupe de produits, auquel est attribué le même niveau de 
remboursement. La référence des médicaments peut dépendre de leurs performances cliniques ou parfois de 
leur comparaison avec le produit générique le moins cher. Dans ces systèmes, le prix de produits novateurs 
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peut être plus proche de la moyenne des prix dans les pays de comparaison, ce qui indique que cette approche 
tarifaire pourrait récompenser les innovations thérapeutiques. 
(20) : Licences obligatoires (d'après Wise, 2006:344) 
Les licences obligatoires permettent à des tiers d'utiliser une invention sans l'autorisation du détenteur du 
brevet. Par exemple, les entreprises pharmaceutiques locales peuvent obtenir des licences obligatoires pour la 
production de versions génériques de médicaments brevetés ou pour l'importation de versions génériques des 
médicaments de sociétés étrangères. 
(21) : Importation/commerce parallèle (d'après Wise, 2006:343) 
L'importation parallèle désigne l'importation et la revente dans un pays, sans l'autorisation du détenteur du 
brevet, d'un produit breveté qui a été légitimement commercialisé dans le pays d'exportation. En d'autres 
termes, des médicaments vendus à moindre prix dans un pays peuvent être importés dans un autre pays, où ils 
seront vendus (=disponibilité), mais à un prix supérieur. 
(22) : Don de médicaments (d'après Henry et Lexchin, 2002:1590) 
Certaines sociétés organisent d'excellents programmes de dons de médicaments, p. ex. certaines ont fait don 
de plus de 100 millions de traitements ou offert la fourniture gratuite d'un certain traitement dans certains 
pays. 
(23) : Don de brevets (licences gratuites) (d'après Gerhardsen, 2006:348) 
Dons de brevets à des parties actives dans des pays pauvres en ressources.  
(24) : Initiatives de niveau d'entreprise (d'après Katrak, 2004:316) 
Ce concept propose des mesures à l'échelle de l'entreprise (de sociétés de toutes sortes, pas seulement de 
firmes pharmaceutiques) qui permettent de rendre les médicaments plus accessibles pour leurs employés 
atteints. Un exemple de mesure pourrait être la fourniture de médicaments gratuits ou subventionnés aux 
employés. Un autre exemple pourrait constituer à aider les employés atteints en leur permettant de continuer à 
travailler, afin d'éviter une baisse des revenus. 
(25) : Prix différentiels/graduation des prix/prix de faveur (d'après Scherer et Watal, 2002:913-928) 
Le mécanisme de prix différentiels, de graduation des prix, de prix équitables ou de prix de faveur (p. ex. 
discrimination à la Ramsey-Baumol-Bradford ou tout simplement prix de Ramsey), utilisé par les entreprises 
pharmaceutiques multinationales, applique, dans les pays dont la capacité de paiement est limitée et/ou 
présentant une grande élasticité de la demande par rapport au prix, des prix nettement inférieurs à ceux des 
pays riches. 
(26) : Remise de prix volontaire, au-delà des prix différentiels (d'après Mascarenhas et al, 2005:407) 
Remises de prix offertes par les fabricants, souvent après une pression intense et croissante émanant de 
contestataires, notamment des décideurs, afin de proposer une solution pour la distribution de médicaments 
d'importance vitale dans les pays en développement. 
 
4.  BIBLIOGRAPHIE 
Une liste des articles mentionnés dans le texte ci-dessus peut être obtenue par l'intermédiaire de courrier 










The narrative document that was sent out was condensed on one sheet by using small left 
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Para : …………………….    
…………………………. 
…………………………. 
          
        Leo Versteynen 
 
        P.B. 35 
        2340 Beerse 
        Bélgica 
 
 
        Beerse, 18 de agosto de 2008




La injusticia de la salud del mundo, especialmente en lo referente a las enfermedades 
infecciosas (principalmente el VIH/SIDA, la tuberculosis y la malaria), está ganando 
importancia en la agenda de las asambleas internacionales de las autoridades, las 
organizaciones no gubernamentales y los desarrolladores de fármacos. ¿Podrá hacer 
frente el mundo al problema del acceso limitado a las medicinas de los países pobres en 
recursos (PPRs)? 
 
Mi nombre es Leo Versteynen. Soy un estudiante del programa DBA (Doctor en 
Administración Empresarial) en la Universidad de Bradford, Reino Unido (Número 
estudiante 06023738), por medio de TiasNimbas, una escuela de ciencias empresariales 
situada en los Países Bajos. Solicito su ayuda para un programa de investigación 
doctoral. 
 
El objetivo de mi proyecto de investigación es descubrir las medidas para 
incrementar el acceso a los fármacos vitales preferidos por las autoridades 
sanitarias, las fundaciones y las organizaciones no gubernamentales (ONG), así 
como desarrolladores, fabricantes o distribuidores de medicinas.  
 
El cuestionario final será enviado a 34 autoridades sanitarias de países que se 
encuentren en diferentes niveles del Índice de Desarrollo Humano (IHD) establecido por la 
OMS. En estos países (países con resultados “bajo” o “medio” o incluso “alto” en el IHD 
de la OMS), también recibirán el cuestionario varias fundaciones / organizaciones no 
gubernamentales y desarrolladores, fabricantes o distribuidores de medicinas.  
 
Esta primera iniciativa es un proyecto experimental para validar el cuestionario y el 
proceso. El estudio experimental se llevará a cabo en países, seleccionados 
arbitrariamente y en una fundación también escogida de forma arbitraria. Según las 
respuestas, el cuestionario se perfeccionará y se utilizará para el estudio definitivo. Por 
favor, comuníqueme sus marcas para las secciones 1 a 8 y sus comentarios sobre el 
contenido del cuestionario (en la sección 9a) y sobre el formato, la facilidad de uso y los 
aspectos lingüísticos (en la sección 9b) del cuestionario. 
 
Aunque se hayan publicado muchas medidas para aumentar el acceso a los fármacos de 
los países pobres, hasta ahora no ha habido intentos de descubrir cómo prefieren enfocar 
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este asunto las partes interesadas. El objetivo de mi investigación es identificar las 
medidas preferidas, suponiendo que éstas tendrán una probabilidad mayor de éxito en un 
futuro. 
De esta manera, espero contribuir al conocimiento teórico y a la gestión práctica real en el 
campo de la mejora del acceso a los fármacos vitales en los países pobres. 
 
Aunque mi patrón, Tibotec-Virco BVBA, que trabaja en Mechelen, Bélgica, haya pagado 
parte de la matrícula y de los cursos de mi programa DBA en la Universidad de Bradford, 
el diseño de este estudio lo he realizado de forma independiente, así como el 
almacenamiento y el análisis de los datos y las conclusiones extraídas. 
 
Las conclusiones de mi programa de investigación serán una tesis doctoral y una 
publicación en un diario reconocido. Me comprometo a mantener el anonimato de los 
nombres de las partes que respondan al cuestionario así como de las organizaciones en 
todos los informes escritos del estudio, de modo que sus respuestas se tratarán con la 
más estricta confidencialidad. 
 
Asumo por el presente, doy por hecho que puedo utilizar los datos de estos informes bajo 
las condiciones de anonimato y confidencialidad descritas anteriormente: no se publicarán 
datos en bruto, solamente los análisis y las conclusiones. Mi patrón sólo tendrá acceso a 
los dos documentos mencionados, como cualquier otra persona, una vez ya publicados. 
 
Por lo tanto, le agradezco sinceramente que usted o uno de sus colaboradores complete 
este cuestionario y me lo devuelva con el sobre prepago. No debería tardar más de 30 
minutos en rellenar el formulario con las instrucciones que se proporcionan. Estaría muy 
agradecido si pudiera enviar por correo ordinario el cuestionario completado en un plazo 
de dos semanas después de haberlo recibido. 
 
Para ayudarle a completar el cuestionario, he adjuntado un documento de apoyo llamado 
“Orientación y Bibliografía”. Este documento contiene algunas instrucciones para 
completar el cuestionario, así como las descripciones de las medidas examinadas por 
parte de varios autores de renombre.  
 
Tras finalizar mi proyecto de investigación, todos los cuestionarios se desecharán. 
 






Leo Versteynen   
 
P.B. 35  
2340 Beerse 
Bélgica 
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Addendum 3-5-B: The pilot-run questionnaire that was used this thesis. (Spanish)  
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Addendum 3-5-B: The pilot-run questionnaire that was used for this thesis. (Spanish) 
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Addendum 3-5-B: The pilot-run questionnaire that was used for this thesis. (Spanish)  
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Addendum 3-5-C: The narrative of the pilot-run questionnaire that was used for this 
thesis. (Spanish)  
 
ORIENTACIÓN Y BIBLIOGRAFÍA 
 
1.  INSTRUCCIONES 
 
1.1 Rellene las secciones en amarillo 1 y 2 (si procede), relacionadas con el tipo y el tamaño de su 
empresa. 
 
1.2 Para cada afirmación, marque la respuesta que mejor se corresponda con su grado de acuerdo o 
desacuerdo. Su valoración deberá reflejar la opinión de su organización.  
 
Ejemplo:      
Totalmente Principalmente Ligeramente Ni de acuerdo Ligeramente Principalmente Totalmente
en desacuerdo en desacuerdo en desacuerdo ni en desacuerdo de acuerdo de acuerdo de acuerdo
 
1.3 Envíe el cuestionario completado por correo ordinario utilizando el sobre con destinatario y 
franqueo pagado que se adjunta en un plazo de dos semanas desde la recepción del cuestionario. 
Gracias. 
 
   2.  DEFINICIONES BÁSICAS 
 
-Acceso a fármacos : disponibilidad de medicamentos a precio asequible. 
 
-Disponibilidad de fármacos : en el ámbito de este proyecto de investigación, este término se 
limita a los resultados del proceso de desarrollo de medicamentos y al grado en que los centros 
pueden proporcionar los medicamentos recetados. No está relacionado con la infraestructura del 
centro de salud local, la organización de transporte público a centros médicos y similares. 
 
-Asequibilidad de fármacos : expresado como el número de salarios diarios de un funcionario con 
el menor sueldo, necesarios para pagar un mes de tratamiento con un fármaco determinado. 
 
3.  DESCRIPCIONES PARA LOS ENFOQUES MENCIONADOS EN EL 
CUESTIONARIO 
 
(1) : Compromisos anticipados de mercado (AMC) (Procedente de: Hollis, 2007:80) 
Un compromiso anticipado de mercado, propuesto por Kremer y Glennerster y el Centro de desarrollo 
global en 2004 y 2005, podría ser útil para ciertos tipos de productos farmacéuticos, principalmente 
vacunas, con el fin de estimular la investigación a través de una subvención de un valor fijo por unidad 
para un determinado número de unidades. 
 
(2) : Compensación opcional basada en el efecto terapéutico  (Procedente de: Hollis, 2007:82-83) 
En 2005, Hollis y Pogge propusieron un sistema de compensación opcional en el que una agencia 
patrocinadora pagara compensaciones anuales en función de la eficacia terapéutica de los medicamentos 
para aquellas enfermedades olvidadas.  
 
(3) : Sistemas de cupones de revisión prioritaria (Procedente de: Ridley et al, 2006:313) 
Este mecanismo proporciona un cupón de revisión prioritaria a los desarrolladores de los tratamientos de 
las enfermedades olvidadas. El cupón podría suponer un ahorro medio de un año de tiempo de revisión 
por parte del organismo estadounidense para el control de alimentos y medicamentos (FDA, del inglés 
Food and Drug Administration) y podría venderse por el desarrollador al fabricante de un fármaco 
estrella (con un alto volumen de ventas).  
 
(4) : Derechos transferibles de propiedad intelectual (prolongación de exclusividad) (Procedente 
de: Barton y Emanuel, 2007:2080) 
La prolongación de exclusividad garantiza a las empresas unos períodos más amplios de exclusividad 
sobre un fármaco estrella a cambio de desarrollar nuevos productos de un considerable valor de 
desarrollo nacional. 
 
(5) : Desgravación fiscal (Procedente de: Gerhardsen, 2006:348) 
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Por ejemplo, Reino Unido ofrece una mayor desgravación fiscal para I+D en vacunas o fármacos para 
enfermedades que afectan principalmente a los países en vías de desarrollo, como la malaria, la 
tuberculosis y el VIH/SIDA. 
 
(6) : Reubicación de I+D en países de bajo coste (Procedente de: Reddy y Sigurdson, 1997:344) 
Realizar (parte de) I+D estratégica para fomentar el desarrollo de los países de Europa oriental con el fin 
de obtener acceso a personal científico, así como reducir los costes de I+D. 
 
(7) : Premios a la innovación médica (Procedente de: Gerhardsen, 2006:348) 
El premio a la innovación médica es una alternativa al sistema de patentes que permite obtener 
financiación para I+D, y que se ha propuesto en el congreso de EE.UU. en un proyecto de ley. Según la 
legislación propuesta, los nuevos fármacos se tratarían como genéricos tan pronto como recibieran la 
aprobación de la normativa y los propietarios de patentes recibirían una compensación a partir de 60.000 
millones de dólares estadounidenses por presentar innovaciones para mejorar la salud. El fondo recibiría 
un 0,5% del PIB anual. 
 
(8) : Innovación de avance decisivo para crear un modelo de negocio de alta calidad y bajo coste 
(Procedente de: Prahalad, 2006a:3; Prahalad, 2006b) 
Innovaciones que resultan en un producto o servicio de calidad internacional, que obtienen al menos el 
90% de reducción de costes de un producto o servicio comparable en Occidente, y que es asequible y 
puede llegar a la base de la pirámide económica, que incluye a personas con los niveles de ingresos más 
bajos de una sociedad determinada. 
 
(9) : Financiación del sector público en I+D de fármacos (Procedente de: Kim, 2007:7) 
Un método obvio de mejorar el acceso a fármacos patentados consiste en financiar la investigación 
farmacéutica del sector público. De este modo, los fármacos patentados pueden entrar directamente en el 
ámbito público. El concepto consiste en que, cuantos más fármacos entren directamente en el ámbito 
público, las empresas farmacéuticas se verán obligadas a competir con fármacos que ya están a la venta 
en el mercado como genéricos, lo que conducirá a una rebaja de los precios. 
 
(10) : Sistemas de incentivos en la carga de enfermedad (Procedente de: Ridley et al, 2006:317) 
Como ejemplo, la ley estadounidense sobre fármacos huérfanos (ODA, del inglés Orphan Drug Act) de 
1983 proporciona siete años de exclusividad de marketing tras la aprobación de la FDA. En segundo 
lugar, los fabricantes de fármacos pueden reunir los requisitos para obtener créditos fiscales de hasta la 
mitad de sus gastos relacionados con pruebas clínicas. En tercer lugar, los desarrolladores pueden recibir 
una modesta subvención de la FDA para investigar tratamientos para enfermedades raras. En cuarto 
lugar, la FDA proporciona asesoramiento con relación a las condiciones de aprobación.  
 
(11) : Tratamiento del exceso normativo (Procedente de: Farrugia, 2004:83) 
A los sistemas de regulación oficial que exigen estándares y otras medidas se les unen los estándares 
voluntarios adoptados por los órganos del sector como características adicionales de un nexo completo 
de acuerdos que contribuyen a la calidad del producto y la reducción de riesgos. “Tratamiento” en este 
contexto significa la simplificación. 
 
(12) : Asociación de sectores público y privado (PPP) (Procedente de: Hale et al, 2005:1058) 
Asociaciones entre las principales organizaciones de salud a nivel mundial, fabricantes farmacéuticos, 
compañías de biotecnología y gobiernos de países en desarrollo que se centran en completar el 
desarrollo y la distribución de los fármacos. 
 
(13) : Empresas farmacéuticas sin ánimo de lucro/Organización médica sin ánimo de lucro 
(Procedente de: Hale et al, 2005:1059) 
A nivel operacional, una compañía farmacéutica sin ánimo de lucro comparte las principales 
características de las asociaciones de los sectores público y privado (PPP) típicas, pero presenta algunas 
diferencias. Su equipo de I+D en plantilla es mayor que el de una PPP clásica, abarca una amplia 
variedad de enfermedades olvidadas y puede seleccionar las mejores oportunidades de desarrollo 
disponibles en cada una de ellas, sin límites en la modalidad de tratamiento: fármacos, vacunas y 
diagnósticos podrían desarrollarse según fuera necesario. 
 
(14) : “Plan Marshall” global (Procedente de: Yunker, 2004:1109) 
Un programa de ayuda al desarrollo extranjero a gran escala sobre el desarrollo futuro de la economía 
mundial con el potencial de reducir considerablemente la desigualdad de la economía mundial y con el 
coste de un retraso muy pequeño en el crecimiento económico de los países ricos. 
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(15) : 0,5% de PNB de países ricos para combatir la pobreza en los países con pocos recursos 
(Procedente de: Sachs, 2005:299-301) 
Jeffrey Sachs ha calculado que, para erradicar la pobreza extrema mundial, se necesita entre 135.000 y 
195.000 millones de dólares al año para el período 2005-2015, lo que equivale a entre el 0,44 y el 0,54 
por ciento del PNB de los países ricos al año durante la próxima década. La idea es acercar la media 
actual de 0,25 por ciento del PNB donante al 0,5% de PNB donante. 
 
(16) : 0,1% de PNB dedicado al desarrollo de fármacos para enfermedades olvidadas (Procedente 
de: Gerhardsen, 2006:348) 
La Organización Mundial de la Salud (OMS) ha emitido una resolución (EB117 R13) respaldada por 
Brasil y Kenia que exige más financiación en I+D para nuevas vacunas y fármacos de enfermedades que 
afectan principalmente a los países en desarrollo, como parte de un nuevo marco global sobre 
investigación y desarrollo sobre salud esencial. Se inspira en una propuesta para un tratado de 
investigación y desarrollo médico que realizó en 2002 la organización no gubernamental CPTech, cuyas 
actividades se centran en campañas para mejorar el acceso a medicamentos. La idea es que los gobiernos 
de los países ricos recauden fondos destinados a I+D en enfermedades olvidadas, mediante la asignación 
de una parte del PNB (por ejemplo, 0,1%). 
 
(17) : Prevención de infecciones (incluida la medicación preventiva) (Procedente de: Mascarenhas et 
al, 2005:409) 
Las compañías farmacéuticas, que otorgan licencias voluntarias y aceleran la producción de genéricos, 
ejercen presión sobre los gobiernos locales y las personas afectadas y sus familiares para que 
intervengan en la prevención de la enfermedad mediante las correspondientes modificaciones de 
comportamiento. 
 
(18) : Subvención/Reembolso de fármacos (Procedente de: Henry y Lexchin, 2002:1591) 
Debido a las fuerzas del mercado, es muy extendida la financiación estatal del uso de los medicamentos 
en sus comunidades. 
 
(19) : Control de precios/Precios de referencia (Procedente de: Henry y Lexchin, 2002:1591) 
-Control de precios: los gobiernos suelen desear unos precios a niveles que no excedan su presupuesto 
destinado a fármacos, pero reconocen que si exigen que un precio baje demasiado, las empresas podrían 
decidir no comercializarlo y se reduciría la inversión local. 
-Precios de referencia: asigna un fármaco a un grupo de productos, que recibe el mismo nivel de 
reembolso. Los fármacos pueden referenciarse según su rendimiento clínico, con respecto al producto 
genérico más económico. En dichos sistemas, los precios que se asignan a los productos innovadores 
pueden, en cierta medida, acercarse más al precio medio de países similares, lo que sugiere que este 
enfoque para la asignación de precios puede ofrecer avances en el tratamiento. 
 
(20) : Licencias obligatorias (Procedente de: Wise, 2006:344) 
Las licencias obligatorias permiten a terceros utilizar un invento sin el consentimiento del propietario de 
la patente. Por ejemplo, es posible que las compañías farmacéuticas locales obtengan licencias 
obligatorias para producir versiones genéricas de fármacos patentados o importar versiones genéricas de 
fármacos procedentes de fabricantes extranjeros. 
 
(21) : Importación paralela/Comercio paralelo (Procedente de: Wise, 2006:343) 
La importación paralela constituye la importación y la reventa en un país, sin el consentimiento del 
propietario de la patente, de un producto patentado que se ha comercializado de manera legítima en el 
país exportador. Esto significa que los fármacos que se venden a un precio menor en un país se pueden 
importar en otro país donde el mismo fármaco se vende a un precio mayor. 
 
(22) : Donación de medicamentos (Procedente de: Henry y Lexchin, 2002:1590) 
Algunas empresas han mantenido excelentes programas de donación de fármacos, por ejemplo, algunas 
han donado más de 100 millones de tratamientos o han ofrecido suministrar un determinado producto de 
manera gratuita en determinados países. 
 
(23) : Donación de patentes (licencias gratuitas) (Procedente de: Gerhardsen, 2006:348) 
Donación de patentes a entidades con pocos recursos.  
 
(24) : Iniciativas a nivel empresarial (Procedente de: Katrak, 2004:316) 
Este concepto propone medidas a nivel empresarial (no sólo empresas farmacéuticas, sino también de 
cualquier otro tipo) que puedan hacer más asequibles los fármacos para sus empleados afectados. Una 
medida consistiría en proporcionar fármacos gratis o con subvención a los empleados. Otra medida 
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consistiría en ayudar a los empleados afectados permitiéndoles seguir trabajando para evitar la reducción 
de sus ingresos. 
 
(25) : Precios diferenciales/Fijación discriminatoria de precios (Procedente de: Scherer y Watal, 
2002:913-928) 
Los precios diferenciales, precios equitativos o discriminación de precios (también denominado precio 
de Ramsey-Baumol o simplemente precio de Ramsey) es un mecanismo utilizado por las multinacionales 
farmacéuticas para fijar precios mucho más bajos en países con poco poder adquisitivo y/o elasticidad 
de altos precios de demanda, con respecto a los países ricos. 
 
(26) : Descuento de precios voluntario, más allá de los precios diferenciales (Procedente de: 
Mascarenhas et al, 2005:407) 
Descuentos de precio que ofrecen los fabricantes, (a menudo tras la intensa y creciente presión de 
protestas procedentes, entre otros, de responsables políticos), para ofrecer una solución común en la 
distribución de medicamentos que puedan salvar vidas en los países en vías de desarrollo.  
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Addendum 3-6-A: The introduction letter of the full-run questionnaire that was used for 
this thesis. (Spanish) 
 
Para :           
        Leo Versteynen 
        P.B. 35 
        2340 Beerse 
        Bélgica 
 
        Beerse, 15 de noviembre de 2008
           
Estimados Señores, 
 
La injusticia de la salud del mundo, especialmente en lo referente a las enfermedades infecciosas, 
está ganando importancia en la agenda de las asambleas internacionales de las autoridades, las 
organizaciones no gubernamentales y los desarrolladores de fármacos. ¿Podrá hacer frente el 
mundo al problema del acceso limitado a las medicinas de los países pobres en recursos (PPRs)? 
 
Mi nombre es Leo Versteynen. Soy un estudiante del programa DBA (Doctor en Administración 
Empresarial) en la Universidad de Bradford, Reino Unido (Número estudiante 06023738). Solicito 
su ayuda para un programa de investigación doctoral. 
 
El objetivo de mi proyecto de investigación es descubrir las medidas para incrementar el 
acceso a los fármacos vitales preferidos por las autoridades sanitarias, las fundaciones y 
las organizaciones no gubernamentales (ONG), así como desarrolladores (incluyendo 
departamentos médicos universitarios), fabricantes o distribuidores de medicinas.  
Por eso, estoy enviando este cuestionario a las partes concernientes en env. 50 paises con niveles 
“alto”, “medio” o “bajo” del Indice de Desarrollo Humano (IHD) establecido por la OMS. 
 
Estoy realizando este examen particular con cuestionario de forma totalmente independiente : 
tengo la libertad total así como el almacenamiento y el análisis de los datos y las conclusiones 
extraídas. Me comprometo a mantener el anonimato de los nombres de las partes que respondan 
al cuestionario así como de las organizaciones en todos los informes escritos del estudio, de modo 
que sus respuestas se tratarán con la más estricta confidencialidad. 
 
Las conclusiones ultimos de mi programa de investigación serán incluido en una tesis doctoral y 
una publicación en un diario reconocido. Cada organización que complete y devuelva el 
cuestionario recibira una copía gratis de mi texto de tesis al fin de mi estudio (2010).    
 
Por lo tanto, le agradezco sinceramente que usted o uno de sus asociados complete este 
cuestionario y me lo devuelva con el sobre prepago. Debería tardar menos de 30 minutos en 
rellenar el formulario con las instrucciones que se proporcionan. Estaría muy agradecido si pudiera 
enviar por correo ordinario el cuestionario completado en un plazo de dos semanas después de 
haberlo recibido. 
 
En caso de que usted podría aconsejarme en otras organizaciones en su país que serían 
interesados y que querrían terminar este cuestionario, déjeme por favor saber, de modo que pueda 
enviarles una copia. 
 




Leo Versteynen   
 
P.B. 35, 2340 Beerse, Bélgica 
E-mail : leopold.versteynen@pandora.be 
 
                      - 65 - 
          
Addendum 3-6-B: The full-run questionnaire that was used for this thesis. (Spanish)  
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Addendum 3-6-B: The full-run questionnaire that was used for this thesis. (Spanish)  
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Addendum 3-6-B: The full-run questionnaire that was used for this thesis. (Spanish)  
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Addendum 3-6-C: The narrative of the full-run questionnaire that was used for this 
thesis. (Spanish)  
 
          ORIENTACIÓN Y BIBLIOGRAFÍA 
 
1.  INSTRUCCIONES 
1.1 Rellene las secciones en amarillo 1 y 2 (si procede), relacionadas con el tipo y el tamaño de su empresa. 
1.2 Para cada afirmación, marque la respuesta que mejor se corresponda con su grado de acuerdo o 
desacuerdo.  
Ejemplo: 
      
Totalmente Principalmente Ligeramente Ni de acuerdo Ligeramente Principalmente Totalmente
en desacuerdo en desacuerdo en desacuerdo ni en desacuerdo de acuerdo de acuerdo de acuerdo
 
 
1.3 Envíe el cuestionario completado por correo ordinario utilizando el sobre con destinatario y franqueo 
pagado que se adjunta en un plazo de dos semanas desde la recepción del cuestionario. Gracias. 
 
    2.  DEFINICIONES BÁSICAS 
-Acceso a fármacos : disponibilidad de medicamentos a precio asequible  
-Disponibilidad de fármacos : en el ámbito de este proyecto de investigación, este término se dirije a las 
innovaciones del proceso de desarrollo de medicamentos y al grado en que los centros pueden proporcionar 
los medicamentos recetados. No está relacionado con la infraestructura del centro de salud local, la 
organización de transporte público a centros médicos y similares. 
-Asequibilidad de fármacos : expresado como el número de salarios diarios de un funcionario con el menor 
sueldo, necesarios para pagar un mes de tratamiento con un fármaco determinado. 
 
3.  DESCRIPCIONES PARA LOS ENFOQUES MENCIONADOS EN EL CUESTIONARIO 
(1) : Compromisos anticipados de mercado (AMC) (Procedente de: Hollis, 2007:80) 
Un compromiso anticipado de mercado, propuesto por Kremer y Glennerster y el Centro de desarrollo global 
en 2004 y 2005, podría ser útil para ciertos tipos de productos farmacéuticos, principalmente vacunas, con el 
fin de estimular la investigación a través de una subvención de un valor fijo por unidad para un determinado 
número de unidades. 
(2) : Compensación opcional basada en el efecto terapéutico  (Procedente de: Hollis, 2007:82-83) 
En 2005, Hollis y Pogge propusieron un sistema de compensación opcional en el que una agencia 
patrocinadora pagara compensaciones anuales en función de la eficacia terapéutica de los medicamentos para 
aquellas enfermedades olvidadas.  
(3) : Sistemas de cupones de revisión prioritaria (Procedente de: Ridley et al, 2006:313) 
Este mecanismo proporciona un cupón de revisión prioritaria a los desarrolladores de los tratamientos de las 
enfermedades olvidadas. El cupón podría suponer un ahorro medio de un año de tiempo de revisión por parte 
del organismo estadounidense para el control de alimentos y medicamentos (FDA, del inglés Food and Drug 
Administration) y podría venderse por el desarrollador al fabricante de un fármaco estrella (con un alto 
volumen de ventas).  
(4) : Derechos transferibles de propiedad intelectual (prolongación de exclusividad) (Procedente de: 
Barton y Emanuel, 2007:2080) 
La prolongación de exclusividad garantiza a las empresas unos períodos más amplios de exclusividad sobre 
un fármaco estrella a cambio de desarrollar nuevos productos de un considerable valor de desarrollo nacional. 
(5) : Desgravación fiscal (Procedente de: Gerhardsen, 2006:348) 
Por ejemplo, Reino Unido ofrece una mayor desgravación fiscal para I+D en vacunas o fármacos para 
enfermedades que afectan principalmente a los países en vías de desarrollo, como la malaria, la tuberculosis y 
el VIH/SIDA. 
(6) : Reubicación de I+D en países de bajo coste (Procedente de: Reddy y Sigurdson, 1997:344) 
Realizar (parte de) I+D estratégica para fomentar el desarrollo de los países de Europa oriental con el fin de 
obtener acceso a personal científico, así como reducir los costes de I+D. 
(7) : Premios a la innovación médica (Procedente de: Gerhardsen, 2006:348) 
El premio a la innovación médica es una alternativa al sistema de patentes que permite obtener financiación 
para I+D, y que se ha propuesto en el congreso de EE.UU. en un proyecto de ley. Según la legislación 
propuesta, los nuevos fármacos se tratarían como genéricos tan pronto como recibieran la aprobación de la 
normativa y los propietarios de patentes recibirían una compensación a partir de 60.000 millones de dólares 
estadounidenses por presentar innovaciones para mejorar la salud. El fondo recibiría un 0,5% del PIB anual. 
(8) : Innovación de avance decisivo para crear un modelo de negocio de alta calidad y bajo coste 
(Procedente de: Prahalad, 2006a:3; Prahalad, 2006b) 
Innovaciones que resultan en un producto o servicio de calidad internacional, que obtienen al menos el 90% 
de reducción de costes de un producto o servicio comparable en Occidente, y que es asequible y puede llegar 
a la base de la pirámide económica, que incluye a personas con los niveles de ingresos más bajos de una 
sociedad determinada. 
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(9) : Financiación del sector público en I+D de fármacos (Procedente de: Kim, 2007:7) 
Un método obvio de mejorar el acceso a fármacos patentados consiste en financiar la investigación 
farmacéutica del sector público. De este modo, los fármacos patentados pueden entrar directamente en el 
ámbito público. El concepto consiste en que, cuantos más fármacos entren directamente en el ámbito público, 
las empresas farmacéuticas se verán obligadas a competir con fármacos que ya están a la venta en el mercado 
como genéricos, lo que conducirá a una rebaja de los precios. 
(10) : Sistemas de incentivos en la carga de enfermedad (Procedente de: Ridley et al, 2006:317) 
Como ejemplo, la ley estadounidense sobre fármacos huérfanos (ODA, del inglés Orphan Drug Act) de 1983 
proporciona siete años de exclusividad de marketing tras la aprobación de la FDA. En segundo lugar, los 
fabricantes de fármacos pueden reunir los requisitos para obtener créditos fiscales de hasta la mitad de sus 
gastos relacionados con pruebas clínicas. En tercer lugar, los desarrolladores pueden recibir una modesta 
subvención de la FDA para investigar tratamientos para enfermedades raras. En cuarto lugar, la FDA 
proporciona asesoramiento con relación a las condiciones de aprobación.  
(11) : Tratamiento del exceso normativo (Procedente de: Farrugia, 2004:83) 
A los sistemas de regulación oficial que exigen estándares y otras medidas se les unen los estándares 
voluntarios adoptados por los órganos del sector como características adicionales de un nexo completo de 
acuerdos que contribuyen a la calidad del producto y la reducción de riesgos. “Tratamiento” en este contexto 
significa la simplificación. 
(12) : Asociación de sectores público y privado (PPP) (Procedente de: Hale et al, 2005:1058) 
Asociaciones entre las principales organizaciones de salud a nivel mundial, fabricantes farmacéuticos, 
compañías de biotecnología y gobiernos de países en desarrollo que se centran en completar el desarrollo y la 
distribución de los fármacos. 
(13) : Empresas farmacéuticas sin ánimo de lucro/Organización médica sin ánimo de lucro (Procedente 
de: Hale et al, 2005:1059) 
A nivel operacional, una compañía farmacéutica sin ánimo de lucro comparte las principales características 
de las asociaciones de los sectores público y privado (PPP) típicas, pero presenta algunas diferencias. Su 
equipo de I+D en plantilla es mayor que el de una PPP clásica, abarca una amplia variedad de enfermedades 
olvidadas y puede seleccionar las mejores oportunidades de desarrollo disponibles en cada una de ellas, sin 
límites en la modalidad de tratamiento: fármacos y diagnósticos podrían desarrollarse según fuera necesario. 
(14) : “Plan Marshall” global (Procedente de: Yunker, 2004:1109) 
Un programa de desarrollo extranjero a gran escala sobre el desarrollo futuro de la economía mundial con el 
potencial de reducir considerablemente la desigualdad de la economía y con el coste de un retraso pequeño en 
el crecimiento económico de los países ricos. 
(15) : 0,5% de PNB de países ricos para combatir la pobreza en los países con pocos recursos 
(Procedente de: Sachs, 2005:299-301) 
Jeffrey Sachs ha calculado que, para erradicar la pobreza extrema mundial, se necesita entre 135.000 y 
195.000 millones de dólares al año para el período 2005-2015, lo que equivale a entre el 0,44 y el 0,54 por 
ciento del PNB de los países ricos al año durante la próxima década. La idea es acercar la media actual de 
0,25 por ciento del PNB donante al 0,5% de PNB donante. 
(16) : 0,1% de PNB dedicado al desarrollo de fármacos para enfermedades olvidadas (Procedente de: 
Gerhardsen, 2006:348) 
La Organización Mundial de la Salud (OMS) ha emitido una resolución (EB117 R13) respaldada por Brasil y 
Kenia que exige más financiación en I+D para nuevas vacunas y fármacos de enfermedades que afectan 
principalmente a los países en desarrollo, como parte de un nuevo marco global sobre investigación y 
desarrollo sobre salud esencial. Se inspira en una propuesta para un tratado de investigación y desarrollo 
médico que realizó en 2002 la organización no gubernamental CPTech, cuyas actividades se centran en 
campañas para mejorar el acceso a medicamentos. La idea es que los gobiernos de los países ricos recauden 
fondos destinados a I+D en enfermedades olvidadas, mediante la asignación de una parte del PNB (por 
ejemplo, 0,1%). 
(17) : Prevención de infecciones (incluida la medicación preventiva) (Procedente de: Mascarenhas et al, 
2005:409) 
Las compañías farmacéuticas, que otorgan licencias voluntarias y aceleran la producción de genéricos, 
ejercen presión sobre los gobiernos locales y las personas afectadas y sus familiares para que intervengan en 
la prevención de la enfermedad mediante las correspondientes modificaciones de comportamiento. 
(18) : Subvención/Reembolso de fármacos (Procedente de: Henry y Lexchin, 2002:1591) 
Debido a las fuerzas del mercado, es muy extendida la financiación estatal del uso de los medicamentos en 
sus comunidades. 
(19) : Control de precios/Precios de referencia (Procedente de: Henry y Lexchin, 2002:1591) 
-Control de precios: los gobiernos suelen desear unos precios a niveles que no excedan su presupuesto 
destinado a fármacos, pero reconocen que si exigen que un precio baje demasiado, las empresas podrían 
decidir no comercializarlo y se reduciría la inversión local. 
-Precios de referencia: asigna un fármaco a un grupo de productos, que recibe el mismo nivel de reembolso. 
Los fármacos pueden referenciarse según su rendimiento clínico, con respecto al producto genérico más 
económico. En dichos sistemas, los precios que se asignan a los productos innovadores pueden, en cierta 
medida, acercarse más al precio medio de países similares, lo que sugiere que este enfoque para la asignación 
de precios puede ofrecer avances en el tratamiento. 
(20) : Licencias obligatorias (Procedente de: Wise, 2006:344) 
Las licencias obligatorias permiten a terceros utilizar un invento sin el consentimiento del propietario de la 
patente. Por ejemplo, es posible que las compañías farmacéuticas locales obtengan licencias obligatorias para 
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producir versiones genéricas de fármacos patentados o importar versiones genéricas de fármacos procedentes 
de fabricantes extranjeros. 
(21) : Importación paralela/Comercio paralelo (Procedente de: Wise, 2006:343) 
La importación paralela constituye la importación y la reventa en un país, sin el consentimiento del 
propietario de la patente, de un producto patentado que se ha comercializado de manera legítima en el país 
exportador. Esto significa que los fármacos que se venden a un precio menor en un país se pueden importar 
en otro país donde el mismo fármaco se vende (=disponibilidad), pero a un precio mayor. 
(22) : Donación de medicamentos (Procedente de: Henry y Lexchin, 2002:1590) 
Algunas empresas han mantenido excelentes programas de donación de fármacos, por ejemplo, algunas han 
donado más de 100 millones de tratamientos o han ofrecido suministrar un determinado producto de manera 
gratuita en determinados países. 
(23) : Donación de patentes (licencias gratuitas) (Procedente de: Gerhardsen, 2006:348) 
Donación de patentes a entidades con pocos recursos.  
(24) : Iniciativas a nivel empresarial (Procedente de: Katrak, 2004:316) 
Este concepto propone medidas a nivel empresarial (empresas de cualquier tipo) que puedan hacer más 
asequibles los fármacos para sus empleados afectados. Una medida consistiría en proporcionar fármacos 
gratis o con subvención a los empleados. Otra medida consistiría en ayudar a los empleados afectados 
permitiéndoles seguir trabajando para evitar la reducción de sus ingresos. 
(25) : Precios diferenciales/Fijación discriminatoria de precios (Procedente de: Scherer y Watal, 
2002:913-928) 
Los precios diferenciales, precios equitativos o discriminación de precios (también denominado precio de 
Ramsey-Baumol o simplemente precio de Ramsey) es un mecanismo utilizado por las multinacionales 
farmacéuticas para fijar precios mucho más bajos en países con poco poder adquisitivo y/o elasticidad de 
altos precios de demanda, con respecto a los países ricos. 
(26) : Descuento de precios voluntario, más allá de los precios diferenciales (Procedente de: Mascarenhas 
et al, 2005:407) 
Descuentos de precio que ofrecen los fabricantes, (a menudo tras la intensa y creciente presión de protestas 
procedentes, entre otros, de responsables políticos), para ofrecer una solución común en la distribución de 
medicamentos que puedan salvar vidas en los países en vías de desarrollo.  
 
4.  BIBLIOGRAFÍA 
Una lista de los artículos mencionados en el texto antedicho se puede obtener vía correo electrónico (vea la 











The narrative document that was sent out was condensed on one sheet by using small left 
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Addendum 3-9: List of countries, number of questionnaires and languages of the 
documents that were sent to the countries.  
p.1/2: sheet 1 
 
COUNTRY SUM Language
Spain (Pilot run 21 ; 1 in full run) 22 S
Senegal (Pilot run 21 ; 12 in full run, however still with pilot-run questionnaire) 33 F
Nigeria (Pilot run 21) 21 E








USA (Pilot run 1 to Worldwide NGO headquartered in US ; 41 in full run) 42 E
UK 27 E















Dominican Rep 18 S
Paraguay 7 S








Côte d'Ivoire 16 F
Dem Rep Congo 13 F
Ethiopia 21 E
Chad 13 F
Centr. Afr. Rep 12 F
Mozambique 17 F
Mali 12 F
Sierra Leone 14 E
Brazil 28 E
Thailand 28 E
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Addendum 3-9: List of countries, number of questionnaires and languages of the 
documents that were sent to the countries. 
















Sri Lanka 5 E
Jamaica 4 E
















Bosnia & Herzegovina 1 E
Russian Federation 1 E
Albania 1 E
Macedonia (TFYR) 1 E
Dominica 1 E




Occupied Palestinian Ter. 1 E
Indonesia 1 E














E: Countries that received the English version of the questionnaire
F: Countries that received the French version of the questionnaire
S: Countries that received the Spanish version of the questionnaire  
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Addendum 3-11: Example: Ten NGOs/Foundations in Germany that were selected from 
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My name is Leo Versteynen. I’m a doctoral student at the University of Bradford, UK.  
In the framework of my doctoral research, I have sent a few weeks ago, by means of the regular 
post, a questionnaire with regard to the “improvement of access to life-saving medicines” to your 






In case your organization has already completed the questionnaire and has sent it back to me by 
means of the “postage pre-paid” envelope that was enclosed, I would like to thank you cordially. 
 
If you have not been able to do so yet, please complete it and return it to me without delay. This 
questionnaire is crucial for me and my research, which I hope will contribute to knowledge and to 
management practice related to access to medicines. 
 
I hope to receive all the completed questionnaires back by …………………. 
In case you didn’t receive my questionnaire, or if you would like to have a new copy, please contact 
me via e-mail : leopold.versteynen@pandora.be 
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Madame, Monsieur,  
Je m’appelle Leo Versteynen. Actuellement je suis étudiant au sein de l'université de Bradford, au 
Royaume-Uni. Dans le cadre de mes recherches doctorales, j’ ai envoyé quelques semaines passées, 
par courrier ordinaire, un questionnaire, sur “l’amélioration de l’accès aux médicaments 





Si votre organisation a déjà complété le questionnaire et me l’a renvoyé a l’aide de l’enveloppe 
“préaffranchie” qui était jointe, je voudrais vous remercier cordialement.  
Dans le cas contraire, je vous serai reconnaissant de bien vouloir le faire et de me le renvoyer dans 
le plus bref délai. Ce questionnaire est crucial pour moi et mes recherches qui je l'espère 
contribueront à la connaissance et à une meilleure gestion en matière d'accès aux médicaments. 
J’espère d’obtenir tous les questionnaires complétés ……………………..  
Dans le cas que vous n’avez pas reçu mon questionnaire, ou si vous voulez une copie nouvelle, 
prière de me contacter par email : leopold.versteynen@pandora.be 




P.B. 35  
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Addendum 3-12-C: The Spanish follow-up e-mail that was used for the data collection of 











Mi nombre es Leo Versteynen. Soy un estudiante de doctorado de la Universidad de Bradford en el 
Reino Unido. Hace unas semanas, envié por correo ordinario un cuestionario sobre la “Mejora del 






Si usted ya ha llenado el cuestionario y me lo ha enviado de vuelta en el sobre de “correo 
prepagado” que estaba incluido, quisiera agradecerle cordialmente su ayuda. 
 
Si usted no ha podido hacerlo todavía, le ruego por favor que trate de completar mi cuestionario y 
me lo envie de vuelta en los próximos días. El cuestionario es muy importante para mi y mi 
investigación. Mi tesis doctoral contribuirá al desarrollo de la ciencia y a la gerencia relacionada 
con el acceso a los fármacos. 
 
Espero poder tener todos los cuestionarios completados en mi poder sobre ................................. 
En caso de que usted no ha recibido mi questionario o si used quiere obtener una copia nueva, por 
favor contacteme por medio de correo electrónico : leopold.versteynen@pandora.be 
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Addendum 3-13: The code book that was used for data collection and analysis by means 
of SPSS. 
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Addendum 3-13: The code book that was used for data collection and analysis by means 
of SPSS. 
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Addendum 3-13: The code book that was used for data collection and analysis by means 
of SPSS. 














































































































































































































































































































































































   
   




   
   
























































































































































































                      - 83 - 
          
Addendum 3-13: The code book that was used for data collection and analysis by means 
of SPSS.  




Hofstede: Mean Values differentiating between "Low" and "High" scores
PDI UAI IDV MAS LTO
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Addendum 3-14: The introduction letter for the oral interviews that were done for this 
thesis. 
         Beerse, May 30, 2009. 
Dear Health Care Professional,         
             
Re. :  INTERVIEW : ACCESS TO LIFE-SAVING MEDICINES IN RESOURCE-POOR 
COUNTRIES 
 
Dear Sir/Madam,     
 
The World’s Health inequity, especially for infectious diseases, is gaining importance on the agenda 
of international assemblies of authorities, non-governmental organisations and drug-developers. 
Will the World be able to cope with the issue of the limited access to medicines in resource-poor 
countries (RPCs)? 
My name is Leo Versteynen. I am a student on the DBA programme (Doctor of Business 
Administration) at Bradford University, United Kingdom (Student no. 06023738). I would like to 
request your help for a doctoral research programme. 
 
The purpose of my research project is to find out which measures to increase access to life-saving 
drugs are preferred by Health Authorities, Foundations & Non-Governmental Organisations (NGOs) 
and Drug-Developers.  
For that purpose, I have very recently performed a worldwide survey by means of a questionnaire. 
As a follow-up on the questionnaire survey, I am now organizing interviews with key stakeholders 
from countries with “High”, “Medium” or “Low” rankings in the WHO Human Development Index.  
 
Although I am an employee of Tibotec bvba, in Mechelen, Belgium, I am doing this investigation 
independently : I have complete freedom in setting up the interviews, safeguarding and analysing 
the data and drawing conclusions.  I guarantee that names of persons, participating parties and 
organizations will remain anonymous in all written reports from my study and that information and 
answers will be handled with the strictest confidentiality.  
 
I will mainly organize the interviews at the occasion of / in the margin of the 5th International 
Congress on HIV Pathogenesis, Treatment and Prevention in Cape Town (South Africa, July 2009), 
and of the 6th European Congress on Tropical Medicine and International Health in Verona (Italy, 
September 2009). At the end of the interviews I will discuss the top-line statistical outcomes of my 
earlier questionnaire survey with the interviewees, of course respecting confidentiality and 
anonymity principles. 
 
The ultimate outcomes of my research programme will be included in my doctoral thesis and a 
publication in a renowned journal. Each person that participates in my interviews will receive a free 
copy of my doctoral thesis script at the end of my study (2010). 
  
I hereby solicit your participation in my interviews and ask your permission to audio-tape 
the interview so that it is available to me for detailed analysis later on. An interview will take less 
than an hour. 
A list of the most important approaches to increase access to medicines, which I found in the 
literature are attached as addendum.  
(On request I could also send you the questionnaire that I used earlier in my doctoral programme.) 
Please let me know by e-mail if you accept my request to participate. In that case I will 
contact you as soon as possible to fix a place, date and time for the interview. 
 
Thanks and best regards, 
 
Yours sincerely, 
Leo Versteynen   
 
P.B.35, 2340 Beerse, Belgium 
leopold.versteynen@pandora.be 
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Addendum 3-15: The list of approaches found in the literature, that served as guidance 
document for the interviews of this thesis.  
 
 
ADDENDUM  - INTERVIEW on IMPROVEMENT OF ACCESS TO LIFE-SAVING 
MEDICINES IN RESOURCE-POOR COUNTRIES  
 
 
   1.   BASIC DEFINITIONS 
 
-Access to medicines : availability of affordable medicines 
-Availability of medicines : in the scope of this research project, this term is focussed on innovations in the 
drug-development process and to the extent that facilities can provide the drugs that are prescribed. It does 
not relate to infrastructure of the local health care, the organization of public transportation to medical centres 
and the like. 
-Affordability of medicines : expressed as the number of days’ salary of the lowest-paid government worker 
to pay for a one month treatment with a particular medicine. 
 
2.    DESCRIPTIONS : 26 APPROACHES FOUND IN THE LITERATURE 
 
A. APPROACHES WITH MAIN FOCUS ON PULL MECHANISMS FOR DRUG DEVELOPMENT 
(1) : Advanced market commitments (AMCs) (Derived from : Hollis, 2007:80) 
An advanced market commitment, proposed by Kremer and Glennerster and the Center for Global 
Development in 2004 and 2005, could be useful for certain types of pharmaceutical products, principally 
vaccines, to stimulate research by promising a subsidy of a fixed value per unit for a given number of units. 
(2) : Optional rewards based on therapeutic effect  (Derived from : Hollis, 2007:82-83) 
An optional reward system was proposed in 2005 by Hollis and Pogge, in which a sponsoring agency would 
pay rewards annually based on the therapeutic effectiveness of drugs for neglected diseases.  
(3) : Priority review voucher systems (Derived from : Ridley et al, 2006:313) 
This mechanism provides developers of treatments for neglected diseases with a priority review voucher. The 
voucher could save an average of one year of U.S. Food and Drug Administration (FDA) review time and be 
sold by the developer to the manufacturer of a blockbuster drug.  
(4) : Transferable intellectual property rights (prolonging exclusivity) (Derived from : Barton and 
Emanuel, 2007:2080) 
Prolonging exclusivity is granting firms longer periods of exclusivity on a blockbuster drug in return for 
developing new products of substantial developing-nation value. 
B. APPROACHES WITH MAIN FOCUS ON PUSH MECHANISMS FOR DRUG DEVELOPMENT 
(5) : Tax reliefs (Derived from : Gerhardsen, 2006:348) 
For example, the United Kingdom offers enhanced tax relief for R&D into vaccines or medicines for diseases 
that mainly affect developing countries, such as malaria, tuberculosis and HIV/AIDS. 
(6) : Re-location of R&D to low-cost countries (Derived from : Reddy and Sigurdson, 1997:344) 
Performing (some of) the strategic R&D in developing and East European countries in an effort to gain access 
to scientific personnel as well as to reduce R&D costs. 
(7) : Medical innovation prizes (Derived from : Gerhardsen, 2006:348) 
An alternative to the patent system and to raise R&D funding is the Medical Innovation Prize which has been 
put forward in a bill in the US Congress. Under the proposed legislation, new drugs would be treated as 
generics as soon as they receive regulatory approval and patent holders would be rewarded from a US$ 60-
billion award fund for coming up with innovations for better health. The fund would receive 0.5% of US 
GDP every year. 
(8) : Breakthrough innovation to create a low-cost, high-quality business model (Derived from : Prahalad, 
2006a:3; Prahalad, 2006b) 
Innovations that result in a product or service of world-class quality, achieving at least 90 percent cost 
reduction of a comparable product or service in the West, and which are scalable and affordable by the 
bottom of the economic pyramid, reaching people with the lowest levels of income in any given society. 
(9) : Public sector funding of Research and Development of medicines (Derived from : Kim, 2007:7) 
An obvious method for improving access to patented drugs is to finance public pharmaceutical research. In 
this way, patented drugs can directly enter the public domain. The notion is that as more patented drugs are 
directly placed in the public domain, pharmaceutical companies would be forced to compete with similar 
drugs that are already being sold in the market as generics, thereby driving down prices. 
C. APPROACHES WITH MAIN FOCUS ON BOTH PUSH AND PULL MECHANISMS FOR DRUG 
DEVELOPMENT 
(10) : Disease burden incentive systems (Derived from : Ridley et al, 2006:317) 
As an example, the US Orphan Drug Act (ODA) of 1983 provides seven years of marketing exclusivity upon 
FDA approval. Second, drug makers can qualify for tax credits for up to half of their clinical testing expenses. 
Third, developers can receive modest FDA grant support to investigate treatments for rare diseases. Fourth, 
the FDA provides counselling regarding conditions for approval.  
(11) : Addressing the regulatory excess (Derived from : Farrugia, 2004:83) 
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Systems of official regulation mandating standards and other measures are now coupled with voluntary 
standards adopted by industry bodies as additional features of a comprehensive nexus of arrangements 
contributing to product quality and risk minimization. “Addressing” means in this context simplification. 
(12) : Public-private partnerships (PPP) (Derived from : Hale et al, 2005:1058) 
Partnerships among global health organizations, pharmaceutical manufacturers, biotech firms, academia, and 
developing-world governments focusing on completing the development and distribution of drugs. 
(13) : Non-profit drug companies/non-profit medicine organization (Derived from : Hale et al, 
2005:1059) 
Operationally, a non-profit pharmaceutical company shares the core characteristics of classic public-private 
partnerships (PPP) but differs from them in several ways. Its in-house R&D team is larger than that of a 
classic PPP, it tackles a wide variety of neglected diseases and can select the best development opportunities 
available in each, and it is not limited in the modality of treatment: drugs, vaccines, and diagnostics could be 
developed as needed. 
D. APPROACHES WITH MAIN FOCUS ON INTERNATIONAL COLLABORATION & 
TREATEES 
(14) : Global “Marshall plan” (Derived from : Yunker, 2004:1109) 
A very-large scale foreign development assistance program on the future development of the world economy 
with the potential to bring a dramatic reduction in world economic inequality, at the cost of only a very minor 
retardation in the economic growth of the rich countries. 
(15) : 0.5% of GNP by rich countries, to combat poverty in the resource-poor countries (Derived from : 
Sachs, 2005:299-301) 
Jeffrey Sachs has calculated that some $135 to $195 billion per year for the period 2005-2015 which is about 
0.44 to 0.54 percent of the rich-world GNP each year during the forthcoming decade is needed, to eradicate 
extreme poverty in the world. The point is to bring the current average 0.25 percent of donor GNP to around 
0.5% of donor GNP. 
(16) : 0.1% of GNP dedicated to development of drugs for neglected diseases (Derived from : 
Gerhardsen, 2006:348)  
A WHO resolution (EB117 R13) sponsored by Brazil and Kenya, called for additional R&D funding for new 
vaccines and medicines for diseases that mainly affect developing countries as part of a new global 
framework on essential health research and development. It draws on a 2002 proposal for a Medical Research 
and Development Treaty by the non-governmental organization CPTech, which campaigns to improve access 
to medicines. The idea is that governments of rich countries raise funds for R&D on neglected diseases by 
allocating a portion of GNP (e.g. 0.1%). 
E. APPROACHES WITH MAIN FOCUS ON COUNTRY AUTHORITIES SUPPORTING THE 
PEOPLE IN NEED 
(17) : Infection prevention (including preventive medication) (Derived from : Mascarenhas et al, 
2005:409) 
The drug companies, who grant voluntary licenses and accelerate generic production, exert pressure on local 
governments and on affected people and their families to do their part in preventing the disease by 
appropriate behaviour modifications. 
(18) : Subsidisation/reimbursement of drugs (Derived from : Henry and Lexchin, 2002:1591) 
Because of market forces, government subsidisation of the use of drugs in their communities is widespread. 
(19) : Price controls/reference pricing (Derived from : Henry and Lexchin, 2002:1591) 
-Price controls : governments generally want prices at levels that will not exceed their drug budget, but 
recognise that if they demand too low a price, companies might decide not to market a product, and could 
reduce local investment. 
-Reference pricing : assigns a drug to a group of products, which receive the same level of reimbursement. 
Drugs can be referenced on the basis of clinical performance, sometimes to the cheapest generic product. In 
such systems, innovative products can be priced somewhat closer to the average of the price in comparison 
countries, suggesting that this approach can reward advances in treatment. 
(20) : Compulsory licensing (Derived from : Wise, 2006:344) 
Compulsory licenses allow third parties to use an invention without the patent holder’s consent. For example, 
local pharmaceutical companies may obtain compulsory licenses to produce generic versions of patented 
medicines or to import generic versions of medicines from foreign manufacturers. 
(21) : Parallel importation / parallel trade (Derived from : Wise, 2006:343) 
Parallel import is the import and resale in a country, without the consent of the patent holder, of a patented 
product that has been legitimately put on the market of the exporting country. This means that drugs sold at a 
lower price in one country can be imported into another country where the same drug is sold (=availability), 
but at a higher price. 
F. APPROACHES WITH MAIN FOCUS ON PHILANTROPY 
(22) : Drug donation (Derived from : Henry and Lexchin, 2002:1590) 
Some companies have maintained excellent programmes of drug donation, e.g. some have given away well 
over 100 million treatments or have offered to supply a particular product free in particular countries. 
(23) : Patent donation (free licenses) (Derived from : Gerhardsen, 2006:348) 
Donation of patents to parties in resource-poor settings.  
(24) : Enterprise-level initiatives (Derived from : Katrak, 2004:316) 
This concept proposes enterprise-level measures (not only pharmaceutical enterprises, but companies of any 
kind) that could make medicines more affordable for their infected employees. One measure would be to 
provide free, or subsidised, medicines to the employees. Another measure would be to help infected 
employees by allowing them to continue to work, to avoid reduced income. 
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(25) : Differential pricing/tiered pricing/discriminatory pricing (Derived from : Scherer and Watal, 
2002:913-928) 
Differential pricing, tiered pricing, equity pricing or discriminatory pricing (e.g. Ramsey-Baumol-Bradford 
pricing or simply Ramsey pricing) is a mechanism used by multinational pharmaceutical companies, under 
which prices are much lower in nations with low ability to pay and/or high price elasticities of demand than in 
wealthy nations. 
(26) : Voluntary discount pricing, beyond differential pricing (Derived from : Mascarenhas et al, 
2005:407) 
Price discounts offered by manufacturers, (often after intense and increasing pressure from protestors, 
including policy makers), to provide a common solution in distributing life-saving drugs to developing 
countries. 
 
3.    BIBLIOGRAPHY 











The narrative document that was sent out was condensed on one sheet by using small left 
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Addendum 3-16: The original tree nodes that were established in NVIVO8 to analyse the 
interviews of this thesis.  




A. Pull Mechanisms for Drug-Development 
A1. POS Advanced Market Commitments 
A1Bis. NEG Advanced Market Commitments 
A2. POS Optional Rewards on Therapeutic Effects 
A2Bis. NEG Optional Rewards on Therapeutic Effects 
A3. POS Priority Review Vouchers 
A3Bis. NEG Priority Review Vouchers 
A4. POS Transferable IP Rights & Against Generics 
A4Bis. NEG Transferrable IP Rights & Pro Generics 
 
 
B. Push Mechanisms for Drug-Development 
B5. POS Bigger Tax Reliefs 
B5Bis. NEG Bigger Tax Reliefs 
B6. POS Strategic Relocation of R&D 
B6Bis. NEG Strategic Relocation of R&D 
B7. POS Medical Innovation Prizes 
B7Bis. NEG Medical Innovation Prizes 
B8. POS Breakthrough Innovation for Low Cost 
B8Bis. NEG Breakthrough Innovation for Low Cost 
B9. POS Public Sector Funding of R&D 
B9Bis. NEG Public Sector Funding of R&D 
 
 
C. Approaches Using Push & Pull 
C10. POS Disease Burden Incentive Systems 
C10Bis. NEG Disease Burden Incentive Systems 
C11. POS Addressing the Regulatory Excess 
C11Bis. NEG Addressing the Regulatory Excess 
C12. POS PPPs for Drug-Development 
C12Bis. NEG PPPs for Drug Development 
C13. POS Non-Profit Drug Companies 
C13Bis. NEG Non-Profit Drug Companies 
 
 
D. International Treaties 
D14. POS Global Marshall Plan 
D14Bis. NEG Global Marshall Plan 
D15. POS 0.5% of GNP by Rich Countries for Poverty Reduction 
D15Bis. NEG 0.5% of GNP by Rich Countries for Poverty Reduction 
D16. POS 0.1% of GNP by Rich Countries for Drugs for Neglected Diseases 
D16Bis. NEG 0.1% of GNP by Rich Countries for Drugs for Neglected Diseases 
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Addendum 3-16: The original tree nodes that were established in NVIVO8 to analyse the 
interviews of this thesis. 
p.2/2: sheet 2 
 
 
E. Government Support of People in Need 
E17. POS Infection Prevention 
E17Bis. NEG Infection Prevention 
E18. POS Subsidisation or Reimbursement 
E18Bis. NEG Subsidisation or Reimbursement 
E19. POS Price Controls 
E19Bis. NEG Price Controls 
E20. POS Compulsory Licensing 
E20Bis. NEG Compulsory Licensing 
E21. POS Parallel Import & Trade 




F22. POS Drug Donation by DDs 
F22Bis. NEG Drug Donation by DDs 
F23. POS Patent Donation & Free Licenses & Voluntary Licenses 
F23Bis. NEG Patent Donation & Free Licenses & Voluntary Licenses 
F24. POS Enterprise-level Initiatives 
F24Bis. NEG Enterprise-level Initiatives 
F25. POS Differential Pricing & Tiered Pricing & Discriminatory Pricing 
F25Bis. NEG Differential Pricing & Tiered Pricing & Discriminatory Pricing 
F26. POS Voluntary Discount Pricing (beyond Differential Pricing) 
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Addendum 3-17: The new tree nodes that were established during the interviews of this 





G01. POS Patent Pooling 
G01Bis. NEG Patent Pooling 
G02. POS National Health Insurance System 
G02Bis. NEG National Health Insurance System 
G03. POS International Health Insurance System 
G03Bis. NEG International Health Insurance System 
G04. POS Appropriate Use of the Drugs & Adherence 
G04Bis. NEG Appropriate Use of the Drugs & Adherence 
G05. POS Improvement of the Quality of the Drugs 
G05Bis. NEG Improvement of the Quality of the Drugs 
G06. POS Micro-financing systems 
G06Bis. NEG Micro-financing Systems 
G07. POS Local Authorities spend 15% of Budget to Health 
G07Bis. NEG Local Authorities spend 15% of Budget to Health 
G08. POS Tendering & Kiwi Model 
G08Bis. NEG Tendering & Kiwi Model 
G09. POS Family Planning & Reduce Population Size 
G09Bis. NEG Family Planning and Reduce Population Size 
G10. POS Diagnostic Testing Point of Care 
G10Bis NEG Diagnostic Testing Point of Care 
G11. POS Early Access via Clinical Trials in RPC 
G11Bis. NEG Early Access via Clinical Trials in RPC 
G12. POS Abandon all Subsidies in the Rich World 
G12Bis. NEG Abandon all Subsidies in the Rich World 
G13. POS Educate RPCs to become Self-sufficient 
G13Bis. NEG Educate RPCs to be Self-Sufficient 
G14. POS Improve Health Infrastructure & Country Infrastructure 
G14Bis. Improve Health Infrastructure & Country Infrastructure 
G15. POS Authorities lower taxes on medication 
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CASES : EVIDENCE FOR PARTICULAR EVENTS OR TRENDS 
 
101. Evidence Patent Based go Generic 
102. Evidence Generics go Patent Based 
103. Evidence Constitutional Brazil & Thailand 
104. Evidence Local Pharma Boost & Kick-Start Brazil & Thailand 
105. Evidence Game Theory & Prisoner's Dilemma 
106. Evidence of Corruption 
107. Evidence for Attention to Paediatric Products & Fixed Dose Combinations 
108. Evidence for Negative Effect of Religion 
109. Evidence for Brazil, Thailand, South Africa as Emerging Markets 
110. Evidence for Shift from HIV&TB&Malaria to Other Diseases 
111. Evidence for too Obvious Questionnaire Answers 
112. Evidence for need to move from horizontal & vertical to diagonal 
113. Evidence for countries copying conflict model 
114. Evidence for Paradigm Shift HA&DD&NGO&Fs 
115. Evidence for Strong Effect of Economic Crisis 
116. Evidence for Sustainability 
117. Evidence of Primary Responsibility of Authorities 
118. Evidence for older & longest treated HIV population in Brazil & Thailand 
119. Evidence for INTENTIONS expressed in questionnaires 
120. Evidence for HAVES who don't want to pay for the HAVE-NOTS in Brazil & 
 Thailand 
121. Evidence for differences in opinion through POLITICS 
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Addendum 3-19: The method of striping in NVIVO8 that was used to analyse the 




L: Leo, researcher 
I: Interviewee 
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Addendum 4-1: The comments that were received on the questionnaires of this thesis. 
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Addendum 4-1: The comments that were received on the questionnaires of this thesis. 
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Addendum 4-1: The comments that were received on the questionnaires of this thesis. 
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Addendum 4-2: The frequency distribution of the 119 questionnaires that were received 




1 ,8 ,8 ,8
1 ,8 ,8 1,7
2 1,7 1,7 3,4
5 4,2 4,2 7,6
2 1,7 1,7 9,2
1 ,8 ,8 10,1
1 ,8 ,8 10,9
3 2,5 2,5 13,4
1 ,8 ,8 14,3
1 ,8 ,8 15,1
1 ,8 ,8 16,0
3 2,5 2,5 18,5
10 8,4 8,4 26,9
4 3,4 3,4 30,3
1 ,8 ,8 31,1
2 1,7 1,7 32,8
1 ,8 ,8 33,6
3 2,5 2,5 36,1
1 ,8 ,8 37,0
1 ,8 ,8 37,8
1 ,8 ,8 38,7
5 4,2 4,2 42,9
1 ,8 ,8 43,7
2 1,7 1,7 45,4
2 1,7 1,7 47,1
4 3,4 3,4 50,4
1 ,8 ,8 51,3
1 ,8 ,8 52,1
1 ,8 ,8 52,9
1 ,8 ,8 53,8
1 ,8 ,8 54,6
1 ,8 ,8 55,5
1 ,8 ,8 56,3
1 ,8 ,8 57,1
3 2,5 2,5 59,7
1 ,8 ,8 60,5
2 1,7 1,7 62,2
6 5,0 5,0 67,2
2 1,7 1,7 68,9
3 2,5 2,5 71,4
1 ,8 ,8 72,3
1 ,8 ,8 73,1
1 ,8 ,8 73,9
12 10,1 10,1 84,0
2 1,7 1,7 85,7
1 ,8 ,8 86,6
2 1,7 1,7 88,2
1 ,8 ,8 89,1
3 2,5 2,5 91,6
2 1,7 1,7 93,3
1 ,8 ,8 94,1
1 ,8 ,8 95,0
5 4,2 4,2 99,2






























































Decimal separator: comma 
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Addendum 4-3: Investigation of the influence that the data from Belgium & Senegal had 
on the results. 
 
1. Overall results of the 119 questionnaires, including those of Belgium and Senegal 
Statistics



















0 0 0 0 0 0
4,779 5,330 5,352 5,565 5,113 5,335
4,800 5,400 5,300 5,700 5,200 5,400
6,0 5,0a 4,8 5,0 5,2 6,4
1,0265 1,1019 1,0567 1,0191 1,1030 1,0724
1,3 1,0 1,0 2,7 1,8 2,0









Multiple modes exist. The smallest value is showna. 
 
Decimal separator: comma 
Statistics
119 119 119 119 119 119 119 119 119
0 0 0 0 0 0 0 0 0
5,03 4,97 4,65 4,41 5,60 4,97 5,08 5,54 5,52
5,00 5,00 5,00 5,00 6,00 5,00 5,00 6,00 6,00
6 6 6 7 7 7 6 7 7
1,551 1,518 1,598 2,097 1,753 1,799 1,616 1,443 1,690
1 1 1 1 1 1 1 1 1





























Decimal separator: comma 
Statistics
119 119 119 119 119 119 119
0 0 0 0 0 0 0
5,34 5,21 5,77 4,95 5,24 5,87 5,60
6,00 5,00 6,00 6,00 5,00 6,00 6,00
6 4 7 7 7 7 7
1,520 1,518 1,368 2,050 1,507 1,207 1,392
1 1 1 1 1 2 1
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Statistics
119 119 119 119 119 119 119 119 119 119
0 0 0 0 0 0 0 0 0 0
6,00 6,00 5,05 4,69 3,82 5,16 5,29 5,50 5,30 5,43
7,00 6,00 5,00 5,00 4,00 5,00 6,00 6,00 6,00 6,00
7 7 7 7 4 7 7 7 7 7
1,334 1,249 1,904 2,066 2,057 1,692 1,719 1,620 1,581 1,516
1 1 1 1 1 1 1 1 1 1













































109 109 109 109 109 109
0 0 0 0 0 0
4,746 5,362 5,334 5,561 5,158 5,386
4,800 5,400 5,300 5,700 5,200 5,400
4,5 5,0a 4,8 5,0 4,0a 6,4
1,0419 1,1204 1,0589 1,0399 1,1002 1,0656
1,3 1,0 1,0 2,7 1,8 2,0




























Multiple modes exist. The smallest value is showna. 
 
Decimal separator: comma 
Statistics
109 109 109 109 109 109 109 109 109
0 0 0 0 0 0 0 0 0
4,97 4,94 4,65 4,32 5,66 4,99 5,17 5,54 5,50
5,00 5,00 5,00 5,00 6,00 5,00 5,00 6,00 6,00
5 6 6 7 7 7 6 7 7
1,590 1,539 1,583 2,112 1,744 1,772 1,574 1,488 1,718
1 1 1 1 1 1 1 1 1
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109 109 109 109 109 109 109
0 0 0 0 0 0 0
5,28 5,11 5,83 4,98 5,22 5,85 5,62
6,00 5,00 6,00 6,00 5,00 6,00 6,00
6 4 7 7 4 7 7
1,551 1,536 1,346 2,046 1,493 1,238 1,386
1 1 1 1 1 2 1
































Decimal separator: comma 
 
Statistics
109 109 109 109 109 109 109 109 109 109
0 0 0 0 0 0 0 0 0 0
5,97 6,01 5,10 4,76 3,94 5,22 5,42 5,56 5,28 5,47
7,00 6,00 6,00 5,00 4,00 5,00 6,00 6,00 6,00 6,00
7 7 7 7 4 7 7 7 7 7
1,364 1,280 1,890 2,050 2,040 1,669 1,618 1,601 1,609 1,519
1 1 1 1 1 1 1 1 1 1













































107 107 107 107 107 107
0 0 0 0 0 0
4,781 5,304 5,383 5,521 5,036 5,274
4,800 5,400 5,300 5,700 5,000 5,200
6,0 6,0 4,8a 5,0 4,0 4,6a
1,0113 1,1283 1,0422 1,0021 1,1172 1,0728
1,3 1,0 1,0 2,7 1,8 2,0




























Multiple modes exist. The smallest value is showna. 
 
 
Decimal separator: comma 
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Statistics
107 107 107 107 107 107 107 107 107
0 0 0 0 0 0 0 0 0
5,03 4,98 4,62 4,45 5,53 4,95 4,97 5,56 5,55
5,00 5,00 5,00 5,00 6,00 5,00 5,00 6,00 6,00
6 6 6 7 7 7 6 7 7
1,587 1,473 1,588 2,116 1,803 1,835 1,634 1,435 1,682
1 1 1 1 1 1 1 1 1





























Decimal separator: comma 
 
Statistics
107 107 107 107 107 107 107
0 0 0 0 0 0 0
5,44 5,28 5,79 4,87 5,19 5,83 5,53
6,00 6,00 6,00 6,00 5,00 6,00 6,00
6 7 7 7 4 7 7
1,448 1,503 1,358 2,097 1,518 1,209 1,403
1 1 1 1 1 2 1
































Decimal separator: comma 
Statistics
107 107 107 107 107 107 107 107 107 107
0 0 0 0 0 0 0 0 0 0
6,00 5,98 4,95 4,53 3,71 5,10 5,21 5,46 5,26 5,36
7,00 6,00 5,00 5,00 4,00 5,00 6,00 6,00 6,00 6,00
7 7 7 7 1 7 7 7 7 6a
1,367 1,266 1,949 2,098 2,074 1,732 1,736 1,621 1,598 1,531
1 1 1 1 1 1 1 1 1 1



































Multiple modes exist. The smallest value is showna. 
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4. Results that were obtained for the complete set of questionnaires minus those from 




97 97 97 97 97 97
0 0 0 0 0 0
4,744 5,337 5,366 5,511 5,078 5,325
4,800 5,400 5,300 5,700 5,200 5,400
4,5 6,0a 4,8a 5,0a 4,0 4,6a
1,0273 1,1521 1,0438 1,0239 1,1190 1,0684
1,3 1,0 1,0 2,7 1,8 2,0




























Multiple modes exist. The smallest value is showna. 
 
Decimal separator: comma 
 
Statistics
97 97 97 97 97 97 97 97 97
0 0 0 0 0 0 0 0 0
4,96 4,96 4,62 4,35 5,60 4,98 5,07 5,57 5,53
5,00 5,00 5,00 5,00 6,00 5,00 5,00 6,00 6,00
6 6 6 7 7 7 6 7 7
1,632 1,492 1,571 2,136 1,801 1,808 1,596 1,485 1,713
1 1 1 1 1 1 1 1 1





























Decimal separator: comma 
 
Statistics
97 97 97 97 97 97 97 97 97 97
0 0 0 0 0 0 0 0 0 0
5,38 5,18 5,86 4,90 5,15 5,81 5,56 5,97 5,99 5,00
6,00 5,00 6,00 6,00 5,00 6,00 6,00 7,00 6,00 5,00
6 4 7 7 4 7 7 7 7 7
1,482 1,528 1,331 2,099 1,502 1,244 1,399 1,403 1,303 1,942
1 1 1 1 1 2 1 1 1 1









































Decimal separator: comma 
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Statistics
97 97 97 97 97 97 97
0 0 0 0 0 0 0
4,60 3,84 5,16 5,34 5,52 5,23 5,39
5,00 4,00 5,00 6,00 6,00 6,00 6,00
7 4 7 7 7 7 6
2,090 2,065 1,712 1,632 1,602 1,630 1,538
1 1 1 1 1 1 1



























Decimal separator: comma 
 
5. Conclusions that were drawn with regard to the influence of the data from Belgium 
and Senegal on the results. 
 
-Overall  
 -Highest scoring Group : D 
 -Top 5 highest scoring questions :  
  1. Q17 (6.00) 
  2. Q18 (6.00) 
  3. Q15 (5.87) 
  4. Q12 (5.77) 
  5. Q05 (5.60) 
      Q16 (5.60) 
 
-Without Belgium 
 -Highest scoring Group : D 
 -Top 5 highest scoring questions :  
  1. Q18 (6.01) 
  2. Q17 (5.97) 
  3. Q15 (5.83) 
  4. Q12 (5.83) 
  5. Q05 (5.66)   
 
-Without Senegal 
 -Highest scoring Group : D 
 -Top 5 highest scoring questions :  
  1. Q17 (6.00) 
  2. Q18 (5.98) 
  3. Q15 (5.83) 
  4. Q12 ( 5.79) 
  5. Q08 (5.56) 
 
-Without Belgium & Senegal 
 -Highest scoring Group : D 
 -Top 5 highest scoring questions :  
  1. Q18 (5.99) 
  2. Q17 (5.97) 
  3. Q12 (5.86) 
  4. Q15 (5.81) 
  5. Q05 (5.60) 
Final conclusion : only very minor variations were observed. 
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6. Comparison of Histograms for datasets that include or exclude the data from 
Belgium and/or Senegal. 
 
 
Example 1 : for the Average Score of Group B :  
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Decimal separator: comma 
 
 
Final Conclusion: only very minor effects on the results were observed. 
 
 
End Conclusion: the results for Belgium and Senegal will be left in the sample : the 
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Addendum 4-4-A: Data obtained for the 119 questionnaires, with the approaches listed 
in the sequence as on the questionnaire. 







Approach/Measure Question Average 
Score
119Q
01. Advanced market commitments Q01 5,03
02. Optional rewards on therapeutic effect Q02 4,97
03. Priority review voucher Q03 4,65
04. Transferable intellectual property rights Q04 4,41
05. Tax reliefs Q05 5,60
06. Re-location of R&D to low-cost countries Q06 4,97
07. Medical innovation prizes Q07 5,08
08. Breakthrough innovation LC/HQ Prahalad Q08 5,54
09. Public sector funding of R&D Q09 5,52
10. Disease burden incentive systems Q10 5,34
11. Addressing the regulatory excess Q11 5,21
12. Public-private partnerships (ppp) Q12 5,77
13. Non-profit companies for medicines Q13 4,95
14. Global Marshall plan Q14 5,24
15. 0.5% of GNP for poverty Q15 5,87
16. 0.1% of GNP for drugs for neglected diseases Q16 5,60
17. Infection prevention Q17 6,00
18. Subsidisation & reimbursement Q18 6,00
19. Price controls/reference pricing Q19 5,05
20. Compusory licensing Q20 4,69
21. Parallel importation & parallel trade Q21 3,82
22. Drug donation Q22 5,16
23. Patent donation & free licenses Q23 5,29
24. Enterprise-level initiatives Q24 5,50
25. Differential & tiered & discriminatory pricing Q25 5,30
26. Voluntary discount prices beyond differential pricing Q26 5,43  
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Addendum 4-4-B: Histogram obtained for the 119 questionnaires, with the approaches 
listed in the sequence as in the questionnaire. 




1,00 2,00 3,00 4,00 5,00 6,00 7,00
26. Voluntary discount prices beyond dif ferent ial pricing
25. Dif ferent ial & t iered & discriminatory pricing
24. Enterprise-level init iat ives
23. Patent donat ion & free licenses
22. Drug donat ion
21. Parallel importat ion & parallel t rade
20. Compulsory licensing
19. Price controls/reference pricing
18. Subsidisat ion & reimbursement
17. Infect ion prevent ion
16. 0.1% of GNP for drugs for neglected diseases
15. 0.5% of GNP for poverty
14. Global M arshall plan
13. Non-prof it  companies for medicines
12. Public-private partnerships (ppp)
11. Addressing the regulatory excess
10. Disease burden incent ive systems
09. Public sector funding of R&D
08. Breakthrough innovat ion LC/HQ Prahalad
07. M edical innovat ion prizes
06. Re-locat ion of R&D to low-cost countries
05. Tax reliefs
04. Transferable intellectual property rights
03. Priority review voucher
02. Opt ional rewards on therapeut ic ef fect





Decimal separator: comma 
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Addendum 4-4-C: Histogram obtained for the 119 questionnaires, with the approaches 
listed in descending order of the average scores. 




1,00 2,00 3,00 4,00 5,00 6,00 7,00
21. Parallel importat ion & parallel t rade
04. Transferable intellectual property rights
03. Priority review voucher
20. Compulsory licensing
13. Non-prof it  companies for medicines
02. Opt ional rewards on therapeutic ef fect
06. Re-location of  R&D to low-cost countries
01. Advanced market commitments
19. Price controls/reference pricing
07. M edical innovation prizes
22. Drug donation
11. Addressing the regulatory excess
14. Global M arshall plan
23. Patent donat ion & free licenses
25. Dif ferential & t iered & discriminatory pricing
10. Disease burden incentive systems
26. Voluntary discount prices beyond dif ferential pricing
24. Enterprise-level init iat ives
09. Public sector funding of R&D
08. Breakthrough innovat ion LC/HQ Prahalad
05. Tax reliefs
16. 0.1% of  GNP for drugs for neglected diseases
12. Public-private partnerships (ppp)
15. 0.5% of  GNP for poverty
17. Infect ion prevention





Decimal separator: comma 
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Addendum 4-5: Average scores of the 26 original approaches based on the analysis of 











Pritority Question Average Question Average Question Average
Score Score Score
1 Q15 5,81 Q18 6,16 Q17 6,20
2 Q12 5,73 Q17 5,95 Q18 6,12
3 Q17 5,69 Q15 5,84 Q12 6,04
4 Q18 5,50 Q10 5,79 Q15 5,92
5 Q09 5,42 Q05 5,79 Q05 5,88
6 Q16 5,35 Q02 5,77 Q08 5,82
7 Q08 5,35 Q25 5,77 Q16 5,76
8 Q07 5,27 Q11 5,67 Q23 5,74
9 Q19 5,23 Q26 5,67 Q24 5,72
10 Q10 5,08 Q16 5,56 Q09 5,66
11 Q13 5,04 Q12 5,49 Q26 5,66
12 Q14 4,96 Q09 5,42 Q13 5,58
13 Q22 4,96 Q04 5,35 Q19 5,56
14 Q20 4,88 Q08 5,33 Q22 5,50
15 Q01 4,81 Q23 5,26 Q06 5,42
16 Q02 4,81 Q14 5,23 Q14 5,40
17 Q25 4,77 Q01 5,21 Q07 5,32
18 Q05 4,73 Q02 5,07 Q20 5,30
19 Q24 4,65 Q22 4,88 Q25 5,18
20 Q03 4,62 Q06 4,70 Q11 5,14
21 Q11 4,58 Q07 4,67 Q10 5,08
22 Q26 4,58 Q03 4,56 Q01 5,00
23 Q06 4,54 Q19 4,35 Q02 4,96
24 Q23 4,50 Q13 4,16 Q03 4,74
25 Q21 4,12 Q20 3,86 Q21 4,60
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Addendum 4-6: Average scores of the 26 original approaches based on the analysis of 












Pritority Question Average Question Average Question Average
Score Score Score
1 Q17 6,15 Q18 5,94 Q17 6,08
2 Q18 6,02 Q24 5,73 Q18 6,03
3 Q12 6,02 Q17 5,70 Q15 6,03
4 Q05 6,02 Q05 5,61 Q12 5,79
5 Q15 6,00 Q16 5,52 Q10 5,67
6 Q09 5,94 Q15 5,48 Q08 5,49
7 Q24 5,91 Q08 5,42 Q01 5,38
8 Q16 5,87 Q25 5,42 Q26 5,38
9 Q26 5,70 Q12 5,39 Q11 5,33
10 Q23 5,68 Q19 5,36 Q16 5,33
11 Q08 5,66 Q9 5,33 Q25 5,31
12 Q07 5,62 Q22 5,33 Q09 5,18
13 Q06 5,60 Q10 5,30 Q14 5,10
14 Q14 5,55 Q11 5,24 Q05 5,08
15 Q13 5,47 Q20 5,21 Q02 4,90
16 Q22 5,40 Q23 5,21 Q23 4,90
17 Q02 5,23 Q26 5,09 Q24 4,82
18 Q25 5,21 Q06 4,97 Q04 4,74
19 Q19 5,13 Q07 4,97 Q22 4,72
20 Q10 5,09 Q14 4,97 Q03 4,69
21 Q11 5,09 Q13 4,88 Q19 4,69
22 Q01 5,06 Q02 4,67 Q07 4,51
23 Q20 5,04 Q01 4,58 Q13 4,38
24 Q03 4,87 Q03 4,27 Q06 4,21
25 Q04 4,36 Q04 4,09 Q20 3,82
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Addendum 4-7: Mann-Whitney U test results for group averages, obtained for the 119 
questionnaires of the thesis research.  
Mann-Whitney U tests are used to analyse whether the information of two sets of data is 
significantly different. The calculated values in the yellow boxes are significantly different 
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Addendum 4-8:  Mann-Whitney U test results for averages on individual questions, 
obtained for the 119 questionnaires of the thesis research.  
Mann-Whitney U tests are used to analyse whether the information of two sets of data is 
significantly different. The calculated values in the yellow boxes are significantly different 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































          
Addendum 4-9: Kruskal-Wallis H test results for group averages, obtained for the 119 
questionnaires of the thesis research.  
Kruskal-Wallis tests are used to analyse whether the information of three or more sets of 
data is significantly different. The calculated values in the yellow boxes are significantly 
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Addendum 4-10: Kruskal-Wallis H test results for group averages, obtained for the 119 
questionnaires of the thesis research.  
Kruskal-Wallis tests are used to analyse whether the information of three or more sets of 
data is significantly different. The calculated values in the yellow boxes are significantly 
































































































































































































































































































































































































































































































































































































































































































                      - 120 - 
          
Addendum 4-11: Pearson correlations between group averages and Hofstede’s cultural 
components, obtained for the 119 questionniares. 
A Pearson correlation describes the direction and strength of a relationship between 
interval variables. In this particular case, on the one hand, the scores on the test items, and 
on the other hand the group averages of the questionnaire. The calculated values in the 
yellow boxes are statistically significant. The tested items are explained in the code book 
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Addendum 4-12: Pearson correlations between average scores on individual questions 
and Hofstede’s cultural components, obtained for the 119 questionnaires. 
A Pearson correlation describes the direction and strength of a relationship between 
interval variables. In this particular case, on the one hand, the scores on the test items, and 
on the other hand the average scores on the individual questions of the questionnaire. The 
calculated values in the yellow boxes are statistically significant. The tested items are 
explained in the code book for SPSS, in Addendum 3-13. 
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Addendum 4-13: Overview of people that participated in the interviews of this thesis.  
For confidentiality reasons, the participants are described only in terms of gender, 
work environment and country or geographic area of their professional a
Interviewees were classified in three groups: Authorities/Politics, Drug 
their 
ctivities. 




Authorities / Politics Drug Developers / (Pharma) Companies NGOs & Foundations
Universities (drug discovery or clinical trials)
1. Male participant 2. Male participant 4. Female participant
Consultant advising health authorities of RPC to Responsible for employee programs at a company Physician at Médecins sans Frontières, responsible
apply drug access programmes in the food & beverage sector; plants in Africa for access programs in Africa.
Dutch / Works worldwide Enterprise level measures to increase access. Belgian / Works in Africa and Belgium
Belgian / Works in Africa and Belgium
5. Female participant 3. Male participant 10. Female participant
Senator (Health, Dev. Coop.) Director in small pharma company Works for an NGO, mainly on new concepts for
Head of deptartment at university Specializing in products for Africa patents.
Ran women's health programs in RPC in earlier years Belgian / Works in Belgium Dutch / Works in Switzerland
Belgian / Works in Belgium
13. Female participant 6. Male participant 11. Female participant
Director and professor at a State intitute Director for "Social Responsibility Programs" of Involved in AIDS Society of India.
Many years ago she was at MSF. international company Worked a lot with the Authorities
Belgian / Works in Belgium Kenyan / Works in Kenya Indian / Works in India
14. Male participant 7. Female participant 12. Male participant
Has been working for the Health Authorities of Director of Public Affairs Médecins sans Frontières
a RPC for 10 years. Recently switched to an NGO Big international company Access to Essential Medicines
From Burkina Faso / Works in Burundi now. American / Works in Switzerland Swiss / Works in Switzerland
18. Male participant 8. Male participant 16. Male participant
Collaborator of the Ministry of Health of Niger. HIV Policy and Public Affairs Essential Medicines and Pharmaceutical
Aggregated doctor of the United Nations. Big international company Policies - WHO
From Niger / Works in Niger German / Works in Namibia and South Africa Dutch / Works in Switzerland
19. Male and female participant (only 1 interview) 9. Male participant 17. Female participant
Ministry of foreign Affairs General Manager Médecins sans Frontières
Dutch / Work in Holland Small pharma company Specialist in access programmes.
(Both worked in the field earlier e.g. MSF) From Uganda / Works in Uganda Italian / Currently works in Belgium
23. Male participant 15. Male participant 21. Male participant
Collaborator of the European Commission for Consultant in access to medicines. Mainly supports Works for one year at a foundation of a USA university
Humanitarian Aid and Development Cooperation pharmaceutical companies with their strategy for Human rights lawyer / Belgian / Works in the USA
Belgian / Works in Belgium (European Commission) access (Has formerly been with Belgian MSF)
Belgian / Works mainly in the USA.
27. Male participant 20. Male participant 22. Male participant
and female assistent from Paraguary (only 1 interview) VP Communications and Access Programs Department Head of local office of global NGO
Mexican / Paraguayan Big international company Ukraine
Working at a state institute in Mexico British, works in USA Ukrainian / Works in Ukraine
(Used to work for WHO on this subject)
26. Male participant 24. Male participant
Big international pharmaceutical company Retired, but active in consultancy to Global Fund,
Brazilian / Works in Brazil IAS etc.
1/2 of career : for government / 1/2 non-government
Australian / Works in Australia
28. Male participant 25. Male participant
Professor of Infectious Diseases, University Works at an International Policy Think Tank 
Thai / Works in Thailand Australian / Works in Australia
29. Male participant
Retired Professor / Associated with Red Cross
Thai / Lives in Thailand
 
Yellow colour: pilot-run interviews 
reen colour: full-run interviews G
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Addendum 4-14-A: Data and histogram that were obtained from the 29 interviews; in 
sequence. 
Approaches are listed in the sequence that the questions (1-26) were on the questionnaire 
oaches (27-41) were identified in the interviews.  
et hits means: the positive hits minus the negative hits. 
.1/2: the data sheet 
 
 




29 interviews - final
Approach/Measure Pos Hits Neg Hits Net Hits 
01. Advanced market commitments 8 0 8
02. Optional rewards on therapeutic effect 1 2 -1
03. Priority review voucher 3 4 -1
04. Transferable intellectual property rights/avoid generics 4 20 -16
05. Tax reliefs 4 2 2
06. Re-location of R&D to low-cost countries 2 1 1
07. Medical innovation prizes 1 0 1
08. Breakthrough innovation LC/HQ Prahalad 4 2 2
09. Public sector funding of R&D 5 4 1
10. Disease burden incentive systems 0 1 -1
11. Addressing the regulatory excess 6 2 4
12. Public-private partnerships (ppp) 28 1 27
13. Non-profit companies for medicines 2 1 1
14. Global Marshall plan 9 2 7
15. 0.5% of GNP for poverty 13 3 10
16. 0.1% of GNP for drugs for neglected diseases 4 1 3
17. Infection prevention 23 4 19
18. Subsidisation & reimbursement 10 4 6
19. Price controls/reference pricing 9 0 9
20. Compulsory licensing 12 2 10
21. Parallel importation & parallel trade 2 1 1
22. Drug donation 6 6 0
23. Patent donation & free licenses/voluntary licenses 11 1 10
24. Enterprise-level initiatives 5 0 5
25. Differential & tiered & discriminatory pricing 26 1 25
26. Voluntary discount prices beyond differential pricing 3 2 1
27. Patent pooling 14 0 14
28. Strengthening national health insurance system 11 0 11
29. Setting up international health insurance system 1 0 1
30. Appropriate use of drugs & adherence 3 0 3
31. Improvement of quality of drugs 11 0 11
32. Setting up microfinancing systems 1 0 1
33. Local authorities to spend 15% of budget to health 5 0 5
34. Tendering and Kiwi model 1 0 1
35. Family planning & reduce population size 2 0 2
36. Diagnostic testing point of care 6 0 6
37. Early access to clinical trials in RPC 2 0 2
38. Abandon all subsidies in the rich world 2 0 2
39. Educate RPCs to become self-sufficient 1 0 1
40. Improve health infrastructure & country infrastructure 8 0 8
41. Authorities lower taxes on medication 2 0 2  
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Addendum 4-14-A: Data and histogram that were obtained from the 29 interviews; in 
sequence. 
Approaches are listed in the sequence that the questions (1-26) were on the questionnaire 
oaches (27-41) were identified in the interviews. Net hits means: the 
ositive hits minus the negative hits. 
.2/2: the histogram 
 
 
and that the new appr
p
p
Net Number of Hits 29 Interviews
-20 -15 -10 -5 0 5 10 15 20 25 30
41. Aut horit ies lower t axes on medicat ion
40. Improve healt h inf rast ruct ure & count ry inf rast ruct ure
39. Educat e RPCs t o become self -suf f icient
38. Abandon all subsidies in t he r ich wor ld
37. Early access t o clinical t r ials in RPC
36. Diagnost ic t est ing point  of  care
35. Family planning & reduce populat ion size
34. Tendering and Kiwi model
33. Local aut hor it ies t o spend 15% of  budget  t o healt h
32. Set t ing up microf inancing syst ems
31. Improvement  of  qualit y of  drugs
30. Appropr iat e use of  drugs & adherence
29. Set t ing up int ernat ional healt h insurance syst em
28. St rengt hening nat ional healt h insurance syst em
27. Pat ent  pooling
26. Volunt ary discount  prices beyond dif f erent ial pr icing
25. Dif f erent ial & t iered & discr iminat ory pr icing
24. Ent erprise-level init iat ives
23. Pat ent  donat ion & f ree licenses/ volunt ary licenses
22. Drug donat ion
21. Parallel import at ion & parallel t rade
20. Compulsory licensing
19. Price cont rols/ ref erence pr icing
18. Subsidisat ion & reimbursement
17. Inf ect ion prevent ion
16. 0.1% of  GNP f or drugs f or neglect ed diseases
15. 0.5% of  GNP f or  povert y
14. Global Marshall plan
13. Non-prof it  companies f or medicines
12. Public-privat e part nerships (ppp)
11. Addressing t he regulat ory excess
10. Disease burden incent ive syst ems
09. Public sect or f unding of  R&D
08. Breakt hrough innovat ion LC/ HQ Prahalad
07. Medical innovat ion prizes
06. Re-locat ion of  R&D t o low-cost  count r ies
05. Tax relief s
04. Transf erable int ellect ual propert y r ight s/ avoid generics
03. Priorit y review voucher
02. Opt ional rewards on t herapeut ic ef f ect
01. Advanced market  commit ment s
Ite
m
Net number of hits
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Addendum 4-14-B:Histogram that was obtained from the 29 interviews; in descending 
order. 
Approaches are listed in the descending order of the net number of hits.  
Net hits means: the positive hits minus the negative hits. 
 
Net Number of Hits 29 Interviews
-20 -10 0 10 20 3
04. Transf erable int ellect ual propert y r ight s/ avoid generics
03. Pr ior it y review voucher
02. Opt ional rewards on t herapeut ic ef f ect
10. Disease burden incent ive syst ems
22. Drug donat ion
09. Public sect or f unding of  R&D
07. Medical innovat ion pr izes
06. Re-locat ion of  R&D t o low-cost  count r ies
39. Educat e RPCs t o become self -suf f icient
34. Tendering and Kiwi model
32. Set t ing up microf inancing syst ems
29. Set t ing up int ernat ional healt h insurance syst em
26. Volunt ary discount  pr ices beyond dif f erent ial pr icing
21. Parallel import at ion & parallel t rade
13. Non-prof it  companies f or medicines
08. Breakt hrough innovat ion LC/ HQ Prahalad
05. Tax relief s
41. Aut horit ies lower t axes on medicat ion
38. Abandon all subsidies in t he rich world
37. Ear ly access t o clinical t r ials in RPC
35. Family planning & reduce populat ion size
30. Appropr iat e use of  drugs & adherence
16. 0.1% of  GNP f or drugs f or neglect ed diseases
11. Addressing t he regulat ory excess
33. Local aut hor it ies t o spend 15% of  budget  t o healt h
24. Ent erprise- level init iat ives
36. Diagnost ic t est ing point  of  care
18. Subsidisat ion & reimbursement
14. Global Marshall plan
40. Improve healt h inf rast ruct ure & count ry inf rast ruct ure
01. Advanced market  commit ment s
19. Pr ice cont rols/ ref erence pr icing
23. Pat ent  donat ion & f ree licenses/ volunt ary licenses
20. Compulsory licensing
15. 0.5% of  GNP f or povert y
31. Improvement  of  qualit y of  drugs
28. St rengt hening nat ional healt h insurance syst em
27. Pat ent  pooling
17. Inf ect ion prevent ion
25. Dif f erent ial & t iered & discr iminat ory pr icing




Net number of hits
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Addendum 4-15: The number of net hits that were obtained for each of the stakeholders. 
ere identified in the interviews. Net hits means: the 
 hits. 
.1/4: the data sheet unsorted  
 
Approaches are listed in the sequence that the questions (1-26) were on the questionnaire 
and that the new approaches (27-41) w





29 interviews - final
Approach/Measure Pos  Neg  Net  Pos  Neg  Net  Pos  Neg  Net  
Hits Hits Hits Hits Hits Hits Hits Hits Hits
01. Advanced market commitments 3 0 3 4 0 4 1 0 1
02. Optional rewards on therapeutic effect 0 1 -1 0 1 -1 0 0 0
03. Priority review voucher 1 0 1 2 2 0 0 2 -2
04. Transferable intellectual property rights/avoid generics 2 3 -1 2 6 -4 0 11 -11
05. Tax reliefs 0 0 0 3 1 2 1 1 0
06. Re-location of R&D to low-cost countries 0 0 0 1 1 0 1 0 1
07. Medical innovation prizes 0 0 0 1 0 1 0 0 0
08. Breakthrough innovation LC/HQ Prahalad 1 0 1 1 2 -1 2 0 2
09. Public sector funding of R&D 0 1 -1 0 2 -2 5 1 4
10. Disease burden incentive systems 0 0 0 0 0 0 0 1 -1
11. Addressing the regulatory excess 1 0 1 4 1 3 1 1 0
12. Public-private partnerships (ppp) 9 1 8 10 0 10 9 0 9
13. Non-profit companies for medicines 1 0 1 0 1 -1 1 0 1
14. Global Marshall plan 2 1 1 5 0 5 2 1 1
15. 0.5% of GNP for poverty 2 0 2 4 2 2 7 1 6
16. 0.1% of GNP for drugs for neglected diseases 0 0 0 2 1 1 2 0 2
17. Infection prevention 5 3 2 6 0 6 12 1 11
18. Subsidisation & reimbursement 4 0 4 1 0 1 5 4 1
19. Price controls/reference pricing 4 0 4 1 0 1 4 0 4
20. Compulsory licensing 3 0 3 1 2 -1 8 0 8
21. Parallel importation & parallel trade 0 1 -1 1 0 1 1 0 1
22. Drug donation 1 1 0 4 2 2 1 3 -2
23. Patent donation & free licenses/voluntary licenses 0 0 0 5 0 5 6 1 5
24. Enterprise-level initiatives 0 0 0 2 0 2 3 0 3
25. Differential & tiered & discriminatory pricing 4 0 4 9 1 8 13 0 13
26. Voluntary discount prices beyond differential pricing 0 0 0 0 2 -2 3 0 3
27. Patent pooling 1 0 1 2 0 2 11 0 11
28. Strengthening national health insurance system 5 0 5 3 0 3 3 0 3
29. Setting up international health insurance system 0 0 0 0 0 0 1 0 1
30. Appropriate use of drugs & adherence 1 0 1 2 0 2 0 0 0
31. Improvement of quality of drugs 5 0 5 2 0 2 4 0 4
32. Setting up microfinancing systems 0 0 0 1 0 1 0 0 0
33. Local authorities to spend 15% of budget to health 2 0 2 1 0 1 2 0 2
34. Tendering and Kiwi model 1 0 1 1 0 1 0 0 0
35. Family planning & reduce population size 2 0 2 0 0 0 0 0 0
36. Diagnostic testing point of care 3 0 3 2 0 2 1 0 1
37. Early access to clinical trials in RPC 0 0 0 1 0 1 1 0 1
38. Abandon all subsidies in the rich world 0 0 0 1 0 1 1 0 1
39. Educate RPCs to become self-sufficient 0 0 0 1 0 1 0 0 0
40. Improve health infrastructure & country infrastructure 3 0 3 1 0 1 4 0 4
41. Authorities lower taxes on medication 1 0 1 0 0 0 1 0 1
NGOs & FDD / COMP.AUTH. / POL.
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Addendum 4-15: The number of net hits that were obtained for each of the stakeholders. 
.2/4: the data sheet sorted in descending order of the net number of hits of the authorities. 
 





29 interviews - final
Approach/Measure Pos  Neg  Net  Pos  Neg  Net  Pos  Neg  Net  
Hits Hits Hits Hits Hits Hits Hits Hits Hits
12. Public-private partnerships (ppp) 9 1 8 10 0 10 9 0 9
28. Strengthening national health insurance system 5 0 5 3 0 3 3 0 3
31. Improvement of quality of drugs 5 0 5 2 0 2 4 0 4
18. Subsidisation & reimbursement 4 0 4 1 0 1 5 4 1
19. Price controls/reference pricing 4 0 4 1 0 1 4 0 4
25. Differential & tiered & discriminatory pricing 4 0 4 9 1 8 13 0 13
01. Advanced market commitments 3 0 3 4 0 4 1 0 1
20. Compulsory licensing 3 0 3 1 2 -1 8 0 8
36. Diagnostic testing point of care 3 0 3 2 0 2 1 0 1
40. Improve health infrastructure & country infrastructure 3 0 3 1 0 1 4 0 4
15. 0.5% of GNP for poverty 2 0 2 4 2 2 7 1 6
17. Infection prevention 5 3 2 6 0 6 12 1 11
33. Local authorities to spend 15% of budget to health 2 0 2 1 0 1 2 0 2
35. Family planning & reduce population size 2 0 2 0 0 0 0 0 0
03. Priority review voucher 1 0 1 2 2 0 0 2 -2
08. Breakthrough innovation LC/HQ Prahalad 1 0 1 1 2 -1 2 0 2
11. Addressing the regulatory excess 1 0 1 4 1 3 1 1 0
13. Non-profit companies for medicines 1 0 1 0 1 -1 1 0 1
14. Global Marshall plan 2 1 1 5 0 5 2 1 1
27. Patent pooling 1 0 1 2 0 2 11 0 11
30. Appropriate use of drugs & adherence 1 0 1 2 0 2 0 0 0
34. Tendering and Kiwi model 1 0 1 1 0 1 0 0 0
41. Authorities lower taxes on medication 1 0 1 0 0 0 1 0 1
05. Tax reliefs 0 0 0 3 1 2 1 1 0
06. Re-location of R&D to low-cost countries 0 0 0 1 1 0 1 0 1
07. Medical innovation prizes 0 0 0 1 0 1 0 0 0
10. Disease burden incentive systems 0 0 0 0 0 0 0 1 -1
16. 0.1% of GNP for drugs for neglected diseases 0 0 0 2 1 1 2 0 2
22. Drug donation 1 1 0 4 2 2 1 3 -2
23. Patent donation & free licenses/voluntary licenses 0 0 0 5 0 5 6 1 5
24. Enterprise-level initiatives 0 0 0 2 0 2 3 0 3
26. Voluntary discount prices beyond differential pricing 0 0 0 0 2 -2 3 0 3
29. Setting up international health insurance system 0 0 0 0 0 0 1 0 1
32. Setting up microfinancing systems 0 0 0 1 0 1 0 0 0
37. Early access to clinical trials in RPC 0 0 0 1 0 1 1 0 1
38. Abandon all subsidies in the rich world 0 0 0 1 0 1 1 0 1
39. Educate RPCs to become self-sufficient 0 0 0 1 0 1 0 0 0
02. Optional rewards on therapeutic effect 0 1 -1 0 1 -1 0 0 0
04. Transferable intellectual property rights/avoid generics 2 3 -1 2 6 -4 0 11 -11
09. Public sector funding of R&D 0 1 -1 0 2 -2 5 1 4
1. Parallel importation & parallel trade 0 1 -1 1 0 1 1 0 1
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Addendum 4-15: The number of net hits that were obtaind for each of the stakeholders. 
ta sheet sorted in descending order of the net number of hits of the drug 
evelopers 
 







29 interviews - final
Approach/Measure Pos  Neg  Net  Pos  Neg  Net  Pos  Neg  Net  
Hits Hits Hits Hits Hits Hits Hits Hits Hits
12. Public-private partnerships (ppp) 9 1 8 10 0 10 9 0 9
25. Differential & tiered & discriminatory pricing 4 0 4 9 1 8 13 0 13
17. Infection prevention 5 3 2 6 0 6 12 1 11
14. Global Marshall plan 2 1 1 5 0 5 2 1 1
23. Patent donation & free licenses/voluntary licenses 0 0 0 5 0 5 6 1 5
01. Advanced market commitments 3 0 3 4 0 4 1 0 1
28. Strengthening national health insurance system 5 0 5 3 0 3 3 0 3
11. Addressing the regulatory excess 1 0 1 4 1 3 1 1 0
31. Improvement of quality of drugs 5 0 5 2 0 2 4 0 4
36. Diagnostic testing point of care 3 0 3 2 0 2 1 0 1
15. 0.5% of GNP for poverty 2 0 2 4 2 2 7 1 6
27. Patent pooling 1 0 1 2 0 2 11 0 11
30. Appropriate use of drugs & adherence 1 0 1 2 0 2 0 0 0
05. Tax reliefs 0 0 0 3 1 2 1 1 0
22. Drug donation 1 1 0 4 2 2 1 3 -2
24. Enterprise-level initiatives 0 0 0 2 0 2 3 0 3
18. Subsidisation & reimbursement 4 0 4 1 0 1 5 4 1
19. Price controls/reference pricing 4 0 4 1 0 1 4 0 4
40. Improve health infrastructure & country infrastructure 3 0 3 1 0 1 4 0 4
33. Local authorities to spend 15% of budget to health 2 0 2 1 0 1 2 0 2
34. Tendering and Kiwi model 1 0 1 1 0 1 0 0 0
07. Medical innovation prizes 0 0 0 1 0 1 0 0 0
16. 0.1% of GNP for drugs for neglected diseases 0 0 0 2 1 1 2 0 2
32. Setting up microfinancing systems 0 0 0 1 0 1 0 0 0
37. Early access to clinical trials in RPC 0 0 0 1 0 1 1 0 1
38. Abandon all subsidies in the rich world 0 0 0 1 0 1 1 0 1
39. Educate RPCs to become self-sufficient 0 0 0 1 0 1 0 0 0
21. Parallel importation & parallel trade 0 1 -1 1 0 1 1 0 1
35. Family planning & reduce population size 2 0 2 0 0 0 0 0 0
03. Priority review voucher 1 0 1 2 2 0 0 2 -2
41. Authorities lower taxes on medication 1 0 1 0 0 0 1 0 1
06. Re-location of R&D to low-cost countries 0 0 0 1 1 0 1 0 1
10. Disease burden incentive systems 0 0 0 0 0 0 0 1 -1
29. Setting up international health insurance system 0 0 0 0 0 0 1 0 1
20. Compulsory licensing 3 0 3 1 2 -1 8 0 8
08. Breakthrough innovation LC/HQ Prahalad 1 0 1 1 2 -1 2 0 2
13. Non-profit companies for medicines 1 0 1 0 1 -1 1 0 1
02. Optional rewards on therapeutic effect 0 1 -1 0 1 -1 0 0 0
26. Voluntary discount prices beyond differential pricing 0 0 0 0 2 -2 3 0 3
09. Public sector funding of R&D 0 1 -1 0 2 -2 5 1 4
4. Transferable intellectual property rights/avoid generics 2 3 -1 2 6 -4 0 11 -11
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Addendum 4-15: The number of net hits that were obtained for each of the stakeholders. 
.4/4: the data sheet sorted in descending order of the net number of hits of the NGO&Fs. 
 







29 interviews - final
Approach/Measure Pos  Neg  Net  Pos  Neg  Net  Pos  Neg  Net  
Hits Hits Hits Hits Hits Hits Hits Hits Hits
25. Differential & tiered & discriminatory pricing 4 0 4 9 1 8 13 0 13
17. Infection prevention 5 3 2 6 0 6 12 1 11
27. Patent pooling 1 0 1 2 0 2 11 0 11
12. Public-private partnerships (ppp) 9 1 8 10 0 10 9 0 9
20. Compulsory licensing 3 0 3 1 2 -1 8 0 8
15. 0.5% of GNP for poverty 2 0 2 4 2 2 7 1 6
23. Patent donation & free licenses/voluntary licenses 0 0 0 5 0 5 6 1 5
31. Improvement of quality of drugs 5 0 5 2 0 2 4 0 4
19. Price controls/reference pricing 4 0 4 1 0 1 4 0 4
40. Improve health infrastructure & country infrastructure 3 0 3 1 0 1 4 0 4
09. Public sector funding of R&D 0 1 -1 0 2 -2 5 1 4
28. Strengthening national health insurance system 5 0 5 3 0 3 3 0 3
24. Enterprise-level initiatives 0 0 0 2 0 2 3 0 3
26. Voluntary discount prices beyond differential pricing 0 0 0 0 2 -2 3 0 3
33. Local authorities to spend 15% of budget to health 2 0 2 1 0 1 2 0 2
16. 0.1% of GNP for drugs for neglected diseases 0 0 0 2 1 1 2 0 2
08. Breakthrough innovation LC/HQ Prahalad 1 0 1 1 2 -1 2 0 2
14. Global Marshall plan 2 1 1 5 0 5 2 1 1
01. Advanced market commitments 3 0 3 4 0 4 1 0 1
36. Diagnostic testing point of care 3 0 3 2 0 2 1 0 1
18. Subsidisation & reimbursement 4 0 4 1 0 1 5 4 1
37. Early access to clinical trials in RPC 0 0 0 1 0 1 1 0 1
38. Abandon all subsidies in the rich world 0 0 0 1 0 1 1 0 1
21. Parallel importation & parallel trade 0 1 -1 1 0 1 1 0 1
41. Authorities lower taxes on medication 1 0 1 0 0 0 1 0 1
06. Re-location of R&D to low-cost countries 0 0 0 1 1 0 1 0 1
29. Setting up international health insurance system 0 0 0 0 0 0 1 0 1
13. Non-profit companies for medicines 1 0 1 0 1 -1 1 0 1
11. Addressing the regulatory excess 1 0 1 4 1 3 1 1 0
30. Appropriate use of drugs & adherence 1 0 1 2 0 2 0 0 0
05. Tax reliefs 0 0 0 3 1 2 1 1 0
34. Tendering and Kiwi model 1 0 1 1 0 1 0 0 0
07. Medical innovation prizes 0 0 0 1 0 1 0 0 0
32. Setting up microfinancing systems 0 0 0 1 0 1 0 0 0
39. Educate RPCs to become self-sufficient 0 0 0 1 0 1 0 0 0
35. Family planning & reduce population size 2 0 2 0 0 0 0 0 0
02. Optional rewards on therapeutic effect 0 1 -1 0 1 -1 0 0 0
10. Disease burden incentive systems 0 0 0 0 0 0 0 1 -1
22. Drug donation 1 1 0 4 2 2 1 3 -2
03. Priority review voucher 1 0 1 2 2 0 0 2 -2
4. Transferable intellectual property rights/avoid generics 2 3 -1 2 6 -4 0 11 -11
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Addendum 4-16: The number of net hits that were obtained for each of the resource 
levels. 
Approaches are listed in the same sequence in which the questions (1-26) were on the 
questionnaire and that the new approaches (27-41) were identified in the interviews. Net 
hits means: the positive hits minus the negative hits. 






29 interviews - final
Approach/Measure Pos  Neg  Net  Pos  Neg  Net  Pos  Neg  Net  
Hits Hits Hits Hits Hits Hits Hits Hits Hits
01. Advanced market commitments 3 0 3 0 0 0 5 0 5
02. Optional rewards on therapeutic effect 0 2 -2 0 0 0 1 0 1
03. Priority review voucher 1 1 0 0 0 0 2 3 -1
04. Transferable intellectual property rights/avoid generics 4 4 0 1 5 -4 2 11 -9
05. Tax reliefs 1 1 0 0 0 0 3 1 2
06. Re-location of R&D to low-cost countries 0 1 -1 1 0 1 1 0 1
07. Medical innovation prizes 1 0 1 0 0 0 0 0 0
08. Breakthrough innovation LC/HQ Prahalad 1 2 -1 2 0 2 1 0 1
09. Public sector funding of R&D 0 2 -2 0 0 0 5 2 3
10. Disease burden incentive systems 0 0 0 0 0 0 0 1 -1
11. Addressing the regulatory excess 4 1 3 1 0 1 1 1 0
12. Public-private partnerships (ppp) 4 1 3 4 0 4 20 0 20
13. Non-profit companies for medicines 1 1 0 1 0 1 0 0 0
14. Global Marshall plan 3 0 3 0 1 -1 6 1 5
15. 0.5% of GNP for poverty 3 1 2 3 0 3 7 2 5
16. 0.1% of GNP for drugs for neglected diseases 0 1 -1 0 0 0 4 0 4
17. Infection prevention 4 1 3 4 2 2 15 1 14
18. Subsidisation & reimbursement 3 0 3 1 3 -2 6 1 5
19. Price controls/reference pricing 2 0 2 3 0 3 4 0 4
20. Compulsory licensing 2 0 2 3 0 3 7 2 5
21. Parallel importation & parallel trade 0 1 -1 1 0 1 1 0 1
22. Drug donation 0 3 -3 1 0 1 5 3 2
23. Patent donation & free licenses/voluntary licenses 4 0 4 4 0 4 3 1 2
24. Enterprise-level initiatives 2 0 2 2 0 2 1 0 1
25. Differential & tiered & discriminatory pricing 5 0 5 5 0 5 16 1 15
26. Voluntary discount prices beyond differential pricing 0 1 -1 1 0 1 2 1 1
27. Patent pooling 0 0 0 0 0 0 14 0 14
28. Strengthening national health insurance system 5 0 5 4 0 4 2 0 2
29. Setting up international health insurance system 0 0 0 0 0 0 1 0 1
30. Appropriate use of drugs & adherence 1 0 1 0 0 0 2 0 2
31. Improvement of quality of drugs 2 0 2 4 0 4 5 0 5
32. Setting up microfinancing systems 0 0 0 0 0 0 1 0 1
33. Local authorities to spend 15% of budget to health 2 0 2 0 0 0 3 0 3
34. Tendering and Kiwi model 0 0 0 0 0 0 1 0 1
35. Family planning & reduce population size 0 0 0 0 0 0 2 0 2
36. Diagnostic testing point of care 1 0 1 2 0 2 3 0 3
37. Early access to clinical trials in RPC 0 0 0 1 0 1 1 0 1
38. Abandon all subsidies in the rich world 1 0 1 0 0 0 1 0 1
39. Educate RPCs to become self-sufficient 1 0 1 0 0 0 0 0 0
40. Improve health infrastructure & country infrastructure 1 0 1 4 0 4 3 0 3
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Addendum 4-16: The number of net hits that were obtained for each of the resource 
levels. 
Net hits means: the positive hits minus the negative hits. 








29 interviews - final
Approach/Measure Pos  Neg  Net  Pos  Neg  Net  Pos  Neg  Net  
Hits Hits Hits Hits Hits Hits Hits Hits Hits
25. Differential & tiered & discriminatory pricing 5 0 5 5 0 5 16 1 15
28. Strengthening national health insurance system 5 0 5 4 0 4 2 0 2
23. Patent donation & free licenses/voluntary licenses 4 0 4 4 0 4 3 1 2
01. Advanced market commitments 3 0 3 0 0 0 5 0 5
11. Addressing the regulatory excess 4 1 3 1 0 1 1 1 0
12. Public-private partnerships (ppp) 4 1 3 4 0 4 20 0 20
14. Global Marshall plan 3 0 3 0 1 -1 6 1 5
17. Infection prevention 4 1 3 4 2 2 15 1 14
18. Subsidisation & reimbursement 3 0 3 1 3 -2 6 1 5
15. 0.5% of GNP for poverty 3 1 2 3 0 3 7 2 5
19. Price controls/reference pricing 2 0 2 3 0 3 4 0 4
20. Compulsory licensing 2 0 2 3 0 3 7 2 5
24. Enterprise-level initiatives 2 0 2 2 0 2 1 0 1
31. Improvement of quality of drugs 2 0 2 4 0 4 5 0 5
33. Local authorities to spend 15% of budget to health 2 0 2 0 0 0 3 0 3
07. Medical innovation prizes 1 0 1 0 0 0 0 0 0
30. Appropriate use of drugs & adherence 1 0 1 0 0 0 2 0 2
36. Diagnostic testing point of care 1 0 1 2 0 2 3 0 3
38. Abandon all subsidies in the rich world 1 0 1 0 0 0 1 0 1
39. Educate RPCs to become self-sufficient 1 0 1 0 0 0 0 0 0
40. Improve health infrastructure & country infrastructure 1 0 1 4 0 4 3 0 3
41. Authorities lower taxes on medication 1 0 1 0 0 0 1 0 1
03. Priority review voucher 1 1 0 0 0 0 2 3 -1
04. Transferable intellectual property rights/avoid generics 4 4 0 1 5 -4 2 11 -9
05. Tax reliefs 1 1 0 0 0 0 3 1 2
10. Disease burden incentive systems 0 0 0 0 0 0 0 1 -1
13. Non-profit companies for medicines 1 1 0 1 0 1 0 0 0
27. Patent pooling 0 0 0 0 0 0 14 0 14
29. Setting up international health insurance system 0 0 0 0 0 0 1 0 1
32. Setting up microfinancing systems 0 0 0 0 0 0 1 0 1
34. Tendering and Kiwi model 0 0 0 0 0 0 1 0 1
35. Family planning & reduce population size 0 0 0 0 0 0 2 0 2
37. Early access to clinical trials in RPC 0 0 0 1 0 1 1 0 1
06. Re-location of R&D to low-cost countries 0 1 -1 1 0 1 1 0 1
08. Breakthrough innovation LC/HQ Prahalad 1 2 -1 2 0 2 1 0 1
16. 0.1% of GNP for drugs for neglected diseases 0 1 -1 0 0 0 4 0 4
21. Parallel importation & parallel trade 0 1 -1 1 0 1 1 0 1
26. Voluntary discount prices beyond differential pricing 0 1 -1 1 0 1 2 1 1
02. Optional rewards on therapeutic effect 0 2 -2 0 0 0 1 0 1
09. Public sector funding of R&D 0 2 -2 0 0 0 5 2 3
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Addendum 4-16: The number of net hits that were obtained for each of the resource 
levels. 
Net hits means: the positive hits minus the negative hits. 








29 interviews - final
Approach/Measure Pos  Neg  Net  Pos  Neg  Net  Pos  Neg  Net  
Hits Hits Hits Hits Hits Hits Hits Hits Hits
25. Differential & tiered & discriminatory pricing 5 0 5 5 0 5 16 1 15
28. Strengthening national health insurance system 5 0 5 4 0 4 2 0 2
23. Patent donation & free licenses/voluntary licenses 4 0 4 4 0 4 3 1 2
12. Public-private partnerships (ppp) 4 1 3 4 0 4 20 0 20
31. Improvement of quality of drugs 2 0 2 4 0 4 5 0 5
40. Improve health infrastructure & country infrastructure 1 0 1 4 0 4 3 0 3
15. 0.5% of GNP for poverty 3 1 2 3 0 3 7 2 5
19. Price controls/reference pricing 2 0 2 3 0 3 4 0 4
20. Compulsory licensing 2 0 2 3 0 3 7 2 5
17. Infection prevention 4 1 3 4 2 2 15 1 14
24. Enterprise-level initiatives 2 0 2 2 0 2 1 0 1
36. Diagnostic testing point of care 1 0 1 2 0 2 3 0 3
08. Breakthrough innovation LC/HQ Prahalad 1 2 -1 2 0 2 1 0 1
11. Addressing the regulatory excess 4 1 3 1 0 1 1 1 0
13. Non-profit companies for medicines 1 1 0 1 0 1 0 0 0
37. Early access to clinical trials in RPC 0 0 0 1 0 1 1 0 1
06. Re-location of R&D to low-cost countries 0 1 -1 1 0 1 1 0 1
21. Parallel importation & parallel trade 0 1 -1 1 0 1 1 0 1
26. Voluntary discount prices beyond differential pricing 0 1 -1 1 0 1 2 1 1
22. Drug donation 0 3 -3 1 0 1 5 3 2
01. Advanced market commitments 3 0 3 0 0 0 5 0 5
33. Local authorities to spend 15% of budget to health 2 0 2 0 0 0 3 0 3
07. Medical innovation prizes 1 0 1 0 0 0 0 0 0
30. Appropriate use of drugs & adherence 1 0 1 0 0 0 2 0 2
38. Abandon all subsidies in the rich world 1 0 1 0 0 0 1 0 1
39. Educate RPCs to become self-sufficient 1 0 1 0 0 0 0 0 0
41. Authorities lower taxes on medication 1 0 1 0 0 0 1 0 1
03. Priority review voucher 1 1 0 0 0 0 2 3 -1
05. Tax reliefs 1 1 0 0 0 0 3 1 2
10. Disease burden incentive systems 0 0 0 0 0 0 0 1 -1
27. Patent pooling 0 0 0 0 0 0 14 0 14
29. Setting up international health insurance system 0 0 0 0 0 0 1 0 1
32. Setting up microfinancing systems 0 0 0 0 0 0 1 0 1
34. Tendering and Kiwi model 0 0 0 0 0 0 1 0 1
35. Family planning & reduce population size 0 0 0 0 0 0 2 0 2
16. 0.1% of GNP for drugs for neglected diseases 0 1 -1 0 0 0 4 0 4
02. Optional rewards on therapeutic effect 0 2 -2 0 0 0 1 0 1
09. Public sector funding of R&D 0 2 -2 0 0 0 5 2 3
14. Global Marshall plan 3 0 3 0 1 -1 6 1 5
18. Subsidisation & reimbursement 3 0 3 1 3 -2 6 1 5
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Addendum 4-16: The number of net hits that were obtained for each of the resource 
levels. 
Net hits means: the positive hits minus the negative hits. 






29 interviews - final
Approach/Measure Pos  Neg  Net  Pos  Neg  Net  Pos  Neg  Net  
Hits Hits Hits Hits Hits Hits Hits Hits Hits
12. Public-private partnerships (ppp) 4 1 3 4 0 4 20 0 20
25. Differential & tiered & discriminatory pricing 5 0 5 5 0 5 16 1 15
17. Infection prevention 4 1 3 4 2 2 15 1 14
27. Patent pooling 0 0 0 0 0 0 14 0 14
31. Improvement of quality of drugs 2 0 2 4 0 4 5 0 5
15. 0.5% of GNP for poverty 3 1 2 3 0 3 7 2 5
20. Compulsory licensing 2 0 2 3 0 3 7 2 5
01. Advanced market commitments 3 0 3 0 0 0 5 0 5
14. Global Marshall plan 3 0 3 0 1 -1 6 1 5
18. Subsidisation & reimbursement 3 0 3 1 3 -2 6 1 5
19. Price controls/reference pricing 2 0 2 3 0 3 4 0 4
16. 0.1% of GNP for drugs for neglected diseases 0 1 -1 0 0 0 4 0 4
40. Improve health infrastructure & country infrastructure 1 0 1 4 0 4 3 0 3
36. Diagnostic testing point of care 1 0 1 2 0 2 3 0 3
33. Local authorities to spend 15% of budget to health 2 0 2 0 0 0 3 0 3
09. Public sector funding of R&D 0 2 -2 0 0 0 5 2 3
28. Strengthening national health insurance system 5 0 5 4 0 4 2 0 2
23. Patent donation & free licenses/voluntary licenses 4 0 4 4 0 4 3 1 2
22. Drug donation 0 3 -3 1 0 1 5 3 2
30. Appropriate use of drugs & adherence 1 0 1 0 0 0 2 0 2
05. Tax reliefs 1 1 0 0 0 0 3 1 2
35. Family planning & reduce population size 0 0 0 0 0 0 2 0 2
24. Enterprise-level initiatives 2 0 2 2 0 2 1 0 1
08. Breakthrough innovation LC/HQ Prahalad 1 2 -1 2 0 2 1 0 1
37. Early access to clinical trials in RPC 0 0 0 1 0 1 1 0 1
06. Re-location of R&D to low-cost countries 0 1 -1 1 0 1 1 0 1
21. Parallel importation & parallel trade 0 1 -1 1 0 1 1 0 1
26. Voluntary discount prices beyond differential pricing 0 1 -1 1 0 1 2 1 1
38. Abandon all subsidies in the rich world 1 0 1 0 0 0 1 0 1
41. Authorities lower taxes on medication 1 0 1 0 0 0 1 0 1
29. Setting up international health insurance system 0 0 0 0 0 0 1 0 1
32. Setting up microfinancing systems 0 0 0 0 0 0 1 0 1
34. Tendering and Kiwi model 0 0 0 0 0 0 1 0 1
02. Optional rewards on therapeutic effect 0 2 -2 0 0 0 1 0 1
11. Addressing the regulatory excess 4 1 3 1 0 1 1 1 0
13. Non-profit companies for medicines 1 1 0 1 0 1 0 0 0
07. Medical innovation prizes 1 0 1 0 0 0 0 0 0
39. Educate RPCs to become self-sufficient 1 0 1 0 0 0 0 0 0
03. Priority review voucher 1 1 0 0 0 0 2 3 -1
10. Disease burden incentive systems 0 0 0 0 0 0 0 1 -1
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Addendum 4-17-A: Data and histogram for evidences that were expressed in the 
interviews of this thesis research; in sequence. 
The evidences are listed in the sequence in which they were picked up for the first time in 
the interviews. The number of references is the number of times, the interviewees made an 
independent reference to the evidence. 







29 interviews - final
EVIDENCE FOR EXISTENCE OF : #
References
101. Patent based pharma goes generic 3
102. Generics go patent based 6
103. Constitutional determinants in Brazil & Thailand 10
104. Local pharma maintenance or boost or kick-start local pharma Brazil & Thailand 20
105. Game theory & prisoner's dilemma at play 13
106. Corruption as disturbing factor 14
107. Attention needed to paediatric products & fixed dose combinations 8
108. Negative effect of religion, culture, tradition 4
109. Brazil, Thailand, South Africa as emerging markets 8
110. Shift from HIV & TB & Malaria to other diseases 11
111. Too obvious / too easy questionnaire answers 3
112. Need to move from horizontal & vertical thinking to diagonal thinking 3
113. Countries repeating or copying the conflict model on compulsory licensing 21
114. Paradigm shift HA & DD & NGO/F 11
115. Strong effect of economic crisis 28
116. Importance of sustainability of solutions 6
117. Primary responsibility of authorities 7
118. Older & longest treated HIV population / highest medical need in Brazil & Thailand 6
119. Intentions expressed in the questionnaire (easy said, but very difficultly done) 5
120. HAVES who don't want to pay for the HAVE-NOTS in Brazil & Thailand 1
121. Differences in opinion through POLITICS 4
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Addendum 4-17-A: Data and histogram for evidences that were expressed in the 
interviews of this thesis research; in sequence. 
The evidences are listed in the sequence in which they were picked up for the first time in 
the interviews. The number of references is the number of times, the interviewees made an 
independent reference to the evidence. 
p.2/2: the histogram  
 
 
Number of References to Evidence for Events or 
Trends - NVIVO 29 Interviews
0 5 10 15 20 25 30
122. Medium count r ies are jealous at  t he pr ices t he poor count r ies get  
121. Dif f erences in opinion t hrough POLITICS
120. HAVES who don' t  want  t o pay f or t he HAVE-NOTS in Brazil & Thailand
119. Int ent ions expressed in t he quest ionnaire (easy said, but  very dif f icult ly done)
118. Older & longest  t reat ed HIV populat ion /  highest  medical need in Brazil & Thailand
117. Primary responsibilit y of  aut horit ies
116. Import ance of  sustainabilit y of  solut ions
115. St rong ef f ect  of  economic cr isis
114. Paradigm shif t  HA & DD & NGO/ F
113. Count r ies repeat ing or copying t he conf lict  model on compulsory licensing
112. Need t o move f rom horizont al & vert ical t hinking t o diagonal t hinking
111. Too obvious /  t oo easy quest ionnaire answers
110. Shif t  f rom HIV & TB & Malar ia t o ot her diseases
109. Brazil, Thailand, Sout h Af r ica as emerging market s
108. Negat ive ef f ect  of  religion, cult ure, t radit ion
107. At t ent ion needed t o paediat r ic product s & f ixed dose combinat ions
106. Corrupt ion as dist urbing f act or
105. Game t heory & prisoner 's dilemma at  play
104. Local pharma maint enance or boost  or kick-st art  local pharma Brazil & Thailand
103. Const it ut ional det erminant s in Brazil & Thailand
102. Generics go pat ent  based
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Addendum 4-17-B: Histogram for evidences that were expressed in the interviews of this 
thesis research; in descending order. 
The evidences are listed in descending order of the number of references. The number of 




Number of References to evidence for Events or 
Trends - NVIVO 29 Interviews
0 5 10 15 20 25 30
120. HAVES who don' t  want  t o pay f or t he HAVE-NOTS in Brazil & Thailand
122. Medium count ries are jealous at  t he pr ices t he poor count r ies get  
101. Pat ent  based pharma goes generic
111. Too obvious /  t oo easy quest ionnaire answers
112. Need t o move f rom horizont al & vert ical t hinking t o diagonal t hinking
108. Negat ive ef f ect  of  religion, cult ure, t radit ion
121. Dif f erences in opinion t hrough POLITICS
119. Int ent ions expressed in t he quest ionnaire (easy said, but  very dif f icult ly done)
102. Generics go pat ent  based
116. Import ance of  sust ainabilit y of  solut ions
118. Older & longest  t reat ed HIV populat ion /  highest  medical need in Brazil & Thailand
117. Primary responsibilit y of  aut horit ies
107. At t ent ion needed t o paediat r ic product s & f ixed dose combinat ions
109. Brazil, Thailand, Sout h Af r ica as emerging market s
103. Const it ut ional det erminant s in Brazil & Thailand
110. Shif t  f rom HIV & TB & Malar ia t o ot her diseases
114. Paradigm shif t  HA & DD & NGO/ F
105. Game t heory & pr isoner 's dilemma at  play
106. Corrupt ion as dist urbing f act or
104. Local pharma maint enance or boost  or kick-st art  local pharma Brazil & Thailand
113. Count r ies repeat ing or copying t he conf lict  model on compulsory licensing
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Addendum 4-18: Comparison of the average scores on the individual questions in the 
questionnaire with the net number of hits obtained in the interviews for the 
corresponding questions.  






29 interviews - final
Approach/Measure Average Score Net # Hits 
Questionnaire Interview
01. Advanced market commitments 5,03 8
02. Optional rewards on therapeutic effect 4,97 -1
03. Priority review voucher 4,65 -1
04. Transferable intellectual property rights/avoid generics 4,41 -16
05. Tax reliefs 5,60 2
06. Re-location of R&D to low-cost countries 4,97 1
07. Medical innovation prizes 5,08 1
08. Breakthrough innovation LC/HQ Prahalad 5,54 2
09. Public sector funding of R&D 5,52 1
10. Disease burden incentive systems 5,34 -1
11. Addressing the regulatory excess 5,21 4
12. Public-private partnerships (ppp) 5,77 27
13. Non-profit companies for medicines 4,95 1
14. Global Marshall plan 5,24 7
15. 0.5% of GNP for poverty 5,87 10
16. 0.1% of GNP for drugs for neglected diseases 5,60 3
17. Infection prevention 6,00 19
18. Subsidisation & reimbursement 6,00 6
19. Price controls/reference pricing 5,05 9
20. Compulsory licensing 4,69 10
21. Parallel importation & parallel trade 3,82 1
22. Drug donation 5,16 0
23. Patent donation & free licenses/voluntary licenses 5,29 10
24. Enterprise-level initiatives 5,50 5
25. Differential & tiered & discriminatory pricing 5,30 25
26. Voluntary discount prices beyond differential pricing 5,43 1  
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Addendum 4-19: Comparison of the ranks of the scores on the individual questions in 
the questionnaire with the ranks of the net number of hits obtained in the interviews for 
the corresponding questions.  






29 interviews - final
Approach/Measure RANK RANK
Average Score Net # Hits
Questionnaire Interview
01. Advanced market commitments 19 8
02. Optional rewards on therapeutic effect 20 24
03. Priority review voucher 24 23
04. Transferable intellectual property rights/avoid generics 25 26
05. Tax reliefs 5 15
06. Re-location of R&D to low-cost countries 21 18
07. Medical innovation prizes 17 17
08. Breakthrough innovation LC/HQ Prahalad 7 14
09. Public sector funding of R&D 8 16
10. Disease burden incentive systems 11 25
11. Addressing the regulatory excess 15 12
12. Public-private partnerships (ppp) 4 1
13. Non-profit companies for medicines 22 21
14. Global Marshall plan 14 9
15. 0.5% of GNP for poverty 3 6
16. 0.1% of GNP for drugs for neglected diseases 6 13
17. Infection prevention 1 3
18. Subsidisation & reimbursement 2 10
19. Price controls/reference pricing 18 7
20. Compulsory licensing 23 5
21. Parallel importation & parallel trade 26 20
22. Drug donation 16 22
23. Patent donation & free licenses/voluntary licenses 13 4
24. Enterprise-level initiatives 9 11
25. Differential & tiered & discriminatory pricing 12 2
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